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Design of selective ligands for conjugate drug targeting to human serum albumin (HSA) 
through cysteine-34 and β-D-galactopyranoside inhibitors towards galectins 
Subhash Rao Rauthu, Ph.D. 
Concordia University, 2011 
Galectins are a large family of 15 structurally related -D-galactopyranoside 
recognizing proteins. In mammals, they play a crucial role in the control of cell 
differentiation, proliferation, activation, metastasis and apoptosis of immune cells. 
Moreover, galectins have recently shown their role in HIV-1 biology by stabilizing the 
viral adhesion and augmentation in virus replication. Consequently, access to potent and 
selective inhibitors of galectins is highly desirable as tools for detailed evaluation of 
galectin function and activities at the cellular level and they would constitute lead 
compounds for the development of galectin blocking drugs. Natural ligands have low 
affinities and being too polar would not pass through the cell membrane. To circumvent 
the above issues we have logically designed and synthesized stable C-galactoside triazole 
derivatives. Some of these compounds exhibit IC50 values of 2.5 mM against Galectin-3. 
To further improve their efficacy, we have designed and synthesized S-galactosides, C-
lactosides, S-lactosides and LacNAc derivatives with a hydrophobic pharmacophoric part 
i.e. substituted triazole moiety through a peptide link at the anomeric position that can 
balance the partition coefficient to cross cell membranes and increase the in vivo stability. 
Biological evaluations of these compounds are in progress. 
iv 
 
Peptides are well known for recognizing and activating specific receptors. 
Peptidase quickly intercepts and cleaves to transform them in to biologically inactive 
fragments that are further cleared by the kidneys. As a consequence peptides have a short 
half-life and brief duration of activity, such issues preclude them from being developed in 
to commercialized drugs. To overcome such issues taking advantage of the characteristic 
nature of HSA to accumulate in tumour tissues is exploited for transport and to increase 
the bioavailability. We have designed and synthesized hetero trifunctional linkers 
(maleimido, vinylsulphonamide and acrylamide) with a Michael acceptor on one side to 
conjugate with the HSA through cysteine-34, and a carboxylic acid and alkyne 
functionality on the other side to couple peptide based drugs and to install a better 
triazole derivative functionality to fit the linker in the hydrophobic binding pocket of 
cysteine-34. The relative reactivities of these linkers were evaluated using cysteine under 
physiological conditions with time, the maleimido derivative found to be the fastest 
reacting Michael acceptor (less than 10 min) and the vinyl sulfonamide which reacts 
completely within 45 min.  The acrylamide functionality did not react at all under 
physiological conditions, requiring the pH to be raised to 8.5 for reaction to occur. Theses 
three linkers are under further evaluation to react with HSA under physiological 
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1.1 Introduction to glycobiology 
“Glycobiology” A new frontier of molecular biology opened to develop new 
technologies to explore structure and function of “glycans”. The word “glycobiology” 
was first coined in 1980 to recognize the union of two traditional disciplines carbohydrate 
chemistry and biochemistry. Defined in the broad view, glycobiology is the study of the 
structure, biosynthesis, biology and evolution of saccharides. Glycoconjugates are formed 
when they are attached to the proteins or lipids. Glycoconjugates are mainly categorized 
as two types 1) “glycolipids” glycoconjugates attached to lipids or 2)“glycoproteins” 
glycoconjugates attached to proteins either through nitrogen (N-linked) or oxygen atom 
(O-linked)1.  
1.1.1 Glycolipids 
Glycans are attached to the head group of lipids, the lipid portion of glycolipid 
embedded in the membrane bilayer and fall into two structural categories. Glycolipids 
built on ceramide are known as glycosphingolipids. Ceramide is formed between a fatty 
acid with the long chain amino alcohol sphingisine by an amide linkage. 
Glycosphingolipids function like membrane glyco protein in the presence of potential 
recognition markers involved in cell-cell interactions. Glycosphingolipids also function in 
the organization of specialized membrane domain. In contrast, glycophospholipids built 




surface. Glycosphingolipids are further divided into two main groups known as 
galactosphingolipids or glucosphingolipids respectively based on whether the first sugar 
attached to sphingosine is galactose or glucose.2 
1.1.2 Glycoproteins  
Glycoproteins are the proteins covalently attached to carbohydrates such as 
glucose, galactose, lactose, fucose, sialic acid, N-acetylglucosamine, N-
acetylgalactosamine, etc. Depending on the linkage between the carbohydrates with the 
protein, glycoproteins are divided in to two groups 1) O-linked glycoproteins, which are 
linked to carbohydrates trough the hydroxyl group of serine, threonine or hydroxylysine. 
2) N-linked glycoproteins in which the protein is linked to carbohydrate through the 
amide group of asparagines (Figure 1). 
 








1.1.3 Carbohydrate binding proteins (CBPs) 
Excluding glycan-specific antibodies, it is possible to classify CBPs into two 
individual groups. 1) Lectins, Most lectins are members of families with “carbohydrate 
recognition domains” (CRD) that apparently evolved from shared ancestrial genes, often 
retaining specific features of primary amino acid sequence or three dimensional structure. 
Lecitns were discovered more than 100 years ago, found from the microbial world to 
humans 2) Glycosaminoglycan-binding proteins. 
1.2 Introduction to galectins 
Lectins are carbohydrate binding proteins that can recognize various 
glycoconjugates on the cell surface and extra cellular matrices. Lectins have many 
functions ranging from mediation of cell adhesion and the promotion of cell-cell 
interactions to the recognition of pathogens. Animal lectins are grouped into several 
families.3, 4, 5 Galectins is one family among them, which are defined by their ability to 
recognize -galactosides and by their consensus amino acid sequences.6,7 The study of 
galectins is one of the most attractive areas for biologists and chemists and the results for 
the word “galectin” in Scifinder Scholar reveals a steady increase in the number of papers 
published per year (Figure 2). New galectins and their biological roles have been 
discovered over the years. There are 15 mammalian galectins found so far and most of 
them are implicated in the pathology of various diseases. The number of publications on 
galectin-1 and galectin-3 are growing remarkably, the number itself tells of their 




their intriguing roles in cancer biology, they are involved in every step of cancer 
processes right from neoplastic transformation to angiogenesis. Moreover, galectins have 
recently shown their role in HIV-1 biology by playing a very initial and pivotal role in 
virion adhesion to the host cell. 
 
Figure 2. Scifinder Scholar data in terms of number of papers published per year 
per galectin 
All galectins contain a conserved carbohydrate recognition domain (CRDs) of 
about 130 amino acids, and these are responsible for the carbohydrate binding.8 To date 
15 mammalian galectins have been identified, which can be subdivided into those that 
have one CRD (Gal-1,2,5,7,10,11,13,14 and 15) and those that have two CRDs (Gal-
4,6,8,9,12). Galectin-3, a one CRD containing galectin, is unique and contains unusual 
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a) Galectins with one CRD; Proto-type: Galectins-1, 2, 5, 7, 10, 11, 13, 14, 15 
 
b) Galectin with one CRD and a proline-glycine rich peptide; Chimera-type: Galectin-3 
 
c) Galectins with a tandem of two distinct CRD; Tandem-repeat-type: Galectins-4, 6, 8, 
9, 12 
 
Figure 3. Schematic representation based on X-ray and spectroscopic analysis of 
various types of galectins: a) galectins with one CRD with possibilities of 
dimerization; b) galectins with one CRD with possibilities of oligomerization 





Many galectins are either bivalent or multivalent with respect to their carbohydrate 
binding activities and are shown in Figure 3. Distribution of some galectins is restricted 
to specific tissues and some are widely distributed in many tissues. The modulation in 
expression of galectins is strongly regulated by development, differentiation and under 
different physiological and pathological conditions.13 Interestingly, the expression of 
galectins is altered in tumor cells compared with the normal counter parts.14 Though there 
is some conflicting data on the expression of galectins under different pathological 
conditions, most of the recent data shows that galectins are elevated in neoplastic 
transformation with some exceptions like colon cancer.15 Expression of certain types of 
galectins is specific to certain types of cancers.12 Galectin-1 is over expressed in breast 
carcinoma,16 high grade bladder carcinomas,17, 18 bladder19 and thyroid cancer.20 In 
contrast, studies have shown that galectin-1 decrease expression in neck cancer.21 
Galectin-3 is over expressed in thyroid,22 central nervous system,23 head and neck 
squamous cell carcinoma,24 stomach,25 pancreas,26 bladder27 and renal carcinoma.28 
Galectin-3 was also found down regulated in colon cancer12 and in urological cancers.29 
Although there is little experimental biological evidence, qualitatively many 
groups have shown that galectins have important functions in several aspects of cancer 
biology like regulation of tumor development and growth, including tumor 
transformation, angiogenesis, metastasis, apoptosis and cell-cycle progression.9 




attachment of virion to host cell.30,31 Herein, a brief implication of galectin into the 
biology world before a review on the galectin inhibitors. 
1.2.1 Role of galectins in tumour transformation and survival 
Anchoring RAS proteins to membranes are crucial to activate downstream 
signaling molecules RAF1 and extracellular signal-regulated kinase (ERK) for 
transformation of a normal cell into a neoplastic cell. Under normal conditions it is not 
possible for RAS proteins to anchor to the membrane for an increase in the downstream 
signalization transformation. Indeed, galectin-1 and galectin-3 could act as anchoring 
partners, thus helping in tumor transformation. Kloog et al. have shown that over 
expression of galectin-1 and galectin-3 in tumor cells increased the tumor transformation. 
Inhibition of galectin-1 using antisense RNA suppressed the transformation induced by 
this protein.32,33 The mechanisms by which galectins are involved in cell transformation 
are not yet fully understood. 
1.2.2 Role of galectins in apoptosis 
Galectins are a family of apoptosis regulating proteins. The study of apoptosis 
regulation has been demonstrated mainly by using two different approaches. In the first 
approach, the recombinant galectins were exogenously added to cells, including tumor 
cells, and were shown to induce apoptosis, probably by binding to cell surface 
glycoconjugates. The second approach was the study of tumor cells transfected with a 
cDNA encoding for an individual galectin and its anti-apoptotic activities was clearly 




has been clearly demonstrated by different groups that regulation of apoptosis depends on 
the localization of galectins.35 Extra cellular galectin-1 and galectin-9 and intracellular 
galectin-12 and galectin-7 are shown to be proapoptotic.36, 37 On the other hand, apoptotic 
regulation of galectin-3 depends on its localization and it has been shown to be anti-
apoptotic in cytoplasm38 and proapoptotic in nucleus. Although galectin-3 is proapoptotic 
intranucleously, this galectin is phosphorylated by casein kinase at Serine-6 and 
translocate in to the cytoplasm.39 Phosphorylation of Serine-6 is compulsory to 
translocate galectin-3 from the nucleus to the cytoplasm and by mutating Serine-6 into 
alanine or glutamic acid, the phosphorylation is not possible and galectin-3 remained in 
the nucleus.40,41 The anti-apoptotic activity of galectin-3 is not yet completely 
understood, but this lectin translocates from the cytosol to the mitochondria along with 
another interacting partner and an anti-apoptotic protein (Bcl-2), which is very close to 
galectin-3 in sequence similarity. Both proteins have a N-terminal end rich in proline, 
glycine and alanine and contain very specific amino acids at the C-terminal end (Asp, 
Try, Gly, Arg). These amino acids are very critical for Bcl-2 regarding its anti-apoptotic 
functions.36,42 This sequence is highly conserved in galectin-3 and important for the 
carbohydrate binding activities. Under normal conditions following exposure to apoptotic 
stimuli, the mitochondrial membrane potential will alter and release proapoptotic proteins 
by opening the mitochondrial pores, like cytochrome-C, SMAC or DIABLO and begin 
the apoptosis process. Galectin-3 with its interacting partner Bcl-2 translocate onto the 




mitochondria to release proapoptotic proteins, thereby preventing apoptosis by arresting 
the mitochondrial pathway of apoptosis (Figure 4).37 
 
Figure 4. Role of galectins in neoplastic transformation and arrest of the 
mitochondrial pathway of apoptosis9 
1.2.3  Role of galectins in tumor metastasis 
Metastasis is a complex multi process of spreading secondary tumors in the body. 
Cells from primary tumor have to disintegrate intravasate into transport media 
(blood/lymph vessels), travel to distal places, extravasate and find a suitable site for 
proliferation. Galectins were shown to facilitate the above complicated process. Galectins 
that are released by tumor cells might interfere with the adhesion of adjacent cells either 
by interacting between two cells or by interacting with integrins which are responsible for 




transports to preferable distal places where they can proliferate. Galectin-3 induces 
intravasation and spread exogenously on the surface of tumor cells.46 Finally, galectins do 
have a role in connecting the new tumor to the blood vessels for nutrients supply. For 
example, galectin-3 has angiogenic activity in vitro by migrating to the endothelial cells. 
Angiogenic activity of galectin-3 is proved by over expression of this lectin in breast 
carcinoma cells. Galectin-3 seems to provide abundant blood capillaries around the tumor 
in which galectin-3 was over expressed compared to control (Figure 5).45 
 




1.2.4  Role of galectins in tumor immune response evasion 
Recent studies indicated that some galectins released by the tumor might help to 
evade the immune surveillance.47 Galectin-1 is the most extensively studied galectin 
among other galectins in context of regulation of immune response and this lectin induces 
the apoptosis on activated T-cells48 when added exogenously to T-cells in vitro. Galectin-
3 can also induce T-cell apoptosis49 and can restrict T-cell receptor initiated signal 
transduction by forming multivalent complexes with glycans present on the T-cell 
receptor.50 Addition of galectin-3 to human eosinophils produced a selective inhibition of 
IL5 transcription, which led to the reduction of immune response. Such inhibition of IL5 
transcription was reversed by incubating the natural galectin inhibitor lactose.48 Galectin-
2 and galectin-9 can also shown to induce T-cell apoptosis.51, 52, 53 
1.2.5 Galectins and HIV-1 
HIV primarily infects vital cells in the human immune system such as helper T 
cells (specifically CD4+ T cells), macrophages and dendritic cells.54 HIV type 1 (HIV-1) 
infection is a dynamic process involving 3 steps: adhesion, infusion, and integration.55 In 
the literature it has been proposed that various types of modulators mediating the 
adhesion process between primary cellular receptor CD4 and virus encoded external 
envelope gp 120.56 
Galectin-1 is shown to have a role in HIV-1 establishment in humans initiated by 
attaching the virion to the target cell surface. The event of infection relies on the 




physiological conditions binding of external envelope gp120 of the virus to cellular 
receptor CD4 is not that strong57 and this finding will open the door to the question what 
are all the other factors or proteins helping in the early and important event (adhesion) of 
HIV type-1 infection. Sachiko Sato et al. have clearly shown the role of galectin-1 in 
virus attachment to host cell,30 using LuSIV reporter cells. They have conducted 
experiments with galectin-1 and galectin-3, with and without galectin antagonist (lactose) 
to cross confirm the role of galectins in cell adhesion. The dose dependent increase in 
infectivity was observed only for galectin-1 but not with galectin-3. 
Galectin-1 promotes HIV-1 infectivity in monocyte-derived macrophages 
(MDMs) by stabilizing the viral adhesion and augmentation in virus replication was dose 
dependent manners. The fusion inhibitors T-20 and TAK779 remained effective at 
reducing infection even in the presence of galectin-1, thus showing participation in the 
early stage of infection prior to fusion. The above results show that galectin-1 facilitates 
HIV-1 infection in monocyte derived macrophages by promoting adsorption.31 An 
interesting contrast was found between galectin-1 and galectin-330,31 and this could be 
explained due to the slight differences in the structure of carbohydrate recognition 









Globally, there are 2 classes of galectin inhibitors (Figure 6). The first class being 
the natural glycoconjugates having a terminal galactosides residue and the second group 
being synthetic inhibitors. The later one can be subdivided into three categories: those 
that posses i) anomeric modification on the galactoside residue; ii) 3’-modification on the 
galactoside residue, and iii) multivalent galactosilated molecules.  
 
Figure 6. Possible ligands that can bind to the galectin family. Naturally occurring 
and synthetic ligands for galectins: Anomeric modification made by Roy et al.71, 3’-
modification made by Nilsson et al.81 and multivalent inhibitor made by Ungaro and 





2.1 Natural ligands for galectins 
There are numerous naturally occurring compounds that have been screened for 
their association with various galectins.60 Some examples are presented in Table 1.  
Table 1. Natural ligands for various galectins. 
Entry Galectin Ligand/Highlights Reference 
1 3 Myelin-associated glycoprotein, tenascin-C and -R/ No 
binding to collagen I. 
61 
2 3 Poly-N-acetyllactosamine/ Present on colon cancer 
mucin. 
62 
3 3 Lactosyl, paraglobosyl, gangliosyl and neolactohexaosyl 
oligosaccharides/ Made by a strain that is highly 
infectious for the male urethra: Neisseria gonorrhoeae. 
63 
4 3 Mycobacterial mycolic acids/ Major constituents of 
Mycobacterium tuberculosis can inhibit the lectin self-
association but not its carbohydrate-binding abilities. 
64 
5 1-5, 7 Multivalent glycoprotein asialofetuin/ Enhanced affinity 
for a specific ligand through a clustering mechanism. 
65 
6 3 O-antigen side-chain of Helicobacter pylori 
lipopolysaccharides/ Promotes adhesion of H. pylori to 
gastric epithelial cells and may enhance colonization of 
the host. 
66 
7 3 Mgat5-modified N-glycans/ Regulates fibronectin matrix 
remodeling in tumor cells. 
67 
8 1 Thomsen-Friedenreich antigen on trophoblast cells/ Gal-1 
is localized at the border between fetal trophoblast and 
maternal stroma. 
68 
9 3 Pectic Polysaccharides from dietary sources/ Reduction 






The exact role of the galectins is not fully understood but analysis of natural 
ligands helps their biological comprehension. Furthermore, the synthesis of non-natural 
ligands provides interesting tools to help understand the complexity of all the biological 
implication of galectins. 
2.2 Synthetic ligands 
As explained in the Introduction to galectins, in mammals galectins play a pivotal 
role in the control of cell differentiation, proliferation, activation, metastasis and 
apoptosis of immune cells. Moreover, galectins have recently shown their role in HIV-1 
biology by stabilizing the viral adhesion and it was shown that the augmentation in virus 
replication was dose dependent. Naturally occurring carbohydrate ligands like methyl β-
D-galactoside, methyl β-D-lactoside and methyl-β-D-N-acetyllactosamine have low 
affinities and are too polar (low partition coefficients) to pass through the cell 
membranes. Consequently, access to potent and selective inhibitors of galectin are highly 
desirable tools for detailed evaluation of galectin function and activities at cellular level. 
In addition they would constitute lead compounds for the development of galectin 
blocking drugs. Synthetic ligands reported until recently were reviewed under 4 different 
categories 1) Anomeric modification 2) 2’-modification 3) 3’-modification and 4) 
multivalent inhibitors. 
2.2.1 Anomerically modified galectin inhibitors 
Subsite-D is one of the binding sites of galectins, which extend towards the 




number of compounds was made by manipulating the anomeric position of galactose, 
lactose and N-acetyl lactosamine (LacNAc) to find a highest affinity compound, 
compared to any other position targeting other binding subsites.   
Table 2. Anomerically modified galectin inhibitors and their potencies (literature) 
 
Entry Compd. No Potency Galectin Reference 
1 2.1 0.18, 2.2 mM(Kd) 7, 8N 70 
2 2.2  1.8, 0.14 mM(Kd) 3, 8N 70 
3 2.3 180 µM (Kd) 3 71, 72 
4 2.4 5 mM (IC50) 1,3 73 
5 2.5 5 mM (IC50) 1, 3 74 
6 2.6 0.313 mM (IC50) 1 74 
7 2.7 2.5 mM (IC50) 1, 3 74 
8 2.8 5 mM (IC50) 1, 3 74 
9 2.9 0.08,0.625 mM (IC50)  1, 3 73 
10 2.10 0.04,0.313 mM (IC50) 1, 3 75 
11 2.11 0.313 mM (IC50) 1, 3 73 






Figure 7. Anomerically modified galectin inhibitors 
2.2.2 2’-position modified galectin inhibitors 
Hindsgaul et al. explored the N- and 2’ position of N-acetyllactosamine (LacNAc) 
and derivatized two different libraries of compounds. 1) Compounds with different aryl 
pharmacophores on the amine functionality of glucosamine and with a long O-alkyl 




very useful to synthesize analogs selectively. 2) Compounds with different 
pharmacophores at the 2’-position of galactose were synthesized by removal of the 
acetate protecting group. Screening libraries of N-and 2’-derivatized type I disaccharides 
with the FAC/MS technique revealed these candidates had an enhanced affinity for 
galectin-3. The best result was obtained with the N-naphthoyl derivative 2.13 (10.6 µM), 
(Kd) which showed a 7-fold increased affinity compared to the parent LacNAc 
compound (Kd) 73.3 µM.77 
Nilsson et al synthesized a library of 8 compounds by exploring the 2-O-position 
on methyl lactose molecule. The ester derivatives were tested for binding to galectin-1, -
3,    -7, -8N, and -9N by using a fluorescence-polarisation assay. All the ester derivatives 
showed greatly increased affinity for galectin-1 and -3, as compared to the parent methyl 
β-lactoside, presumably because of additional beneficial interactions between the ester π-
systems and the arginine guanidinium groups. The best inhibitors of the library are 2.16 









Figure 8. 2, 2’-Modified galectin inhibitors 
2.2.3  3’-position modified galectin inhibitors 
The crystal structure of LacNAc with Galectin-3 complex shows a possible 
extended binding groove close to OH-3 (Gal) Figure 9. This binding groove has been 
exploited in the design of high-affinity inhibitors through synthesis of 3’-benzamido 
derivatives of LacNAc from a 3-azido-3-deoxy galactose precursor.79 The crystal 
structure shows that the side chain of Arg144 stacks against the aromatic moiety of the 
inhibitor, an interaction made possible by a reorientation of the side chain relative to that 
seen in the LacNAc complex. Based on these structures, a large number of 3’-position 






Figure 9. Crystal structure of Galectin-3 with LacNAc showing a possible extended 
binding groove close to OH-3(Gal) 
 
Table 3. 3’-position modified galectin inhibitors and their potencies (literature) 
Entry Compd No Potency Galectin Reference 
1 2.18 107 µM(Kd) 3 80 
2 2.19 1.25, 5.0 mM (Kd) 1, 3 73 
3 2.20 >5 1, 3 73 
4 2.21 4.4 µM(Kd) 3 81 
5 2.22 15 µM(Kd) 3 82 
6 2.23 0.74 mM(Kd) 7 83 





Figure 10. 3’-position modified galectin inhibitors 
2.2.4 Multivalent inhibitors 
Several mechanisms like intramolecular chelate effects and intermolecular 
aggregative process may operate to enhance the relative potency of multivalent inhibitors. 
Several research groups have exploited the idea of using multivalency compounds to find 
high affinity galectin inhibitors. The stronger cluster effect was seen with the divalent 








Table 4. Multivalent inhibitors of galectins and their potencies 
Entry Compound No. Potency Galectin Reference 
1 2.25 0.3 mM (IC50) 1 and 3 73 
2 2.26 5 mM and >5 mM (IC50) 1 and 3 73 
3 2.27 2.5 and >5 mM (IC50) 1 and 3 73 
4 2.28 0.3 and 0.16 mM (IC50) 1 and 3 73 
5 2.29 30.8 µM (IC50) 3 84 
6 2.30 33 nM (Kd) 3 85 
7 2.31 0.3, 0.16 mM (IC50) 1 and 3 74 
8 2.32 0.6, 0.3 mM (IC50) 1 and 3 74 
9 2.33 0.3, 0.16 mM (IC50) 1 and 3 74 
10 2.34 >5, 2.5 mM (IC50) 1 and 3 74 














2.3 Rational strategies for the synthesis of galectin inhibitors 
The amino acids which provide interaction with carbohydrate ligands are highly 
conserved throughout all family members. The eight amino acids of human galectin-3 
(hGal-3) CRD are Arg144, His158, Asn160, Arg162, Glu165, Asn174, Trp181 and 
Glu184. All the interactions between the amino acids of carbohydrate recognition domain 
(CRD) and ligands can be understood by crystallographic analyses of various galectins 
and ligands (Figure 12). First of all, only three water molecules are present in the 
galectin-3 CRD (2NMN) without any ligand (Figure 12a). A first molecule of water 
interacts with His158, Asn160, and Arg162. A second water molecule interacts with 
Asn174 and Glu184 and finally, the last one with Arg162 and Glu184. Interestingly, the 
positions of these water molecules are very close in the space where the 1-OH, 4’-OH 
and 6’-OH of the lactose residue are making hydrogen bonds.87 When complexed to 
lactose (2NN8), the majority of the interactions are formed between sub site C and 
residues His158, Asn160, Arg162, Trp181 and Arg144 (Figure 12b). Sub-site C sits on a 
tryptophan “greasy floor” by making favorable hydrophobic interactions with C-3, C-4 
and C-5. These stacking interactions are made from galactoside C-H bonds with 
proximity of the  orbitals of the aromatic residue.88 Axial 4’OH has the possibility to 
make hydrogen bonds directly with His158, Asn160, Arg162 and indirectly with Arg144 
by the intermediary of a water molecule. All these polar and hydrophobic interactions 
described above are the key to differentiate -galactosides from other natural sugars like 




where synthetic -mannosides substituted at the C1 position can have a better affinity 
than -galactosides with hGal-3 and hGal-9N.89 If 3’-OH and 4’-OH are not found in 
equatorial and axial conformation respectively, then galectins affinity and selectivity to 
-galactosides will be decreased or suppressed. The 6’-OH group is forming direct 
hydrogen bonding with Arg174 and Glu184 in sub-site C. Also, the 3’-OH group 
interacts indirectly with Arg144 via a water molecule. The endocyclic oxygen is forming 
direct hydrogen bonds with Arg162. No important interaction is observed with the 2’-OH 
and the glycosidic oxygen. For the sub-site D, the 3-OH group is forming direct hydrogen 
bonds with Arg162 and Glu184. Because of the interactions with sub-site D, this explains 
the selectivity to -galactosides and no selectivity to -galactosides. Also the 2-OH and 
6-OH groups are forming indirect hydrogen bonding with Glu165 and Glu184 






Figure 12. Comparison of the architecture of the interaction site obtained from 
available crystallographic X-ray for galectin-3 with various ligands: a) ligand free 
(2NMN); b) lactose (2NN8); c) LacNAc (1KJL); d) LacNAcBEK (1KJR). The color 
of each amino acid is used to depict structurally equivalent substitution. 
 
Interactions are almost the same when lactose is replaced by LacNAc (1KJL), 
except for the N-acetyl moiety that is making indirect hydrogen bonding with Glu165. In 




lactose and LacNAc, but not for the subsite B. Foremost, carbonyl and N-H of the amide 
group are forming indirect hydrogen bonding with Arg144 and Trp181, both with 
intermediary of water. Second, as described in earlier papers, 4-methoxy-2,3,5,6-
tetrafluorobenzamido moiety is forming -cation interaction with Arg144. Finally two 
more amino acids Ile145 and Ala146 are participating by making hydrophobic 
interactions with subsite B.90 
By studying the CRDs of some human galectins complexed to lactose many 
similarities and few differences were found (Figure 13). First, no important interaction is 
observed in subunit C with the glycosidic oxygen, 2’-OH, 1-OH,  and in subunit D with 
the endocyclic oxygen and 6-OH. Except for subunit D it is only the glycosidic oxygen in 
hGal-3 that makes indirect hydrogen bonds with Arg44. Second, the main interactions are 
totally conserved and include hydrophobic interactions with tryptophan, direct hydrogen 
bonds with histidine, asparagine and arginine, except for the 4’-OH where it is forming 
indirect hydrogen bonding to Asn63. In some cases, additional interactions were 
observed between the 4’-OH and a water molecule or an arginine (directly or indirectly). 
The endocyclic oxygen and 6’-OH are all conserved, except for hGal-2 endocyclic 
oxygen where there is no important interaction. There is a conserved interaction for 3-
OH, except for hGal-2 where an additional hydrogen bonding with an arginine is found 
and also for hGal-9N where glutamic acid is replaced by arginine. Third, 3’-OH and 2-
OH interactions are variable, in some cases there is no interaction with certain human 




glutamine or asparagine. If interactions are not absent, there is direct hydrogen bonding 
between 2-OH and an arginine or indirect interaction with a glutamine. Moreover, 
Nilsson and co-workers showed some cases where -talosides can have a better affinity 
than -galactosides with hGal-4C and hGal-8N.91 Molecular modeling studies shows that 
in hGal-8N axial 2’-OH interacts directly with Arg52 compared to equatorial 2’-OH that 
has no interaction. Because of the similarities between hGal-8N and hGal-7, molecular 
modeling shows also that axial 2’-OH interacts directly with Arg53 in hGal-7. In 
addition, six amino acids that interact directly or indirectly with a -galactoside ligand 
are always conserved in the sequence alignment throughout the galectins family. A first 
set of three residues are spaced with two residues: His, Asn and Arg. The second set is 
spaced with seven and three residues respectively: Asn, Trp and Glu. A variable distance 
from nine to thirteen residues is observed between two sets of amino acids. Other 
residues included in the CRD are not necessarily conserved. Some of them are found 
before the first set: Arg144 (hGal-3), Arg44 (hGal-9N), Arg52 and Gln54 (hGal-8N). 
Others are found after the second set: Arg87 (hGal-9N), Arg70 and Arg120 (hGal-2). In 
some cases, they are included between the two sets: His52 (hGal-1) and Glu165 (hGal-3). 
The unique exception is hGal-7 where only the conserved six amino acids are present, no 







Figure 13. Comparison of the architecture of the interaction site obtained from 
available crystallographic X-ray for various human galectins complexed to lactose: 
a) hGal-1 (1GZW); b) hGal-2 (1HLC); c) hGal-3 (2NN8); d) hGal-7 (4GAL); e) 
hGal-8N (2YXS); f) hGal-9N (2EAK). Color of each amino acid is used to depict 








3.1 Synthesis of potential inhibitors of galectins 
3.1.1 Retrosynthetic analysis of C-galactopeptidomimetics 
C-galactopeptidomimetics possess a peptide bond that connects the glycan with 
the aglycan pharmacophore, hence the need to prepare the C-galactose acid and triazole 
amino acid. Galactose acid can be synthesized from β-C-allylgalactose by employing 
classical ozonolysis to produce an aldehyde followed by oxidation to an acid. C-
Glycosides are important precursors toward stable and biologically active glycomimetics. 
Amongst these, C-allyl galactosides represent powerful and versatile precursors toward 
other functionalities, and as key intermediates in several natural product syntheses. 
C-Allyl glycosides can be prepared from glycosyl halides, anomeric acetates, 
methyl glycosides, and even sugar lactones using a wide range of procedures.92 Some of 
the most common and practical methods involve treating sugar lactones with excess 
allylmagnesium bromide, followed by reduction of the ensuing tertiary alcohol with 
silanes and a Lewis acid (Kishi’s procedure),93 allylation using allyl trimethylsilane and 
Lewis acids such as BF3 etherate or TMSOTf (Sakurai reaction),94 epoxide opening with 
organometallic reagents,95 and by radical allylation of glycosyl halides using allyl 
stannanes or sulfones (Keck allylation).96 However, most protocols provide anomeric 
mixtures of the desired C-allyl glycosides that are not always readily separable. Although 
there many methods of preparation of C-allyl glycosides, the desired β-configuration can 




stereoselectivity of the formation of the β-glycoside. Thus, peracetylated C-allyl β-D-
galactopyranoside can be obtained in a stereoselective fashion. Aminoacid triazole can be 
synthesized from the alkyne precursor L-propargylglycine (L-pra) using the regio 
selective 1, 3 dipolar cyclo addition reaction (click chemistry) discovered by Prof. K. 
Barry Sharpless (Scheme 1). 
 
Scheme 1. Retrosynthetic analysis of C-galactopeptidomimetics 
3.1.2 2,3,4,6-Tetra-O-acetyl-β-D-galactopyranosyl ethanoic acid (3.6) 
The synthesis of 2,3,4,6-tetra-O-acetyl-β-D-galactopyranosyl ethanoic acid (3.6) was 
initiated by bromination of known per-acetylated galactose (3.1) using HBr/AcOH  to get 
c (3.2) in a stereoselective fashion by the formation of an oxonium intermediate followed 




from both α and β faces and leading to both anomers, the β anomer will get epimerized to 
the α anomer because of the lower energy of the α and β anomers (5 Kcal/mol).98 This is 
followed by Grignard reaction on the bromogalactose (3.2) to obtain 3-(tetra-O-acetyl--
D-galactopyranosyl)-1-propene (3.3) in a stereoselective fashion from α-bromo-2,3,4,6-
tetra-O-acetyl-galactose (3.2) using excess allyl magnesium bromide (10 eq) in SN2 
fashion followed by an aqueous workup and re-O-acetylation (Scheme 2). 
Concomitantly, C-2-allylated anhydro sugar (3.4) was also obtained as side product in 
21% yield. The formation of (3.4) presumably arises from a 1,2-epoxide intermediate, 
followed by the formation of a 2-keto intermediate through a 1,2-hydride shift, and then 
allylation (Scheme 3). The stereochemistry of 3.4, arising from a 2-keto intermediate has 
been unambiguously determined by X-Ray data.97  Upon standard ozonolysis reaction on 
C-allyl galactose (3.3) aldehyde (3.5) was obtained. Oxidation of aldehyde (3.5) using 
CrO3.H2SO4 in acetone (Jones oxidation) gave 2,3,4,6-tetra-O-acetyl-β-D-
galactopyranosyl ethanoic acid (3.6).  
 





Scheme 3. Proposed mechanism for the formation of impurity (3.4) 
3.1.3 Synthesis of L-propargylglycine methyl ester HCl. 
L-propargyl glycine methyl ester HCl synthesis is shown in scheme 32. 
3.1.4 Synthesis of C-galactopeptidomimetics 
Peptide coupling reaction is employed to couple the galactose acid (3.6) and amino acid 
with pre alkyne installed functionality (6.7) (Scheme.32) 99 to further build the 
pharmacophoric part. A series of coupling reagents were tried for peptide coupling 
including DCC (Dicyclohexylcarbodiimide), EDC.HCl (1-Ethyl-3-(3-dimethylamino 
propyl) carbodiimide hydrochloride) and DIPC (Diisopropylcarbodiimide) (Figure 14), 
but none of these traditional coupling reagents worked or produced the product with very 
poor yields. After this series of trials, the peptide coupling reaction finally worked well 
with the BOP reagent and DIPEA as a base in THF to obtain compound (3.7) (Scheme 4). 




compounds synthesized by employing the regio selective 1,3-dipolar cyclo addition 
reaction  (click chemistry) using CuSO4.5H2O as Cu (II) source, sodium ascorbate as 
reducing agent and various azides. The yields of click chemistry reactions were good to 
excellent. Thus a small library of triazole compounds (3.8-3.12) were synthesized. 
Deprotection of O-acetylated sugar was performed using NaOMe/MeOH (Dry) to methyl 
ester derivatives (3.13-3.17). Finally methyl ester hydrolysis using LiOH.H2O in the 
THF:H2O:MeOH (3:1:2) solvent mixture gave final compounds (3.18 - 3.22) in excellent 
yields (Scheme 5). 
 




The BOP coupling reaction is initiated by abstracting the proton on the acid by DIPEA, 
then the caboxylate anion attacks the electron deficient phosphonium ion of BOP reagent 
to initiate the peptide coupling mechanism by releasing benzotriazol-1-yl-oxide. Thus 
released benzotriazol-1-yl-oxide anion will attack carbonyl carbon to activate the 
carbonyl carbon for the amide bond formation by the amino acid. The mechanism of 
coupling in the presence of BOP is shown in scheme 5. 
 







Figure 14. Peptide coupling reagents 
3.1.5 The Huisgen 1,3-dipolar cycloaddition 
The Huisgen cycloaddition is the reaction of dipolarophile (alkyne) and 1,3-dipole 
compound (azide) under thermal conditions leading to the formation of 1,4 and 1,5 





Scheme 6. Huisgen 1,3-dipolar cycloaddition under thermal conditions 
 
Although Huisgen’s 1,3-dipolar cycloaddition is a powerful tool to construct 
biologically important triazole compounds using alkynes and azides, formation of both 
1,4 and 1,5-triazole regioisomers was the drawback of the reaction. In contrast to the 
Huisgen’s 1,3-dipolar cycloaddition, Click chemistry became very popular for it’s 
capacity to control the regioselectivity in 1,3-dipolar cyclo addition. Cu (I) is the key for 
the regioselectivity. A copper compound, for example CuSO4, exists in +2 oxidation 
state. The required Cu (I) is generated in situ adding a reducing agent like sodium 
ascorbate to reduce the Cu (II) species to Cu (I) via Cu (0) by comproportionation and 
disproportionation for the formation of Cu acetylide intermediate the champion of 




combination with amines like triethylamine (TEA) and diisopropylethylamine (DIPEA) 
used as reducing agent.  
 
Scheme 7. In situ generation of Cu (I) and copper acetylide formation 
 
The click chemistry catalytic cycle starts by the formation of copper acetylide formation 
via π-complex using Cu (I) species generated in situ as shown in Scheme 8. One of the 
ligands on the Cu (I) will be replaced by the alkyne. Click chemistry works without the 
need for ligands. However the presence of ligands will help in obtaining pure products 
without many impurities by preventing the Cu (I) interactions and leading to degradation 
and oxidation of Cu (I) to Cu (II). Thus obtained copper acetylide metal centre 
coordinates with the lone pair electrons on nitrogen of the azide to form a copper-azide-
acetylide complex formation by replacing one more ligand. This is the key step in the 




the metal coordination with the electron rich nitrogen of the azide. Metal coordination is 
the contrast to the Huisgen’s 1,3-dipolar cycloaddition under thermal conditions to obtain 
1,4 and 1,5 triazoles. In the next step the distal nitrogen attack the C-2 carbon of the 
acetylide to form a Cu (III) metallocycle, which undergoes ring contraction to form 
triazolyl copper derivative followed by protonation to complete the catalytic cycle. The 
source of proton being the hydrogen pulled off from the alkyne in the initial step of 
catalytic cycle. The catalyst ligand complex is regenerated for further reaction cycles100. 
 
Scheme 8. Stepwise click chemistry mechanism  
3.1.6 Catalytic Zemplén deacylation 
Deacetylation of compounds 3.8-3.12 were carried out under the Zemplen 
conditions (NaOMe/MeOH), emphasizing the use of sodium methoxide in methanol. 




abstracts the proton from methanol and regenerates the sodium methoxide to participate 
in the catalytic cycle. No further purification is necessary because the methoxide was 
neutralized using H+ resin. NaOCH3 is better over the NaOH because it is catalytic and 
with acetate protecting group the product is methylacetate which is volatile and can 
removed from the product easily up on evaporation (scheme 9). 
 
 
Scheme 9.  Catalytic Zemplén deacylation reaction mechanism  
3.2 Biological results 
All compounds and controls (lactose and galactose) were tested by inhibition of 
hemagglutination assay at a concentration of 1 µM of both galectins. Hemagglutination 
assays were performed using red blood cells, type O, fixed with 3% glutaraldehyde-
0.0025% NaN3 in PBS101,102 to confer both lectins equal relative affinities. Table 5 show 
inhibitory properties and relative activities of our derivatives toward Gal-1 and Gal-3. 
The inhibitory potencies varied from inactive to moderately active. Compound 3.17 is the 
best among the library with a IC50 of 2.5 mM (20 times better than galactose), indicating 
that the phenyl group close to the anomeric position increases the affinity toward Gal-3 
over, Gal-1; Methyl ester analogue 3.17 is more potent over its free acid analogue 3.22 




the analogue 3.22 it might become very hydrophilic with two open water soluble 
functionalities, which might hinder the penetration of the molecule through the cell 
membrane. Where as in the case of analogue 3.17 it is tightly balanced between 
hydrophobic and hydrophilic properties with open free sugar on one side and with closed 
amino acid on the other side. It is important to note that compound 3.17 is not only the 
most promising candidate against galectin-3, being less selective against Gal-1. Although 
compound 3.17 is 20 times more potent than the parent molecule galactose it is not a very 
potent molecule. Another reason for the above compounds being less efficient is in 
solution the assays the present work described involve inhibition of hemagglutination 
which are known to usually require higher concentrations of compound. Although 
compound 3.17 is not a very potent molecule it would be a good candidate for further 
















Table 5. Inhibitory properties and relative activity of compounds 3.14-3.23 against 






Galectin-1 Galectin-3 Galectin-1 Galectin-3 
Galactose 50 50 1 1 
Lactose 0.8 0.8 1 1 
3.13 >5 5 <10 10 
3.14 >5 >5 <10 <10 
3.15 5 5 10 10 
3.16 5 5 10 10 
3.17 5 2.5 10 20 
3.18 >5 >5 <10 <10 
3.19 >5 >5 <10 <10 
3.20 >5 >5 <10 <10 
3.21 >5 5 <10 10 
3.22 >5 >5 <10 <10 
 
3.3 Synthesis of 1st generation S-galactosides 
First generation S-galactosides synthesis was initiated from the α-bromo-2,3,4,6-
tetracetyl-galactose (3.2) by nucleophilic substitution reaction with thiourea to obtain the 
isothiouronium salt intermediate, which is hydrolyzed by potassiumpyrosulfate (K2S2O5) 
to obtain 2,3,4,6-tetra-O-acetyl-1-thio-β-D-galactose (3.23) in stereo selective fashion.103 
Stereo selectivity can be attributed to the acetate protecting group, which will block the 
-face completely by anchimeric assistance. Michael addition of thiogalactoside to the 




thiogalactoside (3.24). Diastereomers (3.25 and 3.26) were separated using column 
chromatography. Both the diasteromers were used to build the triazole pharmacophoric 
part using various azides employing the regio selective 1,3 dipolar cyclo addition reaction  
(click chemistry) using CuSO4.5H2O as Cu(II) source, and sodium ascorbate as reducing 
agent to generate Cu(I). Deprotection of final O-acetylated thio galactosides using 
NaOMe/MeOH (Dry) lead to the epimerization of newly formed chiral centre during 
Michael addition (Scheme 10). When de O-acetylation in acidic condition using 
HCl/MeOH as well epimerization took place. A neutral method using KCN/MeOH 
known to be very good for acid and base sensitive compounds104 was attempted but failed 
to deprotect the sugar without epimerization. The possible reason for the epimerization 
could be that the chiral centre being at  to carbonyl group is responding to nucleophile 





Scheme 10. Synthesis of 1st generation S-galactosides 
As discussed above hydrolysis conditions were very sensitive to the chiral centre that 
epimerized in every attempt made to deprotect the acetate protecting groups. To avoid 
this it was planned to change the protecting groups to benzyl as this protecting group can 
be deprotected using Pd/C under H2 pressure. There is a known limitation to the benzyl 
protecting group in that it is hard to deprotect when there is sulfur atom in the molecule. 




evidence that catalytic transfer hydrogenation can be used to cleave benzyl ethers in some 
compounds that contain sulfur, a poison for hydrogenolysis catalysts.105  
Thus we started the synthesis of benzyl ether protecting group version of 1st generation S-
galactosides with the protection of free hydroxyl groups of -methyl galactose (3.37) to 
obtain 2,3,4,6 tetra-O-benzyl--methyl galactose (3.38). Methyl galactose was subjected 
to demethylation using 1M H2SO4 and 80% acetic acid to liberate the free hydroxyl group 
and then convert into an acetate group (3.40), using Ac2O/Py. Having an acetate group 
installed in anomeric position, bromination is carried out using HBr/AcOH to get α- 
bromo-2,3,4,6-tetra-O-benzyl galactose (3.41) in a stereo selective fashion by the 
formation of an oxonium intermediate followed by nucleophilic attack by bromide, to 
have a better leaving group for nucleophilic substitution reaction by thiourea. However 
the benzyl protecting groups were removed by HBr/AcOH in a very unusual way at room 
temperature. The same reaction was carried out at -5-0oC found no or minimum 
deprotection of benzyl protecting group but some of anomeric acetate group hydrolysis 
was observed to get 2,3,4,6-tetra-O-benzyl galactose matching with the reference 
compound on TLC along the desired product bromo galactose (3.41).  Nucleophilic 
substitution reaction of thiourea on bromogalactose to obtain the isothiouronium salt 
followed by mild hydrolysis with potassium pyrosulfate in dichloromethane and water 
mixture at 40oC for about 15-20 min to obtain the mixture of  and β 2,3,4,6-tetra-O-
benzyl-1-thio-β-D-galactose (3.42) with the β isomer as the major product (Scheme 11). 




we acetylated the thiol to see the anomeric proton as a doublet to establish coupling 
constant. In the 1H NMR spectrum of -isomer (3.46) the coupling constant of H1 and 
H2 (J1,2) was found to be  5.22 Hz, as expected, H-1 proton of the -isomer (3.46) found 
to more deshielded (6.2δ) than the β-isomer (3.45)  and the -isomer (3.46) found to be 
less polar on the TLC compared to the β-isomer (3.45). For the β-isomer the coupling 
constant of H1 and H2 found to be 10.16 Hz which is larger in agreement with the 
theoretical value, unlike the -isomer H-1 of β-isomer is more shielded (5.13 δ) and more 
polar (Figure 15). 
 






Figure 15. 1H NMR spectrum showing the coupling constant and chemical shift 
differences of β and α anomers of 2,3,4,6-tetra-O-benzyl-1-thio-β-D-galactose 
 
      Michael addition of 2,3,4,6-tetra-O-benzyl-1-thio-β-D-galactose (3.43) on the maliemido 
propargyl glycine methyl ester HCl (Scheme 12) obtained S-galactoside (3.47) in a very good 
yield with a 50:50 diastereomeric mixture. Both the diastereomers were separated on column 
chromatography and we initially performed click chemistry as discussed above with only 
isopropyl azide to check the deprotection of benzyl protecting groups, before building the library 
of compounds. Hydrogenolysis of benzyl protecting groups were tried using transfer 




method did not work, even after adding the new fresh catalyst by filtering the old one after each 
reaction. All the reagents and conditions attempted are listed in the Table 6.  
 
 











     Having two methods failed in the deprotection of the S-galactosides, “PROTECTIVE 
GROUPS in ORAGNIC SYNTHESIS” by W. Green was searched for a protecting 
group that can be removed under mild neutral conditions. The chloroacetyl protecting 
group was chosen as it can bear all the reactions performed on this molecule and can be 
removed in aqueous pyridine at room temperature. To make sure that aqueous pyridine 
will not epimerize the S-galactoside, aqueous pyridine was added to compound 3.25 
prepared in Scheme 10 and stirred at room temperature for two days and analyzed by 
NMR,  which revealed that the stereochemistry was intact without any epimerization. The 




Michael addition on maleimidopropargyl glycine and follow above mentioned click 
chemistry and deprotection. Starting with the protection of the thiol functional group of 
2,3,4,6-tetra-O-acetyl-1-thio-β-D-galactose (3.23) with tert-Butyl(chloro)diphenylsilane and 
deprotection of acetate protecting groups with NaOMe/MeOH to obtain free sugar. 
Protection of the hydroxyl groups with chloroaceticanhydride/ pyridine and catalytic 
DMAP like classical acetylation reaction somehow this reaction did not work. 
Chloroacetylchloride in pyridine with catalytic DMAP was also attempted but this 
reaction also did not work (Scheme 13). So the self protection strategy of the thiol 
functional group was adapted (Scheme 14) by dimerization, protecting group exchange 
with chloroacetyl group and cleavage of the disulfide using classical disulfide 
reduction106 to obtain 2,3,4,6-tetra-O-chlorocetyl-1-thio-β-D-galactose (3.55). 2,3,4,6-
tetra-O-acetyl-1-thio-β-D-galactose (3.23) in presence of diethylazidodicarboxylate 
(DEAD) and catalytic amount of Hunig’s base dimerized in a quantitative yield.107 The 
dimer (3.56) was deprotected under Zemplén conditions to obtain free sugar (3.57) and 
protected with chloroacetyl group using the same conditions used in Scheme 13 to obtain 
(3.58). It is noteworthy that chloroacetylation worked well on galactose thiol dimer 
whereas it did not work in Scheme 13 in presence of TBDPSi protecting group on thiol. 
Unfortunately disulfide reduction was not successful employing 1) Dithiothritol (DTT) 2) 






Scheme 13. Synthesis of 2,3,4,6-tetra-O-chloroacetyl-1-thio-β-D-thiogalactose 
 
Scheme 14. Synthesis of 2,3,4,6-tetra-O-chloroacetyl-1-thio-β-D-thiogalactose using 
self protecting strategy 
3.4 Synthesis of S-galactosulfonamides 
The synthesis of S-galactosulfonamides was started by 1,4-addition of 2,3,4,6-tetra-O-
acetyl-1-thio--D-galactose (3.23) (Scheme 15) on vinylsulfonamides (6.26-630) using 




galactosulfonamides 3.59-3.63 in a good to excellent yields. Keeping the more potent 
biological results of methyl ester compounds of C-galactosides compared to the acid 
derivatives (Table 5) S-galactosulfonamides were also deprotected using NaOMe/MeOH 
(Dry) to afford the methyl ester derivatives (3.64-3.68). Finally methyl ester hydrolysis 
using LiOH.H2O in the THF:H2O:MeOH (3:1:2) solvent mixture at R.T in about 2 hrs 
gave final compounds (3.69-3.73) in excellent yields (70-90%) (Scheme 15).  
 
Scheme 15. Synthesis of S-Galactosulfonamides 
3.5 Synthesis of C-lactopeptidomimetics 
C-lactopeptidomimetics synthesis was initiated by protecting the lactose (3.74) with 
acetate protecting groups in a very classical way using acetic anhydride in pyridine to 
obtain lactose octaacettate (3.75) in an excellent yield. Bromination of lactose octaacetate 




described in Scheme 2. Grignard reaction on the bromolactose using excess allyl 
magnesium bromide followed by an aqueous workup and re-O-acetylation gave              
3-(2,3,4,6-tetra-O-acetyl-β-D-galactopyranosyl-(1→4)-2,3,6-tri-O-acetyl-β-D-glucopyrano 
syl)-1-propene (3.77)  obtained in a stereo selective fashion. Oxidative cleavage of β-C-
allyl lactose by RuCl3/NaIO4 in ACN:H2O mixture to 2,3,4,6-tetra-O-acetyl-β-D-
galactopyranosyl(1→4)-2,3,6-tri-O-acetyl-β-D-glucopyranosyl ethanoic acid (3.78) 
(Scheme 16) directly in a single step108 in contrast to scheme 2 where alkene is 
ozonolized to aldehyde and then oxidised to acid using the Jones reagent. Peptide 
coupling reaction between lactose acid and L-propragylglycine methyl ester 
hydrochloride 6.7 (scheme 32) using BOP (Benzotriazole-1-yl-oxy-tris-(dimethylamino)-
phosphonium hexafluorophosphate) peptide coupling reagent was performed to get N-
(methyl propargyl-L-glycine)1’-(2,3,4,6-tetra-O-acetyl-β-D-galactopyranosyl(1→4)-2,3,6-
tri-O-acetyl-β-D-glucopyranosyl)-acetamide (3.79). The triazole pharmacophoric part was 
built using regio selective 1,3 dipolar cyclo addition reaction (click chemistry) with 
CuSO4.5H2O as Cu(II) source and sodium ascorbate as reducing agent to obtain a library 
of compounds (3.80-3.86) O-acetyl deprotection carried out using Zemplén deacetylation 
(catalytic NaOMe/DryMeOH) followed by work-up by adding H+ resin, to obtain methyl 
ester derivatives (3.87-3.92). Finally methyl ester hydrolysis was performed using 
LiOH.H2O in the THF:H2O:MeOH (3:1:2) solvent mixture gave final compounds (3.93-











Scheme 17. Synthesis of triazole derivatives of C-lactopeptidomimetics 
3.6 Synthesis of S-lactosulfonamides 
S-lactosulfonamides synthesis was initiated by nucleophilic substitution reaction 
with thiourea on the bromolactose (3.76) to obtain the isothiouronium salt intermediate, 




1-thio-β-D-galactopyranosyl(1→4)-2,3,6-tri-O-acetyl-β-D-glucopyranoside (3.101) in a 
stereoselective fashion in the same way explained for the galactose thiol chemistry shown 
in Scheme 10. 1,4-addition of β-lactose thiol on the vinyl sulfonamide 6.15 (scheme 36), 
resulted in the β-lactose vinyl sulfonamide (3.102) in a decent yield. With an alkyne 
functionality installed “click chemistry” was performed on lactose sulfonamide using 
THF:H2O (3:1) and t-BuOH:H2O (3:1) mixed solvent system conditions, although 
reaction is moving forward to some extent towards triazole formation, it is not going to 
completion of reaction (about 25% starting material left un reacted) and TLC of the 
reaction mixture shows many side products, which is very unusual behavior of click 
chemistry. Usually when analyzing click chemistry reactions by TLC the only major 
product is observed with one or two other faint spot visualized on the plate. Having 
observed an incomplete reaction and numerous impurities formed in the above solvent 
system and reagents, non aqueous (dry) conditions were adopted for “click chemistry” by 
performing reaction in dry DCM using CuI as Cu(I) source and DIPEA. Under these 
conditions the reaction was observed to proceed to completion, with reduced impurities 
formed to produce the triazole library (3.103-3.110) in good yield. The O-acetylated S-
lactosulfonamides were deprotected using NaOMe/MeOH (Dry) to produce methyl ester 
derivatives (3.111-3.118). Finally methyl ester hydrolysis using LiOH.H2O in the 
THF:H2O:MeOH (3:1:2) solvent mixture at R.T in about 2 hrs gave final compounds 









3.7 Synthesis of Lac NAc triazoles 
The disaccharide LacNAc triazole has a β (1→4) glycosidic link between 
galactose and glucose which is the key step in the synthesis of LacNAc triazole 
disaccharide. The β (1→4) glycosidic link can be achieved by glycosylation reaction 
between two building blocks 1) Galactose moiety as a donor (trichloroacetamidate) 
which can be synthesized from per-acetylated galactose by selectively deprotecting the 
anomeric acetate. 2) N-acetyl glucosamine acceptor, although there are many ways and 
methods of glycosylation there are issues with reactivity of the secondary hydroxyl group 
at C-4 of a hexapyranose with a 1C4 conformation rendering it particularly unreactive 
when the remaining hydroxyl groups are acetylated. However there is one regioselective 
open glycosylation method with more than one hydroxyl groups free.109 Acetyl protecting 
groups would be appropriate keeping the stereochemistry requirements on glucose 
acceptor. The β-O-propargyl configuration can be achieved by anchimeric assistance 
during the glycosidation reaction by propargyl alcohol. For the galactose donor the acetyl 
protecting group is also appropriate in terms of selective deprotection of anomeric acetate 
and the formaton of trichloroacetamidate, although DBU needs to be used to block the  β-
face to obtain the α-configuration exclusively, instead of using two differerent protecting 





Scheme 19. Retrosynthetic analysis of LacNAc triazole disaccharide 
3.7.1 Synthesis of O-(2,3,4,6-tetra-O-acetyl-D-galactopyraranosyl)-
trichloroacetamidate donor 
According to the retrosynthetic analysis described in Scheme 19, D-
galactopyranoside donor synthesis begins with a classical acetylation reaction under basic 
conditions, in the presence of acetic anhydride, pyridine and DMAP as a catalyst (method 
of Behrend).110 The acetylation is quasi-quantitative, producing the penta-acetylated 
product 3.130 from D-galactopyranose (3.129) as a mixture of anomers. At room 
temperature, the thermodynamic effect is dominant and the anomeric effect is also 
responsible for the majority of the  product. However this mixture of anomers is 
generally not a problem for the following stages of the synthesis. Selective deprotection 




hydrazine acetate in the DMF to obtain hemiacetal (3.131).111,112 The selectivity of the 
reagent for the anomeric acetate is explained by its biggest sensitivity towards a 
nucleophilic attack on the anomeric position relative to the other other positions. The last 
step is to convert the anomeric alcohol into trichloroacetimidate in dichloromethane by 
using the trichloroacetonitrile in the presence of DBU.  
 
Scheme 20. Synthesis of D-galactoside trichloroacetamidate donor 
3.7.2 Synthesis of D-GlcNAc acceptor 
 As illustrated in the Scheme 21, acceptor 3.136 can be synthesized in a 
stereoselective fashion from β-D-glucopyranoside 3.133. This final product can be 
obtained by synergy between anomeric and anchimeric effects. Anchimeric assistance 
explains the role of the participating functional group on the position 2. After activation 
by a Lewis acid and intramolecular elimination of acetic acid, a free lone pair of electrons 




the anomeric position during the transition state oxonium to form an oxocarbenium. 
Consequently the acetoxycarbenium undergoes nucleophilic attack during the 
glycosidation (glycosydation is the installation of an aglycone) by propargyl alcohol. 
Since one of the faces assisted by the position 2, the nucleophilic attack will take place 
only on the β side, because of steric hinderance. This phenomenon of anchimeric 
participation influences the result of a glycosylation towards the preferred β configuration 
(Scheme 22). This step is followed by removal of the acetate groups under Zemplén 
conditions to liberate the hydroxyl groups. The 6-OH group is then regioselectively 
protected using 1 equivalent of tert-butyldiphenylsilyl chloride to prepare acceptor 3.136. 
 






Scheme 22. Anchimeric assistance during the glycosidation  
3.7.3 Regiospecific glycosylation towards the synthesis of N-acetyllactosamine  
An efficient regiospecific glycosylation between donor trichloroacetamidate 3.132 
and acceptor 3.136 which is bearing two free hydroxyl groups as acceptors using 
BF3.Et2O as a promoter to obtain β (1→4) linked disaccharide (3.137) was attempted.  The 
secondary hydroxyl group at C-4 of a hexapyranose with a 1C4 conformation was 
particularly unreactive when the remaining hydroxyl groups were acetylated.113 However 
the unreactivity problem was improved by protecting the hydroxyl functionalties as 
benzyl groups compared to its acyl counterparts under similar glycosilation conditions.114 
However this procedure involves tedious multiple protection and deprotection steps. To 
overcome such drawbacks a new strategy has been developed to use lightly protected 
acceptors that has hydroxyl group unprotected, especially near the glycosylation site. 
This open glycosylation in which one hydroxyl group preferentially glycosilated in the 




as 6-O-benzyl or 6-O-pivaloyl and 6-O-tert-butyldiphenylsilyl on the 6-OH group.115,116  
Regioselectivity is attributed to the bulky 6-O-tert-butyldiphenylsilyl group. The very 
bulky protecting group could cover the top side (3, 5-cis) of OH-3 of the acceptor and 
block the approach of the glycosyl donor.109 With an alkyne functionality installed on key 
intermediate (3.137) using regiospecific glycosylation, a library of compounds was 
synthesized by employing the regioselective 1,3 dipolar cyclo addition reaction  (click 
chemistry) using CuSO4.5H2O as Cu(II) source, sodium ascorbate as reducing agent and 
various azides to obtain triazole products 3.138 - 3.145. The yields of click chemistry 
reactions were good to excellent. Followed by deprotection of 6-O-tert-butyldiphenylsilyl 
group and acyl groups using TBAF and NaOMe respectively to obtain final compounds 
3.146 - 3.153 in excellent yields (Scheme 23). Residual TBAF was always left in the final 
product and appeared in the NMR spectrums, resulting in isolation of the final products 
as an oil. Even column chromatography was not able to separate the residual TBAF from 

















Camptothecin Anti-cancer pro-drug using galactoside war-head for cell 
delivery 
4.1 Introduction 
Camptothecin, a pentacyclic alkaloid with a novel ring system isolated from 
Camptotheca acuminata (Nyssaceae) stem wood by Wall and co-workers, has shown to 
have an anti tumor activity against the mouse leukemia L1210 system.117 The compound 
has a pentacyclic ring system with an asymmetric center in ring E with a configuration of 
S at C20. The pentacyclic ring system includes a pyrrolo [3, 4-b] quinoline moiety (rings 
A, B, and C), a conjugated pyridine (ring D), and a six-membered lactone (ring E) with 
an R-hydroxyl group. Isolated natural camptothecin itself is not water soluble for 
biological tests, therefore water soluble sodium carboxylate salt was used in clinical 
trials. However this salt was devoid of anticancer activity and produced severe toxicity.  
Insolubility, instability and toxicity led to the discontinuation of phase II clinical trials. 
However camptothecin’s efficacy to inhibit the topoisomerase I118,119,120 revived interest 
in comptothecin. Ever since camptothecin found to be a topoisomerase I inhibitor, 
different groups tried to minimise the drawbacks of camptothecin insolubility, instability 
and toxicity. The sodium carboxylate salt of camptothecin exhibited 1/10th the potency of 
camptothecin, which suggests that the E ring lactone is crucial for the potency of 
camptothecin. Camptothecin is modified on rings A and B to prepare Topotecan and 




lactone ring stability, esters were prepared in an analogous manner.121 β-cyclodextrin 
camptothecin conjugates were found to be superior tumor growth inhibitors over the 
parent camptothecin, and it was observed that a short course of treatment with the 
polymer conjugates gives long-term control of tumor growth that does not occur with 
either CPT or irinotecan because of controlled release of camptothecin.122 A folate 
mediated camptothecin prodrug was synthesized using a hydrophilic peptide spacer 
linked to folate via a releasable disulfide carbonate linker. The conjugate was found to 
possess high affinity for folate receptor-expressing cells with 10 nM inhibition against 
human KB cells.123 Water-soluble poly-(L-glutamic acid)-Gly-camptothecin conjugates 
enhance camptothecin stability and efficacy in vivo.124 Acoustically active nanoemulsions 
for camptothecin encapsulation were used to circumvent the parent camptothecin 
problems with nanoemulsions prepared using liquid perfluorocarbons and coconut oil. 
Ultrasound was effective on the droplets, thus releasing the bioactive drug at specific 
sites.125 New prodrugs of CPT were synthesized, based on a carbamate linkage between 
the 20-hydroxy group of CPT and a linker designed to be enzymatically removed by 
either Penicillin-G-Amidase or catalytic antibody 38C2. Cell growth inhibition assays 
showed an up-to-2250-fold difference in toxicity between the prodrugs and the active 
drug and a significant increase in toxicity was also observed.126 Polyester-drug graft 
copolymer conjugates were made by click cycloaddition of azide-functionalized 
camptothecin derivatives with alkyne-functionalized aliphatic polyesters. Further grafting 




soluble polyester-camptothecin conjugate. Control over PEGylation and drug loading, 
inherent to the graft copolymer design, opens versatile routes to new materials with 
potential utility in polymer therapeutics.127 
 
Figure 16. Commercial camptothecin analogs 
In our strategy to address the limited bioavailability128,129,130 and to improve the 
pharmacokinetic properties of the parent drug, an ester at the C-20-OH group was 
introduced using a hydrolytically stable C-galactoside residue. This modification can also 
increase the steric hindrance around the carbonyl group of the E-ring, thus eliminating the 
intramolecular hydrogen bonding and, consequently increase the key lactone ring 
stability in vivo which is a key feature of camptothecin to be potent. The choice for the 
galactoside is based on the observation that cancer cells over-express a family of 






Figure 17.  Strategic representation of camptothecin prodrug 
4.2 Retrosynthetic analysis of Camptothecin prodrug 
The above proposed galactoside prodrug of camptothecin was envisioned to connect an 
unprotected galactoside synthon with a camptothecin azide using regio selective 1,3 
dipolar cyclo addition reaction (click chemistry) to obtain the final compound to avoid 
camptothecin ester hydrolysis during deprotection of final compound. Aqueous solvent 
conditions of click chemistry (THF:H2O 3:1) are very much in favor of dissolving the 
unprotected galactoside and camptothecin azide. The Camptothecin azide can be 
constructed using an esterification reaction between 6-azidohexanoic acid and 
camptothecin.129 6-azidohexanoic acid can be synthesized from 6-bromohexanoic acid by 






Scheme 24. Retrosynthetic analysis of galactoside camptothecin prodrug 
4.2.1 Camptothecin azide 
Camptothecin azide was initiated by preparation of 6-azidohexanoic acid (4.2) 
from 6-bromohexanoic acid (4.1) using sodium azide in DMF:H2O (1:1) mixture, 
employing a nucleophilic substitution reaction. The 6-azidohexanoic acid then undergoes 
an esterification reaction at the C-20-OH of camptothecin to give the camptothecin azide 
(4.3). To couple the 6-azidohexanoic azide with camptothecin at the C-20-OH group, a 
number of various conditions were attempted (Entry 1) (Table 7) but did not work even 




the anhydride of 6-azidohexanoic acid in pyridine with a catalytic amount of pyridine 
was not successful either. Sc(OTf)3 was investigated to activate the alcohol of 
camptothecin as shown in entry 3131 at room temperature, however the Camptothecin did 
not solubilize. Finally, with higher temperatures shown in Entry 4 (Table 7) the 
esterification proceeded (Scheme 25). 







Scheme 25. Synthesis of camptothecin azide 
4.2.2 Synthesis of camptothecin prodrug 
Having galactoside (4.4) with the alkyne functionality installed and deprotected, 
the copper catalyzed 1,3 dipolar cycloaddition (click chemistry) was carried out using 
CuSO4.5H2O as a Cu(II) source and sodium ascorbate as a reducing agent with 
camptothecin azide  to obtain the final camptothecin prodrug (4.5). Unfortunately the 
click chemistry did not work for unknown reasons although all the reagents and reactants 
were dissolved in the solvent system chosen. Having trouble with the click chemistry 
using unprotected galactoside, the protected galactoside was used instead to successfully 
obtain the galactoside protected camptothecin prodrug under the same conditions as 
above in 75% yield. The final challenge involved deprotection of the acetate groups in 
the presence of the ester linkage between camptothecin and galactoside. In a few trials 




ester (stable under neutral and basic conditions) of camptothecin the acetates groups were 
successfully deprotected to obtain the camptothecin anticancer prodrug 4.5 (Scheme 26).  
 
















Diastereoselective 1, 4 - addition on C-allyl galactose using Evan’s chiral 
auxiliary 
5.1 Introduction 
In recent years glycosides have become very popular in medicinal chemistry 
research for their specificity and efficacy to modulate the activity of various proteins 
involved in disease states. O-linked glycosylation is the classical approach for building a 
pharmacophore on the glycosides because of the convenience of well established 
glycosylation methodology. Although it is very convenient and easy to build 
pharmacophores on a sugar molecule using O-glycosylation, the resulting molecules are 
very susceptible for in vivo degradation, rendering them biologically inactive. This basic 
problem of in vivo stability stops them from being developed further into potent 
commercial drugs. With a special emphasis on galectins and their biological roles from 
cell transformation to metastasis as described in the Introduction, it is very critical to 
build hydrolytically stable galactosides with a stereo specific pharmacophores on the 





Figure 18. Hydrophobic binding pocket extended towards reducing end in galectin-3 
X-ray crystal structure 
C-Allyl-β-D-galactose is one potential galactoside that can serve as platform to 
build pharmacophores on the reducing end. To install the pharmacophores in a 
diastereoslective fashion we have envisioned a way to obtain a diastereoselective 1,4 
addition using the Evans chiral auxiliary.  
5.2 Synthesis 
β-C-allyl galactose was proected with benzyl groups to allow for Grignard 
reagents to be used in 1,4 additions. Thus synthesis started with the protection of free 
hydroxyl groups of -methyl galactose to obtain 2,3,4,6-tetra-O-benzyl--methyl 
galactose (5.2). Methyl galactose was subjected to demethylation using 1M H2SO4 and 




group, by acylaion in a classical way using Ac2O/Py. Having the acetate group installed 
at the anomeric position133, bromination is carried out using HBr/AcOH to get α- bromo-
2,3,4,6-tetrabenzyl-galactose (5.5) in a stereoselective fashion by the formation of an 
oxonium intermediate followed by nucleophilic attack by bromide. However the benzyl 
protecting groups were removed by HBr/AcOH in a very unusual way at room 
temperature. Although benzyl groups were tolerated at lower temperature as described in 
scheme 11 the yield was considerably low.  
 
Scheme 27. Synthesis of 3-(Tetra-O-benzyl--D-galactopyranosyl)-1-propene 
The final steps of the synthesis of 3-(Tetra-O-benzyl--D-galactopyranosyl)-1-propene (5.6) 
(Scheme 27) required alteration due to the unusual deprotection of benzyl protecting 
groups by HBr/AcOH. In a revised approach 2,3,4,6-tetra-O-benzyl galactose (5.3) was 
transformed into 2,3,4,6-tetra-O-benzyl--chlorogalactose (5.7) using oxalylchloride in 
dichloromethane. A Grignard reaction was carried out on compound 5.7 using allyl 
magnesium bromide to obtain selectively the β anomer in SN2 fashion to obtain 3-(Tetra-




expected to be far better on benzylated starting material than the acetylated version as the 
acetyl protecting groups were removed by the by Grignard reagent and 1,2 hydride shift 
leading to C-2-allylated anhydro sugar (3.4) in 21% yield (Scheme 3). Modest yields for 
the Grignard reaction on 2,3,4,6-tetra-O-benzyl--chloro galactose (5.7) can be attributed 
to poor leaving ability of chloro group compared to bromo group. Then the C-allyl 
galactose was subjected to olefin cross metathesis with  N-acryloyl-(S)-4-benzyl-2-
oxazolidinone (5.15) and N-acryloyl-(S)-4-isopropyl-2-oxazolidinone (5.12) using 
Grubb’s 2nd generation catalyst to obtain 5.8 and 5.9 in modest yields (scheme 28). 
 
 
Scheme 28.Synthesis of isopropyl and benzyl oxazolidinone bearing C-allyl 
galactoside 
The chiral auxiliaries N-acryloyl (S)-4-benzyl-2-oxazolidinone (5.15) and N-acryloyl (S)-
4-isopropyl-2-oxazolidinone (5.12) were synthesized from (S)-4-benzyl-2-oxazolidinone 




propionyl chloride  to obtain N-3-bromopropionyl oxazolidinones (5.11 and 5.14)  
followed by triethylamine induced elimination of HBr gave final compounds (5.12) and 
(5.15)  in very good yields (Scheme 29). Attempts to use triethylamine as base to couple 
3-bromopropionyl chloride and insitu dehydrobromination failed to deliver the final 
product. Triethylamine failed to abstract the NH proton of oxazolidinone due to the 
higher pKa value (20.5) of NH proton on the oxazolidinone.135 
 
Scheme 29. Synthesis of N-acryloyl isopropyl and benzyl oxazolidinones 
5.2.1 Primary Screening of chiral auxiliaries 
The above prepared C-galactoside with isopropyloxazolidinone (5.9) was 
examined for the efficacy of the chiral auxiliary to control diastereoselective 1,4-addition 
using simple thioacetic acid, to obtain a thioacetate compound (Scheme 30). Thioacetate 
was chosen for the primary testing considering that the diastereotopic protons of an 
acetate group will show up as a singlet and the peaks would be resolved by 1H-NMR to 




corresponding to two diastereomers. As postulated on C-galactoside (5.9) 1, 4 addition of 
thioacetic acid in presence of triethylamine proceeded with good yields, with almost no 
selectivity (ds 60:40) (Figure 19).  Then keeping the bulky benzyl group (S)-4-benzyl-2-
oxazolidinone (5.15) in view another C-galactoside was synthesized with (S)-4-benzyl-2-
oxazolidinone (5.8) as a chiral auxiliary and performed the 1,4-addition using the 
thioacetic acid under similar conditions as above. Diastereoselectivity is modestly 
improved showing the influence of bulky benzyl group (Table 8). Although the benzyl 
group of oxazolidinone is completely blocking one of the faces to the nucleophile (Figure 
20), the selectivity was not up to the expectations. The poor selectivity could be due to 
rotation of the chiral auxiliary around the single bond between carbonyl carbon and 
nitrogen atom of oxazolidinone in solution as shown in the Figure 20. 
 
 








Table 8. Diastereoselectivity 
 
 







Figure 20. Possible rotation of chiral auxiliary 
5.3 Diastereoselective 1,4-addition with chelation control 
The diastereoselectivity was not optimum in the primary screening of the chiral 
auxiliaries using 1,4-addition of thioacetic acid, for the most probable reason of rotation 
of the chiral auxiliary. To enhance diastereoselectivity it is important to avoid the rotation 
of the chiral auxiliary of the amide bond and to keep the auxiliary in such a position to 
direct the nucleophile completely to one face by blocking the opposite face approach.  It 
was decided to use chelation control employing a Grignard reagent to create an enolate 
intermediate in which a metal coordinates both the oxygens of the oxazolidinone 
carbonyl and the acryloyl carbonyl like locking with two hands to increase the 
conformation population (Figure 21)136. Initial attempts of 1,4-addition on galactoside 
(5.9) using EtMgBr, CuBr.DMS in THF at  -78oC revealed that the reaction was 
completed in 1 hr with little side product in a 77% yield. Initially the ratio was 
approximately determined by integrating the newly generated stereogenic centre proton 
(Figure 22), since this proton couples with six protons on the adjacent carbons it was 
difficult to determine the ratio of diastereomers exactly obtained in 1,4-addition. To 
establish the exact ratio of diastereomers without any ambiguity a HPLC technique was 




be the isopropyl handle on the chiral auxiliary is not covering one face completely. The 
same reaction was then attempted under the same conditions with the galactoside having 
a benzyloxazolidinone chiral auxiliary (5.8). The reaction worked well with 85% yield 
and with very good stereo control. The diastereomeric ratio was unambiguously 
determined by 1H NMR (Figure 22) and HPLC (Figure 24) to be 97:3. HPLC and NMR 
spectrums were recorded on the crude product to avoid any diastereomer separation on 
flash column chromatography.  
 
 













Table 9. Optimization of chiral auxiliaries 
 
 





Figure 23.Quantification of diastereoselectivity using HPLC on 
isopropyloxazilidinone chiral auxiliary 
 
Figure 24. Quantification of diastereoselectivity using HPLC analysis on 





Design of selective ligands for conjugate drug targeting to human serum 
albumin (HSA) through cysteine-34 
6.1 Introduction 
Peptides are well known for recognizing and activating specific receptors within 
the body. Peptidase enzyme quickly intercepts and cleaves the peptides, transforming 
them in to biologically inactive fragments that are further cleared by the kidneys. As a 
consequence peptides have a short half-life typically less than 5 min. This brief duration 
of activity, exclude them from being developed into commercialized drugs. The objective 
of the project is to design a way to circumvent the bioavailability and transportation 
issues of the peptide based drugs. Human serum albumin (HSA) is monomeric protein of 
585 residues having a molecular weight of 66,449 Da. It is the chief circulating protein in 
the blood stream with an approximate concentration of 35 -50 mg/ml.137 It has three 
structurally similar - helical domains I-III which are further divided in to sub domains A 
and B.138 It possesses a unique free thiol residue at cysteine-34139 (Figure 25) which is 
used as a platform technology that involves in vivo drug conjugation through maleimdo-
drug conjugation. It is known that HSA accumulates in tumor tissues140,141  due to an 
enhanced vascular permeability of tumor blood vessels for circulating macromolecules 
combined with a lack of lymphatic drainage in the tumor tissue.142 Under normal 
physiological conditions, oleates and palmitates account for almost 70% of free fatty acid 




acid levels increases dramatically. Under those conditions HSA undergoes favorable 
conformational change (allosteric) in drug binding sites I and II. Indeed this drug binding 
mechanism is now being exploited as an alternative targeting strategy whereby hybrid 
molecules such as Ibuprofen-anti-sense nucleotide conjugates are used for cancer 
therapy.143 
The drug binding site in domain II is found at a distance of 32.5 Å from cysteine-
34 buried in domain I, while it is 25.5 Å away from Trp-214 also found in domain II.143 
Additionally, fluorescence emission spectra of acrylodan, a cysteine-specific fluorescence 
probe, have been used to study the microenvironment surrounding Cysteine -34 following 
exposure to oleate and ionic quenchers. The study also clearly revealed that there were 
electrostatic attractive forces involved, thus demonstrating that upon binding to 
hydrophobic residues, the cysteine-34 site becomes more accessible and that it is 
surrounded by charged amino acids.144 These observations were further substantiated by 
the increased binding of thiol-containing drugs in the presence of fatty acids. 
The above information point towards the feasibility of modulating the reactivity 
of Cys-34 in the presence of fatty acids by a favourable conformational change 
(allosteric). The DAC (Drug Affinity Complex) strategy can be further improved by 
having a thiol-reactive species, such as maleimido derivatives, vinyl sulphonamides and 
acrylamides   possessing charged amino acids in their vicinity. We designed and 
synthesized linkers (maleimide, vinyl sulphonamide and acrylamide Figure 27) with 




functionality on the other side to couple peptide based drugs and to install a better 
triazole derivative functionality (Figure 26). It is known that conjugated peptides have 
greater in vivo stability.145,146 By conjugating the peptide based drugs to HSA trough the 
above ligands (Figure 27) it is possible to circumvent the degradation problems presented 
at the beginning. The relative reactivities of thiol reacting species were tested using 
simple model thiol (Cysteine) under physiological conditions, Maleimido derivatives 
were found to be the fastest reacting Michael acceptor (less than 10 min), followed by 
vinylsulfonamide  reacting completely in 45 min.  Whereas acrylamide functionality did 
not react at all under physiological conditions, in the later case the pH had to be raised to 
8.5 for reaction to occur. Three ligands are under further evaluation by reacting with HSA 
to be in real physiological conditions using HPLC (kinetic data), and MS-FAB 
characterization to assess their reactivity. This concept can be applied to other drugs that 
need to be delivered to a cancer site either by coupling to a carboxylic acid through a 





Figure 25. Free thiol residue at cysteine-34 in human serum albumin crystal 









Figure 27. Linkers designed for conjugate drug targeting to Human Serum Albumin 
(HSA) 
6.2 Synthesis of L-propargyl glycine (L-Pra) 
L-Propargyl glycine is synthesized stereoselectively starting with the 
condensation of the sodium salt of diethylacetamidomalonate and propargyl bromide to 
obtain propargyl diethyl acetamido propargyl malonate (6.2). This compound was 
converted to monoethyl acetamidopropargylglycine (6.3) by hydrolysis of one of the 
ethyl esters selectively using 1 eq base. This was followed by β-keto decarboxylation by 
the formation cyclic transition state to protonate carbonyl functionality with O-H and C-C 
vleavage to release CO2 and formation of π bond to obtain an enol ether (Scheme 33) 
which will quickly rearrange to form D,L-N-acetyl-propargylglycine (6.4). Finally L-
propargylglycine (6.6) was obtained by ethyl ester hydrolysis and stereospecific 
hydrolysis of the acetamide group using porcine kidney acylase147. L-propargyl glycine is 





Scheme 32. Synthesis of L-propargyl glycine 
 
 
Scheme 33. β-Ketoacid decarboxylation mechanism 
6.3 Synthesis of D, L-propargyl glycine 
 
It is important to prove that the purity of L-propargyl glycine obtained by stereospecific 




introduce another chiral centre to create the diastereotopic protons. To compare the purity 
experiments of L-propargyl glycine it was planned to synthesize the D,L-propargyl 
glycine. To prepare D,L-propargyl glycine it is necessary to hydrolyze the acetamide 
bond of 6.4 which requires very harsh conditions such as refluxing in HCl solution148. 
Hence a much smoother route was chosen by activating the amide by introducing the Boc 
group prior to hydrolysis to obtain (6.8)149. Selective hydrolysis of the amide using 
hydrazine in acetonitrile leaves N-Boc-protected D,L-propargyl glycine ethyl ester 
(6.9)150. Transesterification reaction using NaOMe on (6.9) gave N-Boc-protected D,L-
propargyl glycine ethyl ester (6.10). Finally N-Boc-protecting group was successfully 
deprotected using trifluoroacetic acid at room temperature in an excellent yield. 
 
 





6.4 Purity of the L-propargyl glycine. 
D and L-propargyl glycines are enantiomers, having the same physical and 
chemical properties, they are indistinguishable using NMR. In order to distinguish both 
enantiomers another chiral centre must be introduced such as preparation of a derivative 
using Mosher’s acid chloride to make the protons diastereotopic. Since the 
diasteroisomers are chemically and physically distinguishable they are separable and 
measurable using 1H NMR. To establish the purity of the L-propargyl glycine obtained 
from enzymatic hydrolysis of acetamide, the Mosher amides 6.12 and 6.13 of L-
propargyl glycine and D,L-propargyl glycine were synthesized to compare (Scheme 35).  
 
Scheme 35. Synthesis of Mosher amides of L-Propargyl glycine and D, L- Propargyl 
glycine 
As expected the 1H NMR specrtum of Mosher amide of L-propargyl glycine has 
one set of peaks representing the presence of single isomer (L-propargyl glycine). The 
Mosher amide of D, L-propargyl glycine clearly showed two sets of peaks representing 





Figure 28. 1H NMR of Mosher amide of L-propargyl glycine and D,L-propargyl 
glycine. 
6.5 Synthesis of linkers 
As mentioned in the introduction potential peptide drug candidates will be 
conjugated to HSA through linkers. Basically the linkers possess a thiol reacting group, 
and a carboxylic acid group to couple with potential peptide drug candidates. Another 
functionality on the linker is an alkyne group to attain a hydrophobic residue to modulate 
the kinetics of conjugation. The latter two steps (peptide coupling and click chemistry) 




conjugation of peptide through the linker to HSA is the most important step in which 
conjuagtion must complete quickly at physiological conditions before the peptide is 
degraded by peptidase. Hence three types of linkers with a thiol reacting Micheal 
acceptor were designed and synthesized namely 1) acrylamide 2) vinyl sulfonamide 3) 
Maleimide. Acrylamide is synthesized from L-proargyl glycine methyl ester HCl 6.7 and 
acryloyl chloride in presence of base. Vinylsulfonamide is synthesized by reacting L-
proargyl glycine methyl ester HCl 6.7 with 2-bromo ethanesulfonyl chloride using 3 eq of 
base. Maleimide is synthesized by an addition reaction between L-proargyl glycine 
methyl ester HCl 6.7 (Scheme 36) and maleic anhydride followed by a peptide coupling 














Scheme 37. Peptide coupling mechanism using DCC coupling reagent and N-
Hydroxysuccinimide. 
6.6 Reactivity 
Having synthesized three kinds of linkers, the linkers were screened primarily to 
their reactivity towards simple thiol i.e. cysteine in physiological pH conditions, to have 
an approximate idea about their thiophilicity. In three round bottom flasks, the three 
linkers and cysteine (excess) were dissolved in phosphate buffer (pH 7.5) stirred and 
monitored by TLC at 10 min intervals. The maleimide linker was found to be the fastest 
linker by completely reacting with cysteine in under 10 min. Vinyl sulfonamide was 
found to be the second fastest reacting linker undergoing complete reaction in 45 min. 
The acryl amide did not react at all under physiological pH, and it was necessary to raise 




 The two linkers underwent further evaluation by reacting with HSA under 
physiological conditions using HPLC (kinetic data) and MS-FAB characterization to 
monitor their reactivity with HSA with internal standards. The above concept can be 
applied to other drugs that need to be delivered to cancer sites either by coupling to the 
carboxylic acid through a peptide linkage or using click chemistry on the alkyne 
functionality using azide. 
 
Scheme 38. Differential reactivity of linkers with model thiol 
6.6.1 Triazole Analogs to better fit in HSA  
The study also clearly revealed that there were electrostatic attractive forces 




site becomes more accessible and that it is surrounded by charged amino acids.144  A 
molecular model with maleimide in the binding pocket also showed a hydrophobic 
pocket (Figure 29). Using the third hetero alkyne functionality a small library of triazole 
derivatives (6.21-6.30) of maleimide and vinyl sulfonamides were prepared. Different 
azides with different length and size were used to build triazole library of compounds 
using the regio selective 1,3 dipolar cycloaddition reaction. Once the underivatized 
linkers (Figure 27) are studied for their kinetics of conjugation using human serum 
albumin (HSA), this library of compounds (Scheme 39) will be evaluated for the 
competitive conjugation against simple linkers. 
 
























1.      Triazole pharmacophores bearing C-galactopeptidomimetics were successfully 
synthesized using Grignard reaction, peptide coupling reaction and regio selective 1,3 
dipolar cyclo addition reaction (click chemistry). All compounds and controls (lactose 
and galactose) were tested by inhibition of hemagglutination assay at a concentration 
of 1 µM of both galectins. Compound 3.17 is the best among the library with a IC50 of 
2.5 mM (20 times better than galactose), indicating that the phenyl group close to the 
anomeric position increases the affinity towards Galectin-3 over Galectin-1. Methyl 
ester compound 3.17 found to be more potent than the free acid compound 3.22 
perhaps due to balanced log P values. However this molecule needs to be further 
developed for better potency. 
2.      Synthesis of 1st generation S-galactosides using various protecting groups 
including acetyl, benzyl, and chloroacetyl were unsuccessful in keeping the chiral 
centre intact on the maleimido ring. α and β isomers of benzylated galactose thiol 
were isolated and the stereochemistry established using coupling constants of H1 and 
H2 of their acetylated derivatives. 
3.      S-galactosulfonamides using Michael addition of thiogalactoside on triazole 
derivatives of vinyl sulphonamides was successfully synthesized. This library of 




4.       C-lactopeptidomimetics with a similar pharmacophores to C-
galactopeptidomimetics were successfully synthesized to compare the disaccharide 
effect. In this scheme in contrast to C-galactopeptidomimetics lactose acid was 
generated directly from C-allyl lactose using NaIO4 instead of ozonolysis followed by 
oxidation to acid. These C-lactopeptidomimetics are under biological tests for their 
efficacy to inhibit galectin-1 and -3. 
5.      S-lactosulfonamides with a similar pharmacophores on S-galactosulfonamides 
were successfully synthesized to compare the disaccharide effect. These S-
lactosulfonamides are under biological tests for their efficacy to inhibit galectin-1 and 
-3. 
6.      LacNAc triazoles were successfully synthesized by regioselective glycosylation 
reaction between donor D-galactoside trichloroacetamidate and propargyl glucose 
acceptor and click chemistry. LacNAc triazoles are under evaluation to see if there is 
any synergic effect of triazole pharmacophore and N-acetyl group of LacNAc.  
7.      Camptothecin anti-cancer prodrug was successfully synthesized through 
complicated esterification of the 3o alcohol with 6-azidohexanoic acid using 
Sc(OTf)3. Sc(OTf)3 may coordinate with the acyl pyridinium intermediate to produce 
highly reactive species. Acetylated galactose selectively deprotected in presence of 3o 
camptothecin ester with tight control of pH of NaOMe. Camptothecin anti cancer 
prodrug is readily water soluble which is a key physical property of prodrug over the 




biological evaluation for efficacy and toxicological studies in comparison to the 
parent camptothecin. 
8.       Chiral auxiliaries for diastereoselective 1,4-addition using alkyl cuprates were 
successfully synthesized and screened. Benzyl oxazolidinone found to be the best 
chiral auxiliary on C-allyl galactose for diastereoselective 1,4-addition with ds 97:3. 
Diastereoselectivity was primarily established using 1H NMR and finally 
unambiguously using HPLC. 
9.       Three hetero tri functional ligands to conjugate peptide based anti cancer drug 
candidates and other biologically active molecules to human serum albumin (HSA) 
for improved bioavailability and pharmacokinetic properties of peptide based drug 
candidates were successfully synthesized. Primary screening of ligands was 
completed using model thiol (Cysteine) to evaluate the best Michael acceptor. 
Maliemide found to be the fastest reacting Michael acceptor by reacting completely in 
less than 10 minutes, vinyl sulfonamide stood in second place by completely reacting 
in 45 minutes. The acryl amide did not react at all under physiological pH, requiring 
pH 8-8.5 for the reaction to occur. The linkers maliemide and vinyl sulphonamides 
are under further evaluation to react with HSA under physiological conditions using 
HPLC (kinetic data) and MS-FAB characterization to monitor their reactivity with 







The nomenclature used in this thesis was adapted from "International Union of 
Pure and Applied Chemistry and International Union of Biochemistry and Molecular 
Biology (1997) Nomenclature of carbohydrates, J. Carbohydr. Chem., 16, 1191-1280.  
8.1 General 
8.1.1 Solvents 
Solvents were distilled151 as described below and stored on molecular sieves, on 
potassium hydroxide or calcium hydride. Dichloromethane was distilled over phosphorus 
pentoxide (P2O5). The pyridine was distilled over potassium hydroxide. Toluene was 
distilled over calcium hydride. THF was distilled over sodium / benzophenone and ether 
on lithium aluminum hydride. DMF was distilled over ninhydrin and stored over 
molecular sieves. Acetone was dried over calcium sulfate. Methanol is distilled over 
metallic sodium and stored over molecular sieves. During the stages of glycosidation and 
glycosylation, the solvents used were freshly distilled. The solvents used for 
chromatography were of ACS grade and were not distilled before use. The solvents are 
evaporated under reduced pressure (water pump). 
8.1.2 Chromatography 
The progress of reactions was followed by thin layer chromatography (TLC) 




of molecules was performed different methods depending on the class of compounds and 
functional groups present in the molecule 1) By irradiation under UV light (	 = 254 nm). 
2) By soaking in specific mixed acid (sulfuric acid/methanol/water: 5/45/45 v/v/v) 3) By 
oxidizing solution of molybdate (prepared from 25 g of ammonium molybdate and 10 g 
of ceric sulfate dissolved in 900 ml of water and 100 mL of concentrated sulfuric acid, 
followed by heating to 300° C.4) By soaking in KMnO4 solution (prepared by mixing 
equal quantities of 1% KMnO4 solution and 2% Na2CO3 soultion). The rapid 
chromatographic separations were performed under pressure of compressed air on a 
column of silica gel (Silica-P Flash Silica Gel, Silicycle) with the eluent indicated. 
8.1.3 Physico-chemical analysis 
8.1.3.1 General 
The optical rotations were measured on a JASCO Polarimeter P-1010 and are 
recorded at the corresponding temperature. The lyophilization is done on a device Freeze 
Mobile 24 (Virtis). The nominal mass measurements are performed on an LC-MSD 
instrument and accurate mass measurements by high resolution mass spectrometry were 
performed on an LC-MSD-TOF instrument (liquid chromatography mass spectrometry 
time of flight) model 6210 Agilent Technologies by the Laboratory of Mass 
Spectrometry, University of Montreal in electrospray ionization (ESI) and the Laboratory 
"Analytical for organic molecules” of the University of Quebec at Montreal. The source 
used in the TOF-MS is electrospray in positive mode with the condition of the source 




at 35 PSI) and, with the condition of MS (shredders to 100V; skimmer to 60V). A volume 
of 1 µL was injected using a mobile phase of ACN/H2O 50% with 0.1% formic acid. The 
elemental analysis is performed by Elementary Analysis Laboratory at the University of 
Montreal.  
8.1.3.2 Nuclear Magnetic Resonance spectroscopy (NMR) 
The Nuclear Magnetic Resonance (NMR) spectra of proton (1H) and carbon (13C) 
were recorded with Varian-Gemini apparatus 2000 or Varian Innova-AS600. The 1H 
spectra were recorded at a frequency of 300 MHz or 600 MHz and those of 13C at 75 
MHz or 150 MHz 
The chemical shifts (
) were expressed in parts per million (ppm) relative to 
tetramethylsilane and CDCl3 internal references and solvents. Coupling constants (J) 
were measured in Hz. Notations used for describing spectra is as follows: s (singlet), sb 
(broad singlet), d (doublet), dd (doublet of doublet), m (multiplet), Harom. (aromatic 
protons), Cq (quaternary carbon) and Carom. (aromatic carbon). 
For related compounds, the samples are analyzed after lyophilization in D2O 
99.9%. The measurements were performed in heavy water, ≥ 99.97%. The reference is 
used then the peak of residual water in proton spectra (calibrated by the equation 
 = 
5,051-0.0111T, where T is the temperature at the time of the acquisition. Acetone is used 
for the reference for 13C spectrum (internal: methyl signal of acetone adjusted to 





For the protected compounds and / or the compounds soluble in chloroform, 
CDCl3 signal is used as the reference. The signal for proton spectra calibrated to 
 = 7.27 
ppm at whatever the temperature spectrum recorded. The central line of the CDCl3 signal 
was calibrated for the 13C spectra (
 = 77.0 ppm). Bidimensional experiments, homo or 
heteronuclear are calibrated by analogy with the corresponding to one dimension 
spectrum 
The protons were assigned using the correlation of two-dimensional homonuclear 
chemical shift type COSY (Correlated Spectroscopy) experiments. While the assignment 
of carbon is complemented by experiments like DEPT (Distortionless Enhancement by 
Polarization Transfer) which allows to differentiate quaternary carbons and secondary 
carbons linked to an odd number of protons (primary and tertiary carbons), APT 
(Attached Proton Test) which can identify the carbon linked to an even and odd number 
of protons and the correlation of chemical shift heteronuclear two-dimensional inverse 
type HETCOR (Heteronuclear Chemical Shift Correlation) to highlight two types of 
nuclei with different coupling between them more or less strong. 
8.2 General protocols 
8.2.1 General procedure for Click chemistry using CuSO4.5H2O (THF+H2O) 
A solution of azide (0.12 mmol), propargyl β-D-galactopyranoside (0.1 mmol), 
CuSO4.5H2O (10%) and sodium ascorbate (20%) were dissolved in a 1:1 mixture of 
tetrahydrofuran and water. After 12 hrs of the reaction time, reaction mixture was 




with satd. NH4Cl solution (3 x 10 mL) and brine (3 x 10 mL), dried over MgSO4 and 
concentrated to give the crude triazole product which is then purified by column 
chromatography. 
8.2.2 General procedure for Click chemistry using CuSO4.5H2O (t-BuOH+H2O) 
A solution of azide (0.12 mmol), propargyl β-D-galactopyranoside (0.1 mmol), 
CuSO4.5H2O (10% wt mol) and sodium ascorbate (20% wt mol) were dissolved in a 1:1 
mixture of water and t-BuOH. After 12 hrs of reaction time reaction mixture concentrated 
to remove THF and extracted with EtOAc/DCM. Organic layer washed with satd. NH4Cl 
solution (3 x 10 mL) and brine (3 x 10 mL), dried over MgSO4 and concentrated to crude 
triazole product purified by column chromatography. 
8.2.3 General procedure for Click chemistry using CuI 
To the solution of azide (0.12 mmol) and propargyl β-D-galactopyranoside (0.1 mmol) in 
dry THF was added N,N-diisopropylethylamine (DIPEA) (0.2 mmol,) and CuI (0.01 
mmol). The reaction mixture was then allowed to stir at room temperature for 12 h. After 
solvent evaporation, the crude product was dissolved with ethyl acetate, washed with 
NH4Cl solution (3 x 10 mL) and brine (3 x 10 mL), dried over MgSO4 and concentrated 
on a rotary evaporator. The residue was purified by column chromatography. 
8.2.4 De-O-acetylation using sodium methoxide (Zemeplén) 
The compound is dissolved in dry MeOH (0.1M), or directly in the solution of 
sodium methoxide in distilled methanol (pH 10). A catalytic amount of (generally 0.1 




mixture was stirred at room temperature under nitrogen atmosphere. When the 
deprotection is complete, the solution is neutralized by the resin Amberlite IR-120 (H+), 
filtered and concentrated. If necessary, the product was purified by column 
chromatography on silica gel. 
8.2.5 Standard saponification procedure with LiOH solution (1M, THF:MeOH:H2O 
= 3 :2 : 1) 
The compound is dissolved in a mixture MeOH/H2O/THF 8:4:12 (v/v/v). 
LiOH/H2O solution (1M, 1.2 eq) was added and the mixture was stirred at room 
temperature. When the deprotection is complete, the solution is neutralized by the resin 
Amberlite IR-120 (H +), filtered, concentrated, then re-dissolved in water and lyophilized 
to obtain solid final product. If necessary, the product was purified by column 















Allyl magnesium bromide (31.4 mL of a 1 M soln in ether) was added to solution of 2,3,4,6-
tetra-O-cetyl--bromo-D-galactose 3.2 (1.29 g, 3.1 mmol) in THF (15 ml) at -78oC. The 
mixture was warmed up to 23o C within 0.5 h, then poured into H2O (60 mL). Glacial 
acetic acid (6 mL) was added to dissolve the magnesium salts and the mixture was 
shaken with Et2O until two separate layers were observed. Aqueous layer was evaporated 
to dryness and the residue was stirred overnight with Ac2O (30 mL), pyridine (30 mL) 
and a catalytic amount of DMAP. After removal of the solvent , the remaining oil was 
diluted with EtOAc, washed with 1 M HCl soln, water, brine and dried over MgSO4, The 
concentrated crude product was purified by silica gel column chromatography ( 




D  + 4.82 (c 1.0, CH2Cl2); 
1H NMR( 300 MHz, CDCl3):  

5.86-5.73 (m, 1H, H-2’), 5.39 (dd, J = 1.0, 3.4 Hz, 1H, H-4), 5.12-4.95 (m, 4H, H-2,3 
and H3’), 4.14-3.99 (m, 2H, H-6a, 6b), 3.83 (td, J = 1.0, 6.7 Hz, 1H, H-5), 3.44 (td J = 
5.9, 10.1 Hz, 1H, H-1), 2.34-2.22 (m, 2H, H-1’), 2.12 (s, 3H), 2.02 (s, 6H), 1.94 (s,3H), 
all OAc. 13C NMR (75 MHz, CDCl3): 
170.24, 170.14, 170.04, 169.56, 133.20, 117.26, 
77.69, 74.05, 72.16, 69.21, 67.70, 61.50, 35.95, 20.67-20.46 ppm. MS (ESI) calcd for 




2,3,4,6-Tetra-O-acetyl-β-D-galactopyranosyl ethanaldehyde (3.5) 
 
Compound 3.3 (1.3 g, 3.4 mmol) was dissolved in anhydrous CH2Cl2 (100 mL) 
and cooled to -78oC. Ozone was bubbled through the solution until no starting material 
was left (approximately 1 hr). The mixture was deozonized by bubbling nitrogen gas 
through the solution until it was clear. 5 mL of dimethyl sulfide was added and allowed 
the reaction mixture to obtain RT and stirred overnight. Rotary evaporated the reaction 
mixture and flashed the crude product by column chromatography using 10-20% of 
EtOAc in Hexane to obtain aldehyde 3.5 (1.006 g, 2.6 mmol); Rf 0.43 
(EtOAc/Hexane 6.5:3.5);  
22
D  + 14.66 (c 1.0, CH2Cl2); 1H NMR (CDCl3, 300 MHz): δ 
9.75 (t, J = 1.8 Hz, 1H, -C(0)H), 5.46 (dd, 1H, J = 0.93, 3.3 Hz, 1H, H-4), 5.18 – 5.10 (m, 
1H, H-2), 5.08 (dd, J = 10.1, 3.3 Hz 1H, H-3), 4.11- 4.05 (m, 2H, H-6a, H-6b), 4.02 – 3.97 
(m, 1H, H-1), 3.95 (dd, J = 7.11, 10.6 Hz, 1H, H-5), 2.78 (ddd, J = 8.2,16.9Hz, 1.8Hz, 
1H,CHaHb), 2.60 (ddd, J = 3.7, 1.6Hz, 1H, CHaHb), 2.18,2.05,2.04,2.00 (4S,3H each,-
C(O)CH3); 13C NMR (CDCl3, 75 MHz): δ 198.69, 170.80-170.01 (4C), 74.45, 73.42, 
71.84, 68.95, 67.65, 61.70, 45.59, 20.75 (4C); MS (ESI) calcd for C16H22O10+ H+: 





2,3,4,6-Tetra-O-acetyl-β-D-galactopyranosyl ethanoic acid (3.6) 
 
To a solution of compound 3.5 (1.013 g, 2.7 mmol) in acetone 2 mL of 
CrO3.H2SO4 was added drop wise at 0oC and stirred for 1.5 hrs, then 10 mL of Isopropyl 
alcohol was added the reaction mixture concentrated to half and a small amount of 0.1 N 
HCl added then extracted with EtOAc. The organic layers were combined and washed 
with water, brine and dried over MgSO4 and concentrated to dry to obtain 3.6 (0.89 g, 2.2 
mmol).  Rf 0.31 Streak (CH2Cl2/Methanol 9.5:0.5); 1H NMR (CDCl3, 300 MHz): δ 5.48 
(dd, J 3,4 = 3.3 Hz, J4,5 = 0.9 Hz, 1H, H-4), 5.17 (dd, J1,2 = J2,3 = 10.0Hz. 1H, H-2), 5.08 
(dd, J = 10.1, 3.2 Hz, 1H, H-3), 4.15-4.10 (m, 2H, H-6a, H-6b), 3.96-3.90 (m, 2H, H-1, 
H-5), 2.70-2.56 (m, 2H, CHaHb), 2.16, 2.14, 2.11, 2.02 (4sing, 3H each, -C(O)CH3); 13C 
NMR (CDCl3, 75 MHz): δ 171-170 (5C), 74.67, 74.22, 71.55, 68.73, 67.19, 60.97, 36.82, 











To a solution of  compound 3.6 (0.89 g, 2.2 mmol), L-propargyl glycine methyl 
ester HCl (0.559 g, 3.4 mmol) and BOP reagent ( 1.21 g, 2.7 mmol) in dry THF under 
nitrogen atmosphere was added DIPEA (1.0 g, 7.9 mmol) drop wise and reaction mixture 
left to stir overnight. The reaction mixture oncentrated and then dissolved in CH2Cl2 and 
washed with 1M KHSO4, NaHCO3 and brine solution and dried over MgSO4 and 
concentrated. The crude product was purified by column chromatography using 10-30% 
EtOAc in Hexanes to obtain 3.7 (0.608 g, 1.3 mmol); Rf 0.39 (EtOAc/Hexane 6.5:3.5); 
 
22
D  + 56 (c 1.0, CH2Cl2); 1H NMR (CDCl3, 300 MHz): δ 6.9 (d, 1H, NH), 5.36 (d J = 
3.3, 1H, H-4), 5.05 (dd, J = 10.1, 3.3 Hz, H-2, 2H, H-3), 4.84 - 4.71 (m, 1H, H-3’), 4.24 - 
4.04 (m, 2H, H-6a,H-6b), 3.96 (dd, J = 7.9, 6.7 Hz, 1H, H-5), 3.92 - 3.85 (m, 1H, H-1), 
3.71 (s, 3H, H-8’), 2.84 - 2.76 (m, 2H, H-4’), 2.54 - 2.46 (m, 2H, H-1’), 2.07, 1.97, 1.94, 
1.89 (4S,3H each,-C(O)CH3), 2.02-2.00 (m, 1H, H-6’); 13C NMR (CDCl3, 75 MHz): 
δ170.67, 170.55-170.62 (OCOCH3, C=O), 169.24, 78.61, 75.39, 74.40, 71.90, 68.70, 
67.69, 61.55, 52.88, 50.79, 38.90, 22.43, 20.84-20.68 (OCOCH3); MS (ESI)calcd for 







To a solution of compound 3.7 (0.166 g, 332 μmol) in THF:H2O (3:1.5) 4.5 mL, 
isopropyl  azide (0.056 g, 664 μmol) CuSO4.5H2O (0.0122 g 20%) and sodium ascorbate 
(0.0263 g, 40%) were added and after 12h of reaction time following the general 
procedure (7.2.1) described above, β-D-galactopyranoside 3.8 (0.145 g, 249 μmol) was 
obtained. Rf 0.21 (EtOAc/Hexane 7.5:2.5); 1H NMR (CDCl3, 300 MHz): δ 7.35(s, 1H, 
H- 6’), 7.2 (d, 1H, J = 8.79 Hz, NH), 5.45 (d, J = 2.9 Hz, 1H, H-4), 5.11-5.05 (m, 2H, H-
2, H-3), 4.9-4.88 (m, 1H, H-3’), 4.81-4.72 (m, 1H, H-7’), 4.06-4.01 (m, 3H, H-5, H-
6a,6b), 3.93-3.86 (m, 1H, H-1), 3.69 (s, 3H, H-11’), 3.24-3.22 (m, 2H, H-4’), 2.46-2.45 
(m, 2H, H-1’), 2.13, 2.03, 1.99, 1.97 (4s, 3H each,-C(O)CH3), 1.55 (dd, J = 1.09, 5.76 
Hz, 6H, H-8’, H-9’); 13C NMR (CDCl3, 75 MHz): δ 171.49, 170.52, 170.44, 
170.29,170.05 (OCOCH3, C=O), 169.37, 142.64, 119.69, 75.26 , 74.32, 72.09, 68.77, 
67.73, 61.36, 53.13, 52.66, 51.96, 38.92, 27.93, 23.13-20.847 (OCOCH3), 20.787; MS 










To a solution of compound 3.7 (0.15 g, 300 μmol) in THF:H2O (3:1.5)  4.5 mL, n-propyl  
azide (0.051 g, 600 μmol) CuSO4.5H2O (0.015 g 20%) and sodium ascorbate (0.024 g, 
40%) were added and after 12 hrs of reaction time following the general procedure 
(7.2.1) described above, β-D-galactopyranoside 3.9 (0.128g, 219 μmol) was obtained. Rf 
0.25 (EtOAc/Hexane  7.5:2.5); 1H NMR (CDCl3, 300 MHz): δ 7.28 (s, 1H, H-6’), 7.13 
(d, J = 7.96 Hz, 1H, NH), 5.40 (d, J = 2.47 Hz, 1H, H-4), 5.10-4.97 (m, 2H, H-2, H-3), 
4.86-4.84 (m, 1H, H-3’), 4.23 (t, J = 7.14Hz,  1H, H-7’), 4.06-3.96 (m, 3H, H-5, H-6a, H-
6b), 3.90-3.86 (m, 1H, H-1), 3.65 (s, 3H, H-11’), 3.20-3.17 (m, 2H, H-4’), 2.44-2.40 (m, 
2H, H-1’), 2.09, 1.99, 1.92, 1.90 (4S, 3 H each,-C(O)CH3), 1.87-1.77 (m, 2H, H-8’), 0.88 
(t, J = 7.41Hz,  3H, H-9’); 13C NMR (CDCl3, 75 MHz): δ171.46, 170.53, 170.44, 
170.29, 170.06 (OCOCH3, C=O), 169.35, 142.81, 122.06, 75.26, 74.33, 72.08, 68.76, 
67.73, 61.37, 52.69, 52.06, 51.98, 38.93, 27.89, 23.13, 20.94-20.787 (4C,OCOCH3), 










To a solution of compound 3.7 (0.15 g, 300 μmol) in THF:H2O (3:1.5)  4.5 mL, 
cyclopentyl  azide (0.066 g, 600 μmol) CuSO4.5H2O (0.011 g 20%) and sodium 
ascorbate (0.024 g, 40%) were added and after 12 hrs of reaction time following the 
general procedure (7.2.1) described above, β-D-galactopyranoside 3.10 (0.119 g, 195 
μmol) was obtained; Rf 0.27 (EtOAc/Hexane 7.5:2.5); 1H NMR (CDCl3, 300 MHz): 
δ7.28 (s, 1H, H-6’), 7.16 (d, J = 7.96 Hz, 1H, NH), 5.40 (dd, J = 0.82, 3.29 Hz, 1H, H-4), 
5.06-5.00 (m, 2H, H-2, H-3), 4.86-4.82 (m, 2H, H-3’, H-7’), 4.06-3.96 (m, 3H, H-5, H-
6a,6b), 3.88-3.81 (m, 1H, H-1), 3.65 (s, 3H, H-13’), 3.18-3.14 (m, 2H, H-4’), 2.43-2.40 
(m, 2H, H-1’), 2.17 (m, 2H, H-8’), 2.08, 1.98, 1.94, 1.92 (4x, 3 H each,-C(O)CH3), 1.85 -
1.80 (m, 4H, H-9’, H-10’), 1.72-1.70 (m, 2H, H-11’); 13C NMR (CDCl3, 75 MHz): δ 
171.49, 170.50-170.04 (OCOCH3, C=O), 169.36, 142.67, 120.72, 75.25, 74.32, 72.09, 
68.77, 67.73, 61.98, 61.36, 52.66, 51.94, 38.92, 33.54, 27.90, 24.21, 20.93-20.78 (4C, 









To a solution of compound 3.7 (0.15 g, 300 μmol) in THF:H2O (3:1.5)  4.5 mL, allyl  
azide (50 mg, 600 μmol) CuSO4.5H2O (15 mg 20%) and sodium ascorbate (24 mg, 40%) 
were added and after 12 hrs of reaction time following the general procedure (7.2.1) 
described above, β-D-galactopyranoside 3.11 (99 mg, 171 μmol) was obtained; Rf 0.62 
(CH2Cl2/MeOH 9.5 : 0.5);  
22
D  + 10.08 (c 1.0, CH2Cl2); 1H NMR (CDCl3, 300 MHz): δ 
7.35 (s, 1H, H- 6’), 7.2 (d, J = 8.79 Hz, 1H, NH), 6.01-5.85 (m, 1H, H-8’),  5.45 (d, J = 
3.02 Hz, 1H, H-4), 5.27 (dd, J = 10.16, 10.98 Hz, 2H, H-9’), 5.07-5.00 (m, 2H, H-2, H-
3), 4.91-4.81 (m, 3H, H-3’,H-7’), 4.00-3.96 (m, 3H, H-5, H-6a,6b), 3.95-3.90 (m, 1H, H-
1), 3.66 (S, 3H, H-11’), 3.21 (Brs, 2H, H-4’) 2.44-2.41 (m, 2H, H-1’), 2.09-1.92 (4s, 3H 
each,-C(O)CH3); 13C NMR (CDCl3, 75 MHz): δ 171.40, 170.52-170.05 (OCOCH3, 
C=O), 169.36, 143.06, 131.39, 122.14, 120.34, 75.25, 74.30, 72.04, 68.72, 67.71, 61.35, 
52.87, 52.73, 51.94, 38.90, 27.83, 20.95-20.79 (OCOCH3); MS (ESI) calcd for 









To a solution of compound 3.7 (0.166 g, 330 μmol) in THF: H2O (3: 1.5) 4.5 mL, benzyl 
azide (0.088 g, 664 μmol) CuSO4.5H2O (0.0122 g 20%) and sodium ascorbate (0.026 g, 
40%) were added and after 12 hrs of reaction time following the general procedure 
described above, β-D-galactopyranoside 3.12 (0.130 g, 0.088 g, 205 μmol) was obtained. 
Rf 0.67 (CH2Cl2/MeOH  9.0:1.0);  
22
D  - 5.32 (c 0.1, CH2Cl2); 1H NMR (CDCl3, 300 
MHz): δ 7.34 - 7.32 (m, 3H, H-6 and aryl-H), 7.22 - 7.18 (m, 3H, Aryl-H), 7.10 (d, J = 
7.96 Hz, 1H, NH), 5.38 (dd, J = 1.09, 3.29 Hz, 1H, H-4), 5.06 - 4.96 (m, 2H, H-2, H-3), 
4.85 - 4.82 (m, 1H, H-3’), 4.03 - 3.98 (m, 2H, H-6a, H-6b), 3.89 - 3.81(m, 2H, H-5, H-1), 
3.61 (s, 3H, H-15’), 3.16 (d, J = 5.22 Hz, 2H, H-4’), 2.43 - 2.39 (m, 2H, H-1’), 2.10, 
2.00, 1.97, 1.93 (4s, 3H each,-C(O)CH3); 13C NMR (CDCl3, 75 MHz): δ 171.38, 170.51, 
170.41, 170.26, 170.02 (OCOCH3, C=O), 169.30, 143.35, 134.88, 129.32-128.16 (Aryl-
C), 122.12, 75.25, 74.32, 72.03, 68.75, 67.73, 61.37, 54.27, 52.65, 51.95,  38.92, 27.95, 









To a solution of  compound 3.8 (0.046 g, 78 μmol ) in 3 mL of dry methanol, 1M 
NaOMe  solution added until the reaction mixture reached pH of 9-10, within 4 hrs of 
reaction time following the general procedure (7.2.4) described above to obtain 
deprotected β-D-galactopyranoside 3.13 (22 mg, 53 μmol); Rf 0.20 
(CH2Cl2/MeOH 9.0:1.0);  
24
D  + 28.64 (c 1.0, CH3OH); 1H NMR (CD3OD, 300 MHz): δ 
7.72 (s, 1H, H-6’), 4.63 - 4.59 (m, 1H, Hz, H-3’), 4.22 – 4.19 (m, 1H, H-7’),  3.61 (bs, 
1H, H-4), 3.61 (s, 3H, H-11’), 3.55 - 3.52 (m, 1H), 3.38 - 3.35 (m, 1H), 3.32 - 3.27 (m, 
2H), 3.20 - 3.17 (m, 2H), 3.12 - 3.05 (m, 1H), 2.62 (dd, 1H), 0.80 (d, J = 6.7 Hz, 6H, H-
8’, H-9’); 13C NMR (CD3OD, 75 MHz): δ 173.87, 172.77, 143.84, 124.79, 80.39, 78.51, 
76.13, 72.07, 70.92, 62.85, 53.66, 53.04, 52.96, 39.72, 28.54, 22.07; MS (ESI) calcd for 











To a solution of  compound 3.9 (0.101 g, 172 μmol) in 3 mL of dry methanol 1M 
NaOMe  solution added until the reaction mixture reached pH of 9-10, within 4 hrs of 
reaction time following the general procedure (7.2.4) described above to obtain the  
deprotected β-D-galactopyranoside 3.14 (57 mg, 138 μmol); Rf 0.24 (CH2Cl2/MeOH  
9.0:1.0);  
24
D  - 7.56 (c 0.5, CH3OH); 1H NMR (CD3OD, 300 MHz): δ 7.71 (s, 1H, H-
6’), 4.63 (t, J = 5.41 Hz, 1H, H-3’), 4.22 (t, J = 7.41 Hz, 2H, H-7’), 3.60 (bs, 1H, H-4), 
3.60 (s, 3H, H-11), 3.55 - 3.52 (m, 1H), 3.38 - 3.35 (m, 1H), 3.32 - 3.27 (m, 2H), 3.20 - 
3.17 (m, 2H), 3.12 - 3.05 (m, 1H), 2.62 (dd, J = 2.19, 12.63 Hz, 1H), 2.23 - 2.28 (m, 2H, 
H-8’), 0.80 (t, 3H, J = 7.41 Hz, H-9’); 13C NMR (CD3OD, 75 MHz): δ 173.85, 172.75, 
143.82, 124.77, 80.37, 78.48, 76.11, 72.05, 70.90, 62.83, 53.64, 53.02, 52.94, 39.70, 











To a solution of  compound 3.10 (0.087 g, 142 mmol) in 3 mL of dry methanol 1M 
NaOMe  solution added until the reaction mixture reached pH of 9-10, within 4 hrs of 
reaction time following the general procedure (7.2.4) described above to obtain the 
deprotected β-D-galactopyranoside 3.15 (58 mg, 131 μmol); Rf 0.21 (CH2Cl2/MeOH  
9.0:1.0);  
24
D  + 19.31 (c 1.0, CH3OH); 1H NMR (CD3OD, 300 MHz): δ 7.71 (s, 1H, H-
6’), 4.87 - 4.82 (m, 1H, H-7’), 4.66 - 4.62 (m, 1H, H-3’), 3.61 (d, J = 1.64 Hz, 1H, H-4), 
3.61 (s, 3H, H-13’), 3.56 - 3.52 (m, 1H), 3.38 - 3.34 (m, 1H), 3.31 - 3.31 (m, 2H), 3.20 - 
3.18 (m, 2H), 3.10 - 3.04 (m, 1H), 2.62 (dd, J = 2.19, 16.48 Hz, 1H), 2.41 - 2.33 (m, 1H, 
H-1), 2.11 - 2.10 (m, 2H, cyclopentyl-CH2), 1.95 - 1.89 (m, 2H, cyclopentyl-CH2), 1.80 - 
1.75 (m, 2H, cyclopentyl-CH2), 1.67-1.63 (m, 2H,cyclopentyl-CH2); 13C NMR (CD3OD, 
75 MHz): δ173.83, 172.82, 143.76, 123.39, 80.34, 78.46, 76.11, 72.04, 70.85, 63.33, 
62.77,  53.65, 52.93, 39.67, 34.24, 28.57, 25.04; MS (ESI) calcd for C19H30N4O8 + H+: 









To a solution of  compound 3.11 ( 0.131 g, 225 μmol ) in 3 mL of dry methanol, 1M 
NaOMe  solution added until the reaction mixture reached pH of 9-10, within 4 hrs of 
reaction time following the general procedure (7.2.4) described above to obtain 
deprotected β-D-galactopyranoside 3.16 (73 mg, 175 μmol); Rf 0.22 (CH2Cl2/MeOH  
9.0:1.0);  
24
D  + 19.71 (c 1.0, CH3OH); 1H NMR (CD3OD, 300 MHz): δ 8.24 (d, J = 
7.69Hz, 1H, NH), 7.68 (s, 1H, H-6’), 5.95 - 5.90 (m, 1H, H-8’), 5.14 (qd, J = 1.3, 10.43 
Hz, 2H, H-9’), 5.03 - 4.95 (m, 2H, H-7’), 4.63 - 4.75 (m, 1H, H-3’), 3.68 (dd, J = 0.82, 
1.92 Hz, 1H, H-4), 3.60 (s, 3H, H-11’), 3.57 - 3.48 (m, 1H), 3.39 - 3.34 (m, 1H), 3.3 - 
3.30 (m, 1H), 3.19 - 3.17 (m, 1H), 3.12 - 3.00 (m, 2H) 2.16 - 2.59 (m, 1H), 2.31 (dd, J = 
14.8, 8.9 Hz, 1H, H-1); 13C NMR (CD3OD, 75 MHz): δ 173.80, 172.77, 144.12, 132.27, 
124.67, 119.66, 80.25, 78.38, 76.02, 72.06, 70.81, 62.74, 53.60, 53.47, 52.97, 39.64, 










To a solution of  compound 3.12 ( 0.100 g, 158 μmol ) in 3 mL of dry methanol, 1M 
NaOMe solution is added until the reaction mixture reached pH of 9-10, within 4 hrs of 
reaction time following the general procedure (7.2.4) described above to obtain 
deprotected β-D-galactopyranoside 3.17 (59 mg, 126 μmol). Rf 0.24 (CH2Cl2/MeOH  
9.0:1.0);  
24
D  + 9.05 (c 1.0, CH3OH); 1H NMR (CD3OD, 300 MHz): δ 8.20 (d, J = 8.10 
Hz, 1H, NH), 7.70 (s, 1H, H-6’), 7.28 - 7.17(m, 5H, Aryl-H), 5.58 - 5.48 (m, 2H, H-7’), 
4.64 - 4.62 (m, 1H, H-3’), 3.61 (d, J = 1.64 Hz, 1H, H-4), 3.59 - 3.45 (m, 1H), 3.61 (s, 
3H, H-15’), 3.56 - 3.52 (m, 2H), 3.39 - 3.30 (m, 2H), 3.28 - 3.25 (m, 2H), 3.19 - 3.05 (m, 
1H), 2.62 (d, J = 14.97 Hz, 1H), 2.39 - 2.31 (m, 1H, H-1); 13C NMR (CD3OD, 75 MHz): 
δ 173.84, 172.81, 144.44, 136.96, 130.04 - 128.97 (Aryl-C), 124.73, 80.40, 78.42, 76.02, 
72.02, 70.90, 62.85, 54.81, 53.77, 52.89, 39.67, 28.56; MS (ESI) calcd for C21H28N4O8 + 










To a solution of compound 3.13 (32 mg, 76 μmol) in mixed solvent of THF:MeOH:H2O 
(3:2:1) was added a 1M soln of LiOH. (3.8 mg, 92 μmol) followed by the general 
saponification procedure (7.2.5) described above to obtain 3.18 (26 mg, 65 μmol); Rf 0.37 
(CH3CN/H2O 8:2);  
24
D  + 25.54 (c 1.0, H2O); 1H NMR (D2O, 300 MHz): δ 7.90 (s, 1H, 
H-6’), 4.72 - 4.63 (m, 1H, H-3’), 4.72 - 4.66 (m, 1H, H-7’), 3.93 (d, J = 3.29 Hz, 1H, H-
4), 3.70 (d, J = 7.41 Hz, 1H), 3.63 - 3.48 (m, 4H), 3.44 - 3.38 (m, 1H), 3.27 - 3.14 (m, 
2H), 2.76 (dd, J = 2.33, 15.5 Hz, 1H), 2.43 (dd, J = 9.33, 5.76 Hz, 1H), 1.86 - 1.81 (m, 
1H), 2.62 (dd, 1H), 1.51 (d, J = 6.7 Hz, 6H, H-8’, H-9’); 13C NMR (D2O, 75 MHz): δ 
173.98, 173.33, 142.88, 122.18, 78.71, 76.85, 74.14, 70.67, 69.26, 61.27, 67.93, 53.9, 












To a solution of compound 3.14 (25 mg, 60 μmol) in mixed solvent of THF:MeOH:H2O   
(3:2:1) was added a 1M soln of LiOH (3 mg, 71μmol) followed by the general 
saponification procedure (7.2.5) described above to obtain 3.19 (23 mg, 57 μmol); Rf 0.33 
(CH3CN/H2O 8:2);  
24
D  + 20.63 (c 1.0, H2O); 1H NMR (D2O, 300 MHz): δ 8.01 (s, 1H, 
H-6’), 4.75 - 4.71 (m, 1H, H-3’), 4.39 (t, J = 7.00 Hz, 2H, H-7’),  3.93 (d, J = 2.88 Hz, 
1H, H-4), 3.65 - 3.50 (m, 4H), 3.45 - 3.36 (m, 1H), 3.32 - 3.30 (m, 1H), 2.77 (dd, J = 
2.61, 15.10 Hz, 1H), 2.43 (dd, J =  5.90, 9.20, Hz, 1H) 1.95 - 1.83 (m, 2H, H-8’), 0.82 (t, 
J = 7.41 Hz, 3H, H-9’); 13C NMR (D2O, 75 MHz): δ 173.60, 173.48, 142.06, 125.14, 
78.61, 76.76, 73.99, 70.59, 69.18, 61.24, 52.78, 52.36, 38.45, 26.75, 23.12, 10.24; MS 












To a solution of compound 3.15 (50 mg, 113 μmol) in mixed solvent of THF:MeOH:H2O 
(3:2:1) was added a 1M soln of LiOH (5.6 mg, 135 μmol) followed by the general 
saponification procedure (7.2.5) described above to obtain 3.20 (42 mg, 99 μmol); Rf 0.31 
(CH3CN/H2O 8:2);  
24
D  + 47.22 (c 1.0, H2O); 1H NMR (D2O, 300 MHz): δ 7.98 (s, 1H, 
H-6’), 5.00 - 4.96 (m, 1H, H-3’), 4.37 - 4.71 (m, 1H, H-7’) 3.91 (d, 1H, J = 3.29 Hz, H-
4), 3.63 - 3.59 (m, 2H), 3.58 - 3.47 (m, 2H), 3.43 - 3.37 (m, 1H), 3.30 - 3.26 (m, 2H), 
3.24 - 3.16 (m, 1H), 2.75 (d, J = 14.69 Hz, 1H), 2.40 (dd, 1H, J = 5.63, 8.92 Hz), 2.26 - 
2.17 (m, 2H, cyclopentyl-CH2), 1.97 -1.89 (m, 2H, cyclopentyl-CH2), 1.78 - 1.67 (m, 4H, 
cyclopentyl-CH2); 13C NMR (D2O, 75 MHz): δ 173.71, 173.47, 142.09, 123.61, 78.60, 
76.78, 74.01, 70.59, 69.17, 63.05, 61.20,  52.42, 38.45, 32.96, 26.88, 23.75; MS (ESI) 











To a solution of compound 3.16 (40 mg, 96 μmol) in mixed solvent of THF:MeOH:H2O 
(3:2:1) was added a 1M soln of LiOH. (4.8 mg, 115μmol) followed by the general 
saponification procedure (7.2.5) described above to obtain 3.21 (34 mg, 86 μmol); Rf 0.34 
(CH3CN/H2O 8:2);  
24
D  - 89.11 (c 1.0, H2O); 1H NMR (D2O, 300 MHz): δ 7.94 (s, 1H, 
H-6’), 6.08 - 5.98 (m, 1H, H-8’ ), 5.32 (d, 1H, J =  9.88 Hz, H-9a’), 5.16 (d, J = 17.03 Hz, 
1H, H-9b’), 5.01 (d, J = 5.90 Hz, 2H, H-7’), 4.74 - 4.72 (m, 1H, H-3’), 3.92 (t, J = 2.61 
Hz, 1H, H-4), 3.71 - 3.68 (m,1H), 3.63 - 3.48 (m, 2H), 3.44 - 3.40 (m, 1H), 3.30 - 3.17 
(m, 2H), 2.17 (d, J = 15.24 Hz, 1H) 2.45 - 2.36 (m, 1H); 13C NMR (D2O, 75 MHz): δ 
173.78, 173.53, 142.54, 131.27, 124.98, 119.77, 78.59, 76.75, 73.95, 70.58, 69.17, 61.21, 












To a solution of compound 3.17 (50 mg, 107 μmol) in mixed solvent of THF:MeOH:H2O 
(3:2:1) was added a 1M soln of LiOH. (5.4 mg, 129 μmol) followed by the general 
saponification procedure (7.2.5) described above to obtain 3.22 (38 mg, 86 μmol); Rf 0.41 
(CH3CN/H2O 8:2);  
24
D  + 26.22 (c 1.0, H2O); 1H NMR (D2O, 300 MHz): δ 7.90 (s, 1H, 
H-6’), 7.44 - 7.40 (m, 3H, HArom),7.34 - 7.30 (m, 2H, HArom), 5.41 (s, 2H, H-7’), 4.58 - 
4.54 (m, 1H, H-3’), 3.69 (d, J = 2.88 Hz, 1H, H-4), 3.49 - 3.48 (m, 1H), 3.39 - 3037 (m, 
2H), 3.33 - 3.29 (m, 1H), 3.24 - 3.13 (m, 2H), 3.11 - 3.07 (m, 2H), 3.04 - 2.96 (m, 1H), 
2.53 (d, J = 14.97 Hz, 1H), 2.23 - 2.15 (m, 1H, H-1); 13C NMR (D2O, 75 MHz): δ 
173.37, 172.97, 142.42, 134.31, 129.02-127.60 (Aryl-C), 124.21, 77.85, 76.17, 73.19, 
69.91, 68.51, 60.53, 53.62, 51.78, 37.81, 26.32; MS (ESI) calcd for C20H26N4O8 + H+: 
451.17, found 451.3.  
2,3,4,6-tetracetyl-1-thio--D-galactose 3.23 
 
To a solution of known compound 3.2 (1.67 g, 4 mmol) in 20 ml of acetone was added 




mixture was concentrated to obtain 2.2 g of thiouronium salt. The thiouronium salt was 
dissolved in 4.5 ml of water and 6.6 ml of dichloromethane to which was added K2S2O5 
(1.2 g, 5.5mmol) and refluxed for 20. The reaction mixture was allowed to cool to room 
temperature, both layers were separated and the organic layer was dried to obtain 1.65 g 
of crude thiol galactose. The crude product was purified by flash chromatography using 
dichloromethane alone to obtain 3.23 (0.904 g, 2.5 mmol); Rf 0.71 
(EtOAc/Hexane 6.5:3.5); 1H NMR (CDCl3, 300 MHz): δ5.40 (dd, J3,4 = 3.3 Hz, J4,5 = 0.9 
Hz, 1H,  H-4), 5.15 (t, J = 9.9 Hz, H-2), 4.99 (dd,  J = 10.1, 3.4 Hz, 1H, H-3), 4.52 (t, J = 
9.8 Hz, 1H, H-1), 4.10 (d, J = 6.6 Hz, 2H, H-6a, H-6b), 2.35 (d, J = 9.9Hz, 1H, SH), 2.13, 
2.06, 2.02, 1.95 (4S, 3 H each,-C(O)CH3; 13C NMR (CDCl3, 75 MHz): δ170.54, 170.33, 
170.13, 170.00, (OCOCH3, C=O), 79.32 ( C – 5), 75.10 ( C-2), 71.73 ( C-3) 71.01 ( C-1) 
67.43 ( C-6) 61.64 ( C-4) 20.99 – 20.71 (4C,OCOCH3); MS (ESI) calcd for C14H20O9S + 
H+: 365.08, found 365.2. 
Compound 3.24  
 
To a solution of compound 6.17 (57 mg, 0.27 mmol) and compound 3.24 (100 mg, 0.27 
mmol) in CH2Cl2 (5mL), was added 4 drops of TEA and stirred at RT overnight. The 
reaction mixture concentrated on rotovap to get crude product as a 50:50 mixture of 




column using 5-10% EtOAc in hexane to separate both the β-D-thiogalactoyranoside 
diastereomers 3.25 and 3.26 
Compound 3.25 
 
1H-NMR (CDCl3, 300 MHz) 5.47 (d, J = 3.3Hz, 1H, H-4), 5.23 (td, J = 7.3Hz, J = 
19.4Hz, 1H, H-3), 5.10 (dd, J = 3.3Hz, J=9.5Hz, 1H, H-2), 4.92 (dd, J = 5.1Hz, J = 
11.1Hz, 1H, H-1) 4.18 - 4.08 (m, 1H, H-5’), 4.01 (t, J = 7.0Hz, 1H, H-2’), 3.76 (s, 1H) 
3.28 (dd, J = 9.4Hz, J = 19.0Hz, 1H, H-6) 3.17 - 2.95 (m, 1H, H-3’), 2.64 (dd, J = 19.0, 
4.0 Hz, 1H, H-1’), 2.17, 2.06, 1.99, (3S, 12H, -(O)CH3); 13C NMR (CDCl3, 75 MHz): 
δ175.50, 173.26, 170.09, 167.50, 82.91, 78.69, 74.77, 71.72, 71.39, 67.42, 67.33, 67.28, 
61.53, 53.37, 51.19, 36.81, 35.39, 36.81, 35.39, 20.91, 20.87, 20.85, 20.74, 18.55; MS 
(ESI) calcd for for C24H29NO13S + H+: 572.14, found 572.1. 
Compound 3.26. 
 
1H-NMR (300 MHz) 5.36 (d, J = 3.3Hz, 1H, H-4), 5.02 (d, J =3.3Hz, 1H,  H-3), 5.03 - 
4.95 (m, 1H, H-2) 4.87 (d, J = 9.9Hz, 1H, H-1) 4.11 - 3.99 (m, 4H, H-5’,H-6,H-5) 3.92 (t, 




= 8.1Hz, J = 7.6Hz, J = 17.4Hz, 1H, H-1’) 2.09, 2.03, 1.99, 1.92 (4s, 12H,3 H each,-
C(O)CH3);  13C NMR (CDCl3, 75 MHz): δ 173.75, 170.04, 169.80, 167.24, 82.42, 78.92, 
74.24, 71.34, 71.21, 67.16, 66.78, 61.48, 53.34, 51.57, 40.63, 37.85, 20.69, 20.67, 20.58, 
20.52, 20.47, 18.50; MS (ESI) calcd for for C24H29NO13S + H+: 572.14, found 572.1. 
Compound 3.27 
 
To a solution of compound 3.25  (0.050 g, 87 μmol) in THF:H2O (3;1.5)  4.5 mL, n-
propyl azide (0.015 g, 174 μmol) CuSO4.5H2O (0.004 g 20%) and sodium ascorbate 
(0.007 g, 40%) were added and after 12 hrs of reaction time following the general 
procedure (7.2.1) described above, β-D-thiogalactopyranoside 3.27 (0.087 g, 76%) was 
obtained; Rf 0.35 (EtOAc/Hexane 7:3);  
22
D  - 29.03 (c = 1.0 in CH2Cl2); 1H NMR 
(CDCl3, 300 MHz): δ7.36 (s, 1H, H-10’), 5.43 (d, J = 3.29 Hz, 1H, H-4), 5.18 - 5.16 (m, 
2H, H-2, H-3), 5.10 - 5.07 (m, 1H, H-5), 4.92 (d, J = 11.3, 4.0 Hz, 1H, H-5’), 4.25 (t, J = 
7.14 Hz, 2H, H-11’), 4.12 (d, J = 6.04 Hz, 2H, H-6a, 6b), 4.04 - 3.98 (m, 2H, H-2’), 3.77 
(s, 3H, H-7’), 3.53 - 3.47 (m, 2H, H-8’), 3.21 (dd, J = 9.34, 18.67 Hz, 1H, H-1), 2.55 (dd, 
J =  18.95, 4.39 Hz, 1H, H-1’), 2.15 - 1.97 (4S, 12H, 3H each, -(O)CH3), 1.89 - 1.85 (m, 
2H, H-12’), 0.90 (t, J = 7.41 Hz, 2H, H-13’); 13C NMR (CDCl3, 75 MHz): δ175.36, 




67.55, 67.34, 61.56, 53.19, 52.64, 52.02, 37.73, 35.83, 29.86, 24.26, 23.83, 20.91, 20.86, 
20.84, 20.7311.13; MS (ESI) calcd for C27H36N4O13S + H+: 657.65, found 657.3. 
Compound 3.28 
 
To a solution of compound 3.25 (0.050 g, 87 μmol) in THF : H2O (3:1.5)  4.5 mL, 
isopropyl azide (0.015 g, 174 μmol) CuSO4.5H2O (0.004 g 20%) and sodium ascorbate 
(0.007 g, 40%) were added and after 12 hrs of reaction time following the general 
procedure (7.2.1) described above, β-D-thiogalactopyranoside 3.28 (47 mg, 82%) was 
obtained; Rf 0.18 (EtOAc/Hexane 7:3);  22D  - 25.08 (c = 1.0 in CH2Cl2);  
1H NMR 
(CDCl3, 300 MHz): δ7.38 (s, 1H, H-10’), 5.43 (d, J = 3.29 Hz, 1H, H-4), 5.18 - 5.16 (m, 
2H, H-2, H-3), 5.10 - 5.07 (m, 1H, H-5), 4.91 (d, J = 4.0 Hz, 1H, H-5’), 4.75 - 4.71 (m, 
1H, H-11’), 4.12 (d, J = 6.04 Hz, 2H, H-6a, 6b), 4.05 - 3.96 (m, 2H, H-2’), 3.77 (s, 3H, H-
7’), 3.53 - 3.48 (m, 2H, H-8’), 3.21 (d, J = 9.6 Hz, 1H, H-1), 2.55 (dd, J =  4.39, 18.95 
Hz, 1H, H-1’), 2.15-1.97 (4S, 3H each, 12H, -(O)CH3), 1.53 (dd, J = 1.92, 6.86 Hz, 6H, 
H-12’,13’); 13C NMR (CDCl3, 75 MHz): δ 175.35, 173.59, 170.10, 168.43, 142.56, 
131.08, 128.98, 119.74, 82.97, 74.68, 71.080, 68.33, 67.55, 67.34, 61.57, 53.20, 52.64, 
37.76, 35.85, 30.53, 29.88, 29.44, 24.30, 23.91, 23.21, 20.88;  ; MS (ESI) calcd for 








To a solution of compound 3.25  (0.050 g, 87 μmol) in THF:H2O (3:1.5)  4.5 mL, allyl 
azide (0.014 g, 174 μmol) CuSO4.5H2O (0.004 g 20%) and sodium ascorbate (0.007 g, 
40%) were added and after 12 hrs of reaction time following the general procedure 
(7.2.1) described above, β-D-thiogalactopyranoside 3.29 (45 mg, 78%) was obtained; Rf 
0.37 (EtOAc/Hexane 7:3);  
22
D  - 28.25 (c = 1.0 in CH2Cl2); 1H NMR (CDCl3, 300 
MHz): δ 7.38 (s, 1H, H-10’), 6.1 - 5.9 (m, 1H, H-12’), 5.43 (d, J = 0.82, 2.47 Hz, 1H, H-
4), 5.32 - 5.29 (m, 2H, H-13’), 5.20 - 5.16 (m, 2H, H-2, H-3), 5.10 - 5.07 (m, 1H, H-5), 
4.95 - 4.91 (m, 3H, H-11’, H-5’), 4.41 (d, J = 7.41 Hz, 2H, H-6a,6b), 4.04 - 3.98 (m, 2H, 
H-2’), 3.77 (s, 3H, H-7’), 3.54 - 3.48 (m, 2H, H-8’), 3.22 (d, J = 9.34, 1H, H-1), 2.54 (dd, 
J =  4.39, 18.68 Hz, 1H, H-1’), 2.15 - 1.98 (4S, 12H, 3H each, -(O)CH3); 13C NMR 
(CDCl3, 75 MHz): δ175.38, 173.63, 170.58, 170.38, 170.10, 170.01, 168.36, 143.11, 
131.46, 122.15, 120.13, 82.97, 74.668, 71.80, 67.53, 67.33, 61.56, 53.22, 52.76, 52.61, 
37.73, 35.83, 24.25, 20.938, 20.89, 20.85, 20.74;  MS (ESI) calcd for C27H34N4O13S + 










To a solution of compound 3.25  (0.050 g, 87 μmol) in THF:H2O (3:1.5)  4.5 mL, 4-(2-
azidoethyl) phenol (0.028 g,  174 μmol) CuSO4.5H2O (0.004 g 20%) and sodium 
ascorbate (0.007 g, 40%) were added and after 12 hrs of reaction time following the 
general procedure (7.2.1) described above, β-D-thiogalactopyranoside 3.30 (51 mg, 79%) 
was obtained; Rf 0.25 (EtOAc/Hexane 7:3);  22D  - 16.7 (c = 1.0 in CH2Cl2); 
1H NMR 
(CDCl3, 300 MHz): δ7.13 (s, 1H, H-10’), 6.86 (d, J = 8.51 Hz, H-14’, 2H, HArom), 6.74 
(d, J = 6.74 Hz, H-15’, 2H, HArom), 5.43 (d, J = 3.29 Hz, 1H, H-4), 5.18 - 5.13 (m, 2H, H-
2, H-3), 5.10 - 5.09 (m, 1H, H-5), 4.95-4.80 (m, 1H, H-5’), 4.48 (t, J = 6.59 Hz, 2H, H-
11’), 4.14 - 4.11 (m, 2H, H-6a, 6b), 4.03 - 3.97 (m, 2H, H-2’), 3.76 (s, 3H, H-7’), 3.49 - 
3.43 (m, 2H, H-8’), 3.17 (dd, J = 9.34, 18.68 Hz, 1H, H-1), 3.07 (t, J = 6.86 Hz, 2H, H-
12’), 2.54 (dd, J =  4.39, 18.95 Hz, 1H, H-1’), 2.15 - 1.98 (4S, 12H, 3H each, -(O)CH3); 
13C NMR (CDCl3, 75 MHz): δ 175.33, 173.79, 170.79, 170.46, 170.19, 168.36, 155.41, 
142.54, 130.00, 128.64, 122.70, 115.92, 83.07, 74.6271.79, 67.62, 67.39, 61.62, 53.52, 
52.67, 52.04, 38.07, 35.95, 35.84, 24.15, 20.94, 20.89, 20.85, 20.75; MS (ESI) calcd for 









To a solution of compound 3.25  (0.050 g, 87 μmol) in THF : H2O (3:1.5)  4.5 mL, 
benzyl azide (0.023 g, 174 μmol) CuSO4.5H2O (0.004 g, 20%) and sodium ascorbate 
(0.007 g, 40%) were added and after 12 hrs of reaction time following the general 
procedure (7.2.1) described above, β-D-thiogalactopyranoside 3.31 (51 mg, 79%) was 
obtained; Rf 0.38 (EtOAc/Hexane 7:3);  
22
D  - 21.04 (c = 1.0 in CH2Cl2); 1H NMR 
(CDCl3, 300 MHz): δ 7.34 - 7.31 (m, 3H, HArom), 7.22 (s, 1H, H-10’), 7.17 - 7.15 (m, 2H, 
HArom), 5.44 -5.35 (m, 3H, H-4, H-11’), 5.14 - 5.12 (m, 2H, H-2, H-3), 5.06 - 5.04 (m, 
1H, H-5), 4.95-4.80 (m, 1H, H-5’), 4.08 (d, J = 6.31 Hz, 2H, H-6a, 6b), 3.96 - 3.91 (m, 
2H, H-2’), 3.71 (s, 3H, H-7’), 3.47 - 3.42 (m, 2H, H-8’), 3.12 (dd, J = 9.34, 18.68 Hz, 1H, 
H-1), 2.35 (dd, J =  4.39, 18.68 Hz, 1H, H-1’), 2.12 - 1.94 (4S, 12H, 3H each, -(O)CH3); 
13C NMR (CDCl3, 75 MHz): δ 175.16, 173.26, 170.15, 169.86, 169.77, 168.05, 143.13, 
134.73, 121.9482.68, 74.46, 71.57, 67.29, 67.10, 61.31, 54.01, 52.98, 52.31, 37.20, 








To a solution of compound 3.26 (0.050 g, 87 μmol) in THF:H2O (3:1.5) 4.5 mL, n-propyl 
azide (0.015 g, 174 μmol) CuSO4.5H2O (0.004 g 20%) and sodium ascorbate (0.007g, 
40%) were added and after 12 hrs of reaction time following the general procedure 
(7.2.1) described above, β-D-thiogalactopyranoside 3.32 (0.045 g, 79%) was obtained; Rf 
0.37 (EtOAc/Hexane 7:3);  
22
D  - 48.68° (c = 1.0 in CH2Cl2); 1H NMR (CDCl3, 300 
MHz): δ7.39 (s, 1H, H-10’), 5.47 - 5.44 (m, 2H, H-1’, H-4), 5.14 - 5.04 (m, 2H, H-2’), 
4.89 (dd, J = 4.12,11.26 Hz, 1H, H-5’), 4.42 - 4.39 (m, 1H, H-5), 4.30 (t, J = 7.37 Hz, 
1H, H-11’), 4.13 (dd, J 3,4 = 5.29, J3,2 = 11.53 Hz, 1H, H-3), 4.01 - 3.91 (m, 2H, H-6a,6b), 
3.80 (s, 3H, H-7’), 3.64 (dd, J = 11.26, 15.10 Hz, 1H, H-2), 3.47-3.33 (m, 2H, H-8’), 3.14 
(d, J = 9.61, Hz, 1H, H-1), 2.14-1.97 (4S, 3H each, -C(O)CH3), 1.89 (m, 2H, H-12’), 0.90 
(t, J = 7.41 Hz, 3H, H-13’); 13C NMR (CDCl3, 75 MHz): δ174.27 (C-3’), 173.92 (C-4’), 
170.54, 170.25, 169.98, 169.84 (OCOCH3, C=O), 168.14 (C-6’), 142.71 (C-9’), 121.86 
(C-10’), 82.43 (C-5), 73.93 (C-1), 71.20 (C-3), 67.71 (C-2), 67.08 (C-4), 62.02 (C-6), 
53.10 (C-11’), 53.06 (C-5’), 51.78 (C-7’), 41.81 (C-2’), 36.91 (C-1’), 23.64 (C-8’), 23.56 
(C-12’), 20.71-20.56 (4C, OCOCH3), 10.843 (C-13’); MS (ESI) calcd for C27H36N4O13S 







To a solution of compound 3.26 (0.050 g, 87 μmol) in THF:H2O (3:1.5)  4.5 mL, 
Isopropyl azide (0.015 g, 174 μmol) CuSO4.5H2O (0.004 g 20%) and sodium ascorbate 
(0.007 g, 40%) were added and after 12 hrs of reaction time following the general 
procedure (7.2.1) described above, β-D-thiogalactopyranoside 3.33 (0.046 g, 81%) was 
obtained; Rf 0.20 (EtOAc/Hexane 7:3);  
22
D – 39.49° (c = 1.0 in CH2Cl2); 1H NMR 
(CDCl3, 300 MHz): δ 7.41 (s, 1H, H-10’), 5.45 - 5.42 (m, 2H, H-1’, H-4), 5.16 - 5.12 (m, 
2H, H-2’), 4.92 - 4.81 (m, 2H, H-5’, H-11’), 4.43 - 4.40 (m, 1H, H-5), 4.14 (dd, J3,4 = 
4.94, J3,2 = 11.53 Hz, 1H, H-3), 4.02 - 3.92 (m, 2H, H-6a,6b), 3.80 (s, 3H, H-7’), 3.64 (dd, 
J = 11.26, 15.10 Hz, 1H, H-2), 3.47 - 3.34 (m, 2H, H-8’), 3.14 (dd, J = 9.61, 18.68 Hz, 
1H, H-1), 2.14 - 1.97 (4S, 3H each, -C(O)CH3), 1.54 (2d, J = 1.92, 6.86 Hz, 6H, H-
12’,13’); 13C NMR (CDCl3, 75 MHz): 174.50 (C-3’), 174.18 (C-4’), 170.9, 170.49, 
170.21, 170.09 (OCOCH3, C=O), 168.41 (C-6’), 142.73 (C-9’), 119.71 (C-10’), 82.64 
(C-5), 74.14 (C-1), 71.51 (C-3), 67.91 (C-2), 67.34 (C-4), 62.28 (C-6), 53.34 (C-11’, C-
5’), 53.17 (C-7’), 42.02 (C-2’), 37.15 (C-1’), 23.87 (C-8’), 23.15, 25.13 (C-12’, 13’), 







To a solution of compound 3.26 (0.050 g, 87 μmol) in THF:H2O (3:1.5)  4.5 mL, allyl 
azide (0.015 g, 174 μmol) CuSO4.5H2O (0.004 g, 20%) and sodium ascorbate (0.007 g, 
40%) were added and after 12 hrs of reaction time following the general procedure 
(7.2.1) described above, β-D-thiogalactopyranoside 3.34 (0.044 g, 77%) was obtained; Rf 
0.39 (EtOAc /Hexane 7:3);  
22
D –33.19° (c = 1.0 in CH2Cl2); 1H NMR (CDCl3, 300 
MHz): δ 7.42 (s, 1H, H-10’), 6.00 - 5.94 (m, 1H, H-12’), 5.46 - 5.43 (m, 2H, H-1’, H-4), 
5.30 (dd, J = 0.82, 12.91Hz, 2H, H-13’), 5.21 - 5.11 (m, 2H, H-2’), 5.05 - 4.96 (m, 2H, 
H-11’), 4.93 - 4.88 (dd, J = 3.6, 4.12 Hz, 1H, H-5’), 4.40 - 4.38 (m, 1H, H-5), 4.14 (dd, 
J3,4= 4.94, J3,2 = 11.53 Hz, 1H, H-3), 4.01 - 3.92 (m, 2H, H-6a,6b), 3.80 (s, 3H, H-7’), 
3.70 - 3.61 (m, 1H, H-2), 3.48 - 3.33 (m, 2H, H-8’) 3.15 (d, J  = 9.34, 1H, H-1), 2.14, 
2.05, 2.04, 1.97 (4S, 12H, 3H each,-C(O)CH3); 13C NMR (CDCl3, 75 MHz): δ 174.31(C-
3’), 173.93 (C-4’), 170.55-169.90 (OCOCH3, C=O), 168.11 (C-6’), 143.02 (C-9’), 131.30 
(C-12’), 121.97 (C-10’), 119.83 (C-13), 82.47 (C-5), 73.97 (C-1), 71.26 (C-3), 67.70 (C-
2), 67.08 (C-4), 62.02 (C-6), 53.14 (C-11’), 53.01 (C-5’), 52.53 (C-7’), 41.81 (C-2’), 
36.91 (C-1’), 23.58 (C-8’), 20.58-20.56 (4C, OCOCH3); MS (ESI) calcd for 






To a solution of compound 3.26 (0.063 g, 113 μmol) in THF:H2O (3:1.5)  4.5 mL, 4-(2-
azido ethyl) phenol (0.037 g, 227 μmol) CuSO4.5H2O (0.005 g 20%) and sodium 
ascorbate (0.008 g, 40%) were added and after 12 hrs of reaction time following the 
general procedure (7.2.1) described above, β-D-thiogalactopyranoside 3.35 (0.065 g, 
80%); (0.191 g, 79%) was obtained; Rf 0.27 (EtOAc/Hexane 7:3);  
22
D  – 64.45° (c = 1.0 
in CH2Cl2); 1H NMR (CDCl3, 300 MHz): δ 7.00 (s, 1H, H-10’), 6.85 - 6.75 (m, 4H, 
HArom), 5.55 - 5.52 (m, 1H, H-1’), 5.44 (dd, J = 1.09, 3.57 Hz, 1H, H-4), 5.25-5.04 (m, 
2H, H-2’), 4.80 (dd, J = 3.57, 11.26 Hz, 1H, H-5’), 4.65 - 4.61(m, 1H, H-5), 4.46 - 4.40 
(m, 2H, H-11’), 4.14 (dd, J = 5.21,11.53Hz, 1H, H-3), 4.06 - 3.91(m, 2H, H-6a,6b), 3.80 
(s, 3H, H-7’) 3.58 (dd, J = 11.26, 15.10 Hz, 1H, H-2), 3.47 - 3.33 (m, 2H, H-8’), 3.15 
(dd, J = 9.61, 18.68 Hz, 1H, H-1), 3.06 (t, J = 6.59 Hz, 2H, H-12’), 2.16,2.06,2.00,1.99 
(4s, 12H, 3H each,-C(O)CH3); 13C NMR (CDCl3, 75 MHz): δ 174.45 (C-3’), 174.07 (C-
4’), 170.84, 170.40, 170.10, 169.98 (OCOCH3, C=O), 168.15 (C-6’), 154.99 (CArom), 
142.73 (C-9’), 130.04 (CArom), 128.799 (CArom)122.80 (C-10’), 115.64 (CArom), 82.42 (C-
5), 73.94 (C-1), 71.21 (C-3), 67.87 (C-2), 67.21 (C-4), 62.14 (C-6), 53.16 (C-11’, C-5’), 









To a solution of compound 3.26 (0.050 g, 87 μmol) in THF:H2O (3:1.5)  4.5 mL, benzyl 
azide (0.023 g, 174 μmol) CuSO4.5H2O (0.004 g, 20%) and sodium ascorbate (0.007g, 
40%) were added and after 12 hrs of reaction time following the general procedure 
(7.2.1) described above, β-D-thiogalactopyranoside 3.36 (0.047 g, 76%) was obtained; Rf 
0.40 (EtOAc/Hexane 7:3);  
22
D – 36.06° (c = 1.0 in CH2Cl2); 1H NMR (CDCl3, 300 
MHz): δ7.37 - 7.34 (m, 3H, HArom), 7.31 (s, 1H, H-10’),7.24 - 7.21 (m, 2H, HArom), 5.53 -
5.44 (m, 4H, H-11’, H-1’, H-4), 5.20 - 5.07 (m, 2H, H-2’) 4.89 (dd, J = 4.21, 11.53 Hz, 
1H, H-5’), 4.40 - 4.39 (m, 1H, H-5), 4.14 (dd, J = 5.22, 11.53 Hz, 1H, H-3), 4.02 - 3.88 
(m, 2H, H-6a,6b), 3.79 (s, 3H, H-7’), 3.63 (dd, J = 11.26, 15.10 Hz, 1H, H-2), 3.44 - 3.32 
(m, 2H, H-8’), 3.11 (dd, J = 9.61, 18.67 Hz, 1H, H-1), 2.15, 2.06, 2.04, 1.97 (4S, 12H, 3 
H each,-C(O)CH3); 13C NMR (CDCl3, 75 MHz): δ 174.53 (C-3’), 174.12 (C-4’), 170.78, 
170.49, 170.25, 170.14 (OCOCH3, C=O), 168.31 (C-6’), 142.73 (C-9’), 134. 95 (CArom), 
129.28-128.21 (CArom), 122.29 (C-10’), 82.72 (C-5), 74.23 (C-1), 71.48 (C-3), 67.95 (C-




(C-1’), 23.83 (C-8’), 21.00-20.79 (4C, OCOCH3); MS (ESI) calcd for C31H36N4O13S + 
H+: 705.70, found 705.21. 
Compound 3.43 
 
To a solution of known α-bromo galactose 3.41 (0.171 g, 283 µmol) was added 10 ml of 
acetone, thiourea (0.032 g, 420 µmol) and the reaction mixture refluxed overnight. The 
reaction mixture was rotovapped to get the thiouronium salt. The thiouronium salt was 
dissolved in 2.2 ml of water and 3.3 ml of dichloromethane. Then 75 mg of K2S2O5 was 
added and refluxed for 20 minutes. The reaction mixture was allowed to drop to room 
temperature, both the aqueous and organic layers were separated and the organic layer 
dried to get 79 mg of crude α and β anomeric mixture thiol galactose. The crude product 
was purified by flash chromatography column using dichloromethane alone to obtain α 
(3.43) and β anomer (3.43) ; Rf 0.33 (Hex/EtOAc 8.0:2.0);  
24
D + 0.74 (c 1.0, CH2Cl2); 
1H NMR (300 MHz, CDCl3) δ 7.38 - 7.18 (m, 20H, Harom), 4.88 (dd, J = 17.8, 7.8 Hz, 
2H, CH2-Ph ), 4.68 (s, 1H, CH2-Ph), 4.58 (d, J = 11.6 Hz, 1H, CH2-Ph), 4.46 - 4.33 (m, 
3H, CH2-Ph), 3.93 (d, J = 2.8 Hz, 1H, H-4), 3.72 (t, J = 9.3 Hz, 1H, H-1), 3.58 - 3.47 (m, 
5H, H-2,3,5,6,6’), 2.26 (d, J = 8.4 Hz, 1H, SH); 13C NMR (75 MHz, CDCl3) δ 138.55, 
138.41, 137.84, 128.37, 128.33, 128.27, 128.22, 127.85, 127.83, 127.71, 127.62, 127.52, 
127.46, 79.60, 78.66, 75.80, 74.80, 74.73, 73.40, 73.24, 72.54, 70.36, 68.56; MS (ESI) 






Rf 0.41 (Hex : EtOAc 8.0 : 2.0); 1H NMR (300 MHz, CDCl3) δ 7.48 - 7.14 (m, 20H), 
5.83 - 5.79 (m, 1H, H-1), 4.85 (d, 11.6 Hz, 2H, CH2-Ph), 4.74 - 4.51 (m, 4H, CH2-Ph), 
4.42 (d, J = 11.9 Hz, 2H, CH2-Ph), 4.31 (t, J = 6.3 Hz, 1H, H-5), 4.22 (dd, J = 9.8, 5.3 
Hz, 1H, H-2), 3.94 (d, J = 1.6 Hz, 1H, H-4), 3.78 (dd, J = 9.8, 2.8 Hz, 1H, H-3), 3.50 (d, 
J = 6.4 Hz, 2H, H-6,6’), 1.80 (d, J = 3.9 Hz, 1H, SH); 13C NMR (75 MHz, CDCl3) δ 
138.53, 137.92, 128.34, 128.30, 128.24, 128.19, 127.82, 127.68, 127.59, 127.49, 127.42, 
79.58, 78.63, 75.78, 74.77, 74.71, 73.37, 73.21, 72.50, 70.34, 68.54; MS (ESI) calcd for 
C34H36O5S + H+: 557.23, found 557.21. 
Compound 3.48 
 
To a solution of galactose thiol 3.45 (0.1 g, 179 µmol) and L-propargyl maliemide (0.037 
g, 179 µmol) in dichloromethane (5 mL) was added 2 drops of TEA and stirred at RT 
overnight. The reaction mixture was concentrated on rotovap and purified by flash 
chromatography column using 2-4% ether in toluene to get α and β-D-thiolactoyranoside 
mixture in almost 50:50 mixture. Both the diastereomers were separated by column 
chromatography. 3.48 is α isomer, 3.49 is β isomer (134 mg, 98% together); Rf 0.27 




J = 24.8, 16.2, 7.8 Hz, 4H), 4.76 - 4.65 (m, 2H), 4.65 - 4.53 (m, 2H), 4.47 - 4.32 (m, 2H), 
4.07 (dd, J = 8.3, 5.3 Hz, 1H), 3.93 (t, J = 9.3 Hz, 2H), 3.66 (s, 3H), 3.61 (d, J = 6.5 Hz, 
1H), 3.58 - 3.43 (m, 4H), 3.21 - 3.07 (m, 2H), 3.06 - 2.89 (m, 2H), 1.87 (t, J = 2.5 Hz, 
1H); 13C NMR (75 MHz, CDCl3) δ 174.14, 173.70, 166.94, 138.08, 137.66, 137.61, 
137.26, 127.96, 127.85, 127.83, 127.78, 127.56, 127.50, 127.38, 127.27, 127.24, 127.14, 
127.09, 83.16, 82.88, 78.46, 76.58, 75.13, 74.08, 72.99, 72.71, 72.04, 70.78, 67.66, 52.62, 




Rf 0.20 (Toluene/Ether 8.5:1.5);  23D - 17.68 (c 1.0, CH2Cl2); 
1H NMR (300 MHz, 
CDCl3) δ 7.43 - 7.14 (m, 20H), 5.03 (d, J = 9.7 Hz, 1H), 4.97 - 4.84 (m, 2H), 4.75 (d, J = 
4.0 Hz, 2H), 4.69 (s, 2H), 4.60 (d, J = 11.6 Hz, 1H), 4.47 - 4.34 (m, 2H), 4.13 (dd, J = 
9.3, 4.0 Hz, 1H), 3.95 (d, J = 2.5 Hz, 1H), 3.80 (t, J = 9.5 Hz, 1H), 3.68 (s, 3H), 3.57 
(ddd, J = 22.6, 15.0, 7.9 Hz, 5H), 3.25 - 3.12 (m, 1H), 2.97 (dd, J = 5.1, 2.6 Hz, 1H), 2.91 
(dd, J = 5.2, 2.7 Hz, 1H), 2.67 (dd, J = 18.9, 4.0 Hz, 1H), 1.88 (t, J = 2.6 Hz, 1H); 13C 
NMR (75 MHz, CDCl3) δ 176.27, 173.81, 167.47, 138.49, 138.30, 137.89, 137.82, 
128.42, 128.34, 128.30, 128.26, 127.78, 127.68, 127.66, 127.56, 127.50, 83.54, 78.95, 
78.49, 75.80, 74.76, 74.69, 73.54, 73.45, 71.82, 71.19, 71.03, 69.34, 52.95, 50.74, 35.43, 






To a solution of compound 3.48  ( 43 mg, 56 μmol) in THF:H2O (1:1)  2 mL, isopropyl  
azide (7 mg, 82 μmol) CuSO4.5H2O (2 mg 0.2eq) and sodium ascorbate (4 mg, 0.4eq) 
were added and after 12h of reaction time following the general procedure described 
above, β-D-thio galactopyranoside 3.50 (0.033g, 70%) was obtained; Rf 0.12 (Toluene 
/Ether 8.5:1.5);  
24
D - 21. (c 1.0, CH2Cl2); 1H NMR (300 MHz, CDCl3) δ 7.41 - 7.14 (m, 
20H), 5.00 - 4.87 (m, 2H), 4.81 (q, J = 10.4 Hz, 2H), 4.68 (d, J = 2.5 Hz, 2H), 4.66 - 4.60 
(m, 2H), 4.60 - 4.53 (m, 1H), 4.40 (q, J = 11.8 Hz, 2H), 4.01 (t, J = 6.8 Hz, 1H), 3.95 (d, 
J = 2.3 Hz, 1H), 3.86 (t, J = 9.4 Hz, 1H), 3.68 (s, 3H), 3.67 - 3.53 (m, 3H), 3.52 - 3.37 
(m, 3H), 3.03 (d, J = 6.8 Hz, 2H), 1.44 (t, J = 6.6 Hz, 6H); 13C NMR (75 MHz, CDCl3) δ 
174.73, 174.30, 168.28, 142.45, 138.59, 138.19, 138.16, 137.81, 128.35, 128.32, 128.20, 
128.17, 128.00, 127.91, 127.73, 127.62, 127.59, 127.50, 127.48, 119.43, 83.64, 83.46, 
77.98, 76.77, 75.50, 74.52, 73.36, 73.27, 72.51, 68.06, 52.88, 52.77, 52.47, 39.74, 38.14, 








To a solution of compound 3.49 (34 mg, 44 μmol) in THF : H2O (1:1)  2 mL, isopropyl  
azide (6 mg, 82 μmol) CuSO4.5H2O (2 mg 0.2eq) and sodium ascorbate (4 mg, 0.4eq) 
were added and after 12h of reaction time following the general procedure described 
above, β-D-thio galactopyranoside 3.51 (32 mg, 70%) was obtained; Rf 0.1 
(Toluene/Ether 8.5:1.5);  
24
D - 50.50 (c 1.0, CH2Cl2); 1H NMR (300 MHz, CDCl3) δ 
7.38 - 7.15 (m, 1H), 5.05 - 4.85 (m, 20H), 4.76 (dd, J = 22.1, 10.9 Hz, 3H), 4.66 (d, J = 
2.1 Hz, 2H), 4.64 - 4.52 (m, 2H), 4.47 - 4.28 (m, 2H), 4.04 (dd, J = 9.4, 4.1 Hz, 2H), 3.94 
(d, J = 2.1 Hz, 1H), 3.77 (t, J = 9.4 Hz, 1H), 3.70 (s, 1H), 3.65 - 3.52 (m, 1H), 3.48 (s, 
3H), 3.11 (dd, J = 18.9, 9.4 Hz, 4H), 2.51 (dd, J = 18.9, 4.1 Hz, 2H), 1.40 (t, J = 6.6 Hz, 
6H); 13C NMR (75 MHz, CDCl3) δ 175.31, 173.42, 168.19, 142.08, 138.25, 137.84, 
137.49, 128.24, 128.21, 128.04, 128.00, 127.98, 127.75, 127.65, 127.59, 127.50, 127.41, 
127.38, 119.54, 83.66, 83.60, 77.93, 76.42, 75.03, 74.38, 73.30, 73.15, 72.52, 68.23, 
52.69, 52.53, 52.15, 37.17, 35.72, 24.02, 22.71, 22.69. HRMS (ESI) calculated for 









To the solution of compound 3.23 (0.450 g, 1.2 mmol) in DCM added TBDPSiCl (0.37 
ml 1.2 eq), TEA (0.33 mL, 2 eq) and DMAP (catalytic) and stirred at RT for 1 hr and 
concentrated the RM under vacuum and flashed the crude product using 10-20% EtOAc 
in hexane to obtain pure product 3.52 ( 0.446g, 60%); 1H NMR (300 MHz, CDCl3) δ 
7.87 - 7.69 (m, 4H), 7.54 - 7.33 (m, 6H), 5.28 (t, J = 9.9 Hz, 1H), 5.20 (dd, J = 3.4, 1.0 
Hz, 1H), 4.68 (dd, J = 10.0, 3.4 Hz, 1H), 4.01 (d, J = 9.8 Hz, 1H), 3.85 (dd, J = 11.2, 7.3 
Hz, 1H), 3.67 (dd, J = 11.2, 6.2 Hz, 1H), 3.16 (t, J = 6.8 Hz, 1H), 2.12 (s, 3H), 2.06 (s, 
3H), 1.92 (s, 3H), 1.89 (s, 3H), 1.11 (s, 9H); 13C NMR (75 MHz, CDCl3) δ 170.20, 
170.03, 170.00, 169.38, 136.41, 136.14, 131.95, 131.67, 130.20, 130.03, 127.81, 127.50, 
81.16, 73.96, 71.75, 69.57, 66.93, 60.76, 27.45, 20.75, 20.62, 20.47, 20.44, 20.22; 




To the solution of compound 3.52 (0.1 g, 166 μmol ) in 2 mL of dry methanol, 0.2 ml of 
NaOMe/MeOH solution (pH = 10) was added and stirred at RT for 4 hrs of reaction time 
following the general procedure (7.2.4) to obtain deprotected β-D-S-galactopyranoside 




6H), 4.42 - 4.00 (m, 1H), 3.89 - 3.74 (m, 1H), 3.65 (d, J = 10.4 Hz, 2H), 3.46 - 3.23 (m, 
1H), 2.80 (s, 1H), 2.37 - 2.16 (m, 1H), 1.15 - 0.94 (m, 9H). 
Compound 3.58 
 
To a solution of 3.57 (0.053 g, 135 µmol) in dry DCM was added chloroacetic anhydride, 
(0.278 g, 1.6 mmol), DMAP, pyridine (catalytic) and stirred the reaction mixture  for 12 
hrs and concentrated the reaction mixture in vaccuo. Crude product purified by flash 
chromatography using DCM alone to obtain chloroacetylated galactosethiol dimer 3.58 
(0.74 g, 55%); 1H NMR (300 MHz, CDCl3) δ 6.50 (d, J = 2.7 Hz, 2H), 5.61 (s, 2H), 5.49 
(dd, J = 9.2, 6.7 Hz, 3H), 5.31 (d, J = 0.6 Hz, 2H), 4.49 (t, J = 6.8 Hz, 2H), 4.28 (d, J = 
6.7 Hz, 2H), 4.18 (d, J = 0.5 Hz, 4H), 4.17 (s, 4H), 4.07 (d, J = 0.5 Hz, 4H), 4.03 (d, J = 











To a solution of 6.26 (24 mg, 79 μmol) and 2,3,4,6-tetra-O-acetyl-β-D-
thiogalactoyranoside 3.23 ( 35 mg, 96 μmol) in CH2Cl2 5 mL was added 4 drops of TEA 
and stirred at RT overnight. The reaction mixture was concentrated on a rotovap and 
crude purified by flash column chromatography using 30% EtOAc in hexane to obtain β-
D-thiogalactoyranoside 3.59 (38 mg, 57 μmol). Rf 0.26 (CH2Cl2/MeOH 9.5:0.5);  
22
D  + 
9.99 (c 1.0, CH2Cl2); 1H NMR (CDCl3, 300 MHz): δ 7.38 (s, 1H, H-6’),  5.80 (d, J = 
8.51Hz, 1H, NH), 5.36 (d, J = 3.29 Hz, 1H, H-4), 5.17 (t, J = 9.88 Hz, 1H, H-5), 5.00 
(dd, J = 3.29, 3.29 Hz, 1H, H-3), 4.57 (d, J = 9.88 Hz, 1H, H-2), 4.44 – 4.40 (m, 1H, H-
3’), 4.24 (t, J = 7.41 Hz, 2H, H-7’) 4.06 - 4.00 (m, 2H, H-6a,b), 3.94 (d, J = 9.8 Hz, 1H, 
H-1), 3.70 (s, 3H, H-11’), 3.39 - 3.31 (m, 2H, H4’), 3.23 - 3.20 (m, 2H, H-2’), 3.04 (t, J = 
8.24 Hz, 2H, H-1’). 2.10 - 2.00 (4S, 3 H each,-C(O)CH3), 1.86 - 1.81 (m, 2H, H-8’), 0.88 
(t, J = 7.41 Hz, 3H, H-9’); 13C NMR (CDCl3, 75 MHz): δ 173.243, 143.91, 124.85, 
88.00, 80.690, 76.21, 71.17, 70.47, 62.65, 57.13, 55.42, 53.23, 52.98, 30.18, 24.67, 








To a solution of 6.27 (20 mg, 66 μmol) and 2,3,4,6-tetra-O-acetyl-β-D-thiogalactoyran- 
oside 3.23 ( 25.9 mg, 79 μmol) in CH2Cl2 5mL was added 4 drops of TEA and stirred at 
RT overnight. The reaction mixture was concentrated on a rotovap and crude purified by 
flash column chromatography using 30% EtOAc in hexane to obtain β-D-
thiogalactoyranoside 3.60 (32 mg, 47.9 μmol); Rf 0.22 (CH2Cl2 /MeOH 9.5:0.5);  
22
D  + 
23.40 (c 1.0, CH2Cl2); 1H NMR (CDCl3, 300 MHz): δ7.37 (s, 1H, H-6’), 5.95 – 5.90 (m, 
1H, H-8’) 5.71 (d, J = 8.51Hz, 1H, NH), 5.38 (d, J = 2.4 Hz, 1H, H-4), 5.30 (dd, J = 10.2, 
1.1, Hz, 1H, H-9’), 5.19 (ddd, J = 0.824,9.34, 9.88 Hz, 1H, H-5), 5.01 (dd, J = 3.29, 3.57 
Hz, 1H, H-3), 4.91 (d, J = 3.57 Hz, 1H, H-7’), 4.58 (d, J = 9.89 Hz, 1H, H-2), 4.44 - 4.40 
(m, 1H, H-3’), 4.07 - 4.01 (m, 2H, H-6a,b), 3.95 (d, J = 9.8 Hz, 1H, H-1), 3.79 (s, 3H, H-
11’), 3.39 - 3.31 (m, 2H, H4’), 3.23 - 3.21 (m, 2H, H-2’), 3.04 - 3.00 (m, 2H, H-1’). 2.11 
- 1.93 (4S, 3H each,-C(O)CH3); 13C NMR (CDCl3, 75 MHz): δ171.68 ( C-10’), 170.73 - 
169.83 (OCOCH3, C=O), 142.62 (C-5’), 131.280 (C-8’), 122.34 (C-6’), 120.527 (C-9’), 
85.06 (C-1), 74.74 (C-5) 71.92 (C-2), 67.45 ( C-4), 67.09 (C-3), 62.01 (C-6), 55.49 (C-
3’), 54.92 (C-2’), 53.15(C-11’), 53.00 (C-7’), 29.15 (C-4’), 24.98 (C-1’), 20.99–20.78 






To a solution of 6.28 (16 mg, 53 μmol) and 2,3,4,6-tetra-O-acetyl-β-D-
thiogalactoyranoside 3.23 ( 19.2 mg, 52 μmol) in CH2Cl2 5mL was added 4 drops of TEA 
and stirred at RT overnight. The reaction mixture was concentrated on a rotovap and 
crude purified by flash column chromatography using 30% EtOAc in hexane to obtain β-
D-thiogalactoyranoside 3.61 (20 mg, 30 μmol). Rf  0.24 (CH2Cl2/MeOH 9.5:0.5);  
22
D  + 
41.96 (c 1.0, CH2Cl2); 1H NMR (CDCl3, 300 MHz): δ7.38 (s, 1H, H-6’), 5.72 (d, J = 
8.79Hz, 1H, NH), 5.38 (d, J = 2.47 Hz, 1H, H-4), 5.18 (t, J = 9.88 Hz, 1H, H-5), 5.01 
(dd, J = 3.29, 3.29 Hz, 1H, H-3), 4.74 (qu, J = 6.86 Hz, 1H, H-7’), 4.59 (d, J = 9.88Hz, 
1H, H-2) 4.46 – 4.40 (m, 1H, H-3’), 4.08 - 4.01 (m, 2H, H-6a,b), 3.95 (d, J = 9.8 Hz, 1H, 
H-1), 3.72 (s, 3H, H-11’), 3.41- 3.33 (m, 2H, H4’), 3.23 - 3.19 (m, 2H, H-2’), 3.06 (t, J = 
7.41 Hz, 2H, H-1’), 2.12 - 1.94 (4S, 3 H each,-C(O)CH3), 1.53 (d, J = 6.86 Hz,  6H, H-8’ 
and 9’); 13C NMR (CDCl3, 75 MHz): δ 171.74 ( C-10’), 170.74–169.81 (OCOCH3, 
C=O), 142.12 (C-5’), 119.92 (C-6’), 85.12 (C-1), 74.74 (C-5) 71.95 (C-2), 67.48 ( C-4), 
67.11 (C-3), 62.03 (C-6), 55.49 (C-3’), 54.96 (C-2’), 53.15(C-11’), 29.88 (C-8’), 
29.44(C-9’) 25.09(C-4’), 23.18 (C-1’), 21.00–20.79 (OCOCH3); MS (ESI) calcd for 






To a solution of 6.29 (38 mg, 115 μmol) and 2,3,4,6-tetra-O-acetyl-β-D-
thiogalactoyranoside 3.23 (50.5 mg, 138 μmol) in CH2Cl2 5mL was added 4 drops of 
TEA and stirred at RT overnight. The reaction mixture was concentrated on a rotovap 
and crude purified by flash column chromatography using 30% EtOAc in hexane to 
obtain β-D-thiogalactoyranoside 3.62 (61 mg, 88 μmol). Rf 0.22 (CH2Cl2/MeOH 9.5:0.5); 
 
22
D  + 8.06 (c 1.0, CH2Cl2); 1H NMR (CDCl3, 300 MHz): δ7.36 (s, 1H, H-6’),  5.77 (d, 
J = 8.51Hz, 1H, NH), 5.37 (d, J = 3.29 Hz, 1H, H-4), 5.17 (t, J=9.89 Hz, 1H, H-5), 5.04 
(dd, J = 3.57, 3.29 Hz, 1H, H-3), 4.82 (qu, J = 6.04 Hz, 1H, H-7’), 4.58 (d, J=9.88Hz, 
1H, H-2) 4.44 - 4.41 (m, 1H, H-3’), 4.08 - 4.01 (m, 2H, H-6a,b), 3.96 (d, J = 9.8 Hz, 1H, 
H-1), 3.71 (s, 3H, H-13’), 3.39 - 3.32 (m, 2H, H4’), 3.22 - 3.19 (m, 2H, H-2’), 3.04 (t, J = 
7.41 Hz, 2H, H-1’). 2.11 - 1.69 (4m, 8H, H-8’,9’,10’,11’) 2.11 - 1.93 (4S, 3H each,-
C(O)CH3); 13C NMR (CDCl3, 75 MHz): δ 171.77 ( C-12’), 170.72–169.81 (OCOCH3, 
C=O), 142.15 (C-5’), 121.03 (C-6’), 85.10 (C-1), 74.71 (C-5) 71.93 (C-2), 67.47 ( C-4), 
67.12 (C-3), 62.01 (C-6), 55.51 (C-3’), 54.95 (C-2’), 53.11(C-13’), 33.54 (C-11, C-8), 
29.36 (C-4’), 25.05 (C-1’), 24.20 ( C-9’, C-10’), 21.00 – 20.79 (OCOCH3); MS (ESI) 






To a solution of 6.30 (25 mg, 71 μmol) and 2,3,4,6-tetra-O-acetyl-β-D-
thiogalactoyranoside 3.23 (43 mg, 60 μmol) in CH2Cl2 5mL was added 4 drops of TEA 
and stirred at RT overnight. The reaction mixture was concentrated on a rotovap and 
crude purified by flash column chromatography using 30% EtOAc in hexane to obtain β-
D-thiogalactoyranoside 3.63 (35 mg, 49 μmol); Rf  0.31 (CH2Cl2/MeOH 9.5:0.5);  
22
D  + 
15.29 (c 1.0, CH2Cl2); 1H NMR (CDCl3, 300 MHz): δ 7.31 - 7.27 (m, 3H, H-6’ and 
HArom), 7.20 - 7.18 (m, 2H, HArom), 5.77 (d, J = 8.51Hz, 1H, NH), 5.37 (d, J = 2.47 Hz, 
1H, H-4), 5.17 (t, J = 9.88 Hz, 1H, H-5), 5.01 (dd, J = 3.29, 3.29 Hz, 1H, H-3), 4.58 (d, J 
= 9.88Hz, 1H, H-2), 4.43 - 4.39 (m, 1H, H-3’), 4.06 - 4.01 (m, 2H, H-6a,b), 3.94 (d, J = 
9.8 Hz, 1H, H-1), 3.66 (s, 3H, H-15’), 3.35 - 3.29 (m, 2H, H4’), 3.25 (t, J = 6.31, Hz, 2H, 
H-2’), 3.04 (t, J = 7.41 Hz, 2H, H-1’), 2.11 - 1.93 (4S, 3 H each,-C(O)CH3); 13C NMR 
(CDCl3, 75 MHz): δ171.67 ( C-14’), 170.73 –169.83 (OCOCH3, C=O), 142.84 (C-5’), 
134.99 (C-8’), 129.35 - 128.21 (C-9,10,11,12,13), 122.45 (C-6’), 85.06 (C-1), 74.74 (C-




(C-7’),  53.08 (C-15’), 29.41 (C-4’), 25.00 (C-1’), 21.00 - 20.79 (OCOCH3); MS (ESI) 
calcd for C29H38N4O13S2 + H+: 715.18, found 715.20. 
Compound 3.64 
 
To a solution of compound 3.59 (0.038 g, 56 μmol) in 3 mL of dry methanol, 1M 
NaOMe  solution was added until reaction mixture pH was 9-10. After 4 hrs of reaction 
time following the general procedure described above (8.2.4). The deprotected β-D-
thiogalactopyranoside 3.64 (21 mg, 42 μmol) was obtained; Rf 0.25 (CH2Cl2/MeOH  
9.0:1.0);  
22
D  - 9.96 (c 1.0, CH2Cl2); 1H NMR (CD3OD, 300 MHz): δ 7.76 (s, 1H, H-6’) 
4.28 (t, J = 10.1Hz , 1H, H-7’) 3.81 (d, J = 2.2Hz, 1H, H-4) 3.69 (s, 1H, H-11’), 3.68 - 
3.61 (m,1H), 3.55 - 3.49 (m, 2H), 3.25 - 3.21 (m, 1H) 3.38 - 3.31 (m, 4H), 3.09 (t, J = 
8.3Hz, 2H, H-2’) 2.93 (t, J = 7.5Hz, 2H, H-1’) 1.94 - 1.83 (m, 2H, H-8’), 0.85 (t, J = 
7.4Hz, 3H, H-9’); 13C NMR (CDCl3, 75 MHz): δ 173.24, 143.91, 124.82, 88.00, 80.69, 
76.21, 71.17, 70.47, 62.65, 57.13, 55.42, 53.23, 52.98, 49.85, 30.18, 24.671, 11.251; MS 









To a solution of  compound 3.60 (0.032 g, 48 μmol) in 3 mL of dry methanol, 1M 
NaOMe  solution was added until reaction mixture pH was 9-10, after 4 hrs of reaction 
time following the general procedure described above (8.2.4). The deprotected β-D-
thiogalactopyranoside 3.65 (15 mg, 30 μmol) was obtained; Rf 0.24 (CH2Cl2/MeOH  
9.0:1.0);  
22
D  - 1.34 (c 1.0, CH2Cl2); 1H NMR (CD3OD, 300 MHz): δ7.37 (s, 1H, H-6’), 
5.61 - 5.57 (m, 1H, H-8’), 4.82 (dd, J = 1.3Hz, J = 13.6Hz, 2H, H-9’), 4.56 (td, J = 
1.4Hz, J = 5.9Hz, 1H, H-7’), 3.92 – 3.87 (m, 1H, H-3’), 3.42 (d, J = 2.4 Hz, 1H, H-4), 
3.30 (s, 1H, H-11’), 3.24 - 3.19 (m, 1H), 3.09 - 3.04 (m, 2H) 3.01 (dd, J = 3.2Hz, J = 
9.1Hz,1H), 2.94 - 2.76 (m, 4H), 2.64 (dd, J = 8.5Hz, J = 14.8Hz, 2H, H-2’), 2.51 (t, J = 
7.8Hz, 2H, H-1’); 13C NMR (CDCl3, 75 MHz): δ 173.23, 144.19, 133.24, 124.89, 
119.77, 88.03, 80.69, 76.22, 71.18, 70.48, 62.66, 57.10, 55.43, 53.59, 53.23, 30.17, 










To a solution of  compound 3.61 (0.020 g, 30 μmol ) in 3 mL of dry methanol, 1M 
NaOMe  solution was added until reaction mixture pH was 9-10, after 4 hrs of reaction 
time following the general procedure described above (8.2.4). The deprotected β-D-
thiogalactopyranoside 3.66 (12 mg, 24 μmol) was obtained; Rf 0.25 (CH2Cl2/MeOH  
9.0:1.0);  
22
D  + 23.68 (c 0.5, CH2Cl2); 1H NMR (CD3OD, 300 MHz): δ 7.88 (s, 1H, H-
6’), 4.28 (d, J = 9.6Hz, 1H, H-1), 4.14 - 4.28 (m, 1H, H-7’), 4.20 (dd, J = 4.7Hz, J = 
8.3Hz, 1H, sugar-H), 3.95 (d, J=3.0Hz, 1H, H-4), 3.67(s, 3H, H-11’), 3.35 - 3.60 (m, 2H, 
sugar-H), 3.22 - 3.30 (m, 2H sugar-H), 3.22 (ddd, J = 4.5Hz, J = 10.5Hz, J = 14.5Hz, 2H, 
H-1’), 2.99 (dd, J = 7.2Hz, J=15.3Hz, 2H, H-2’), 2.77 (td, J = 5.8Hz, J = 9.9Hz, 1H, H-
4’), 1.32 (d, J = 6.7Hz, 6H, H-8’,9’); 13C NMR (CDCl3, 75 MHz): δ 173.43, 143.99, 
122.71, 87.91, 80.71, 70.08, 62.60, 57.28, 54.77, 53.21, 30.67, 25.01, 23.14; MS (ESI) 










To a solution of  compound 3.62 (0.059 g, 85 μmol) in 3 mL of dry methanol, 1M NaOMe  
solution was added until reaction mixture pH was 9-10, after 4 hrs of reaction time 
following the general procedure described above (8.2.4). The deprotected β-D-
thiogalactopyranoside 3.67 (34 mg, 65 μmol) was obtained; Rf 0.20 (CH2Cl2/MeOH  
9.0:1.0);  
22
D  - 12.06 (c 1.0, CH2Cl2); 1H NMR (CD3OD, 300 MHz): δ7.39 (s, 1H, H-
6’), 4.55 - 4.48 (m, 1H, H-7’), 3.95 - 3.88 (m, 1H, H-3’), 3.42 (d, J = 2.7Hz, 1H, H-4) 
3.31 (s, 1H, H-13’), 3.28 - 3.18 (m, 1H), 3.12 -  3.06 ( m, 2H), 3.00 (dd, J = 3.2, 9.2Hz, 
1H), 2.95 - 2.75 (m,4H), 2.64 (t, J = 8.3Hz, 2H, H-2’), 2.51 (t, J = 7.5Hz, 2H, H-1’), 1.87 
- 1.75 (m, 2H, cyclopentyl-CH2),1.64 - 1.53 (m, 2H, cyclopentyl-CH2), 1.49 - 1.41(m, 
2H, cyclopentyl-CH2), 1.36 - 1.25 (m, 2H, cyclopentyl-CH2); 13C NMR (CDCl3, 75 
MHz): δ 173.25, 143.82, 123.46, 88.00, 80.69, 76.23, 71.19, 70.48, 63.35, 62.66, 57.09, 
55.50, 53.22, 34.25, 30.21, 25.00, 24.89; MS (ESI) calcd for C19H32N4O10S2 + H+: 









To a solution of  compound 3.63 (0.035 g, 49 μmol) in 3 mL of dry methanol, 1M NaOMe  
solution was added until reaction mixture pH was 9-10, after 4 hrs of reaction time 
following the general procedure described above (8.2.4). The deprotected β-D-
thiogalactopyranoside 3.68 (16 mg, 29 μmol) was obtained. Rf 0.3 (CH2Cl2/MeOH  
9.0:1.0);  
22
D  - 11.92 (c 1.0, CH2Cl2); 1H NMR (CD3OD, 300 MHz): δ 7.42 (s, 1H, H-
6’), 6.99 - 6.89 (m, 5H, HArom), 5.18 (s, 2H, H-7’), 3.97 (t, J = 8.4Hz, 1H, H-3’), 3.48 (d, 
J = 2.4Hz, 1H, H-4), 3.38 - 3.24 (m, 1H),  3.30 (s, 1H, H-11’), 3.19 - 3.13 (m, 2H), 3.07 
(dd, J=3.3, 9.2Hz, 1H), 3.01 - 2.79 (m, 4H), 2.68 (dd, J = 8.6, 14.8Hz, 2H, H-2’), 2.56 (t, 
J = 7.41Hz, 2H, H-1’); 13C NMR (CDCl3, 75 MHz): δ 173.26, 144.37, 136.79, 130.01, 
129.49, 129.03, 124.99, 87.99, 80.68, 76.21, 71.18, 70.48, 62.66, 57.10, 55.39, 54.92, 










To a solution of compound 3.64 (15 mg, 30 μmol) in mixed solvent of THF : MeOH : 
H2O (3:2:1) was added a 1M soln. of LiOH (1.5 mg, 36 μmol) followed by general 
saponification procedure (8.2.5) to obtain β-D-thiogalactopyranoside 3.69 as product (13 
mg, 27 μmol); Rf 0.22 (CH3CN/H2O 8:2);  
21
D - 2.30 (c 1.0, MeOH); 1H NMR (D2O, 300 
MHz): δ 8.14 (s, 1H, H-6’), 4.43 - 4.52 (m, 2H, H-7’), 3.87 - 4.04 (m, H-3’), 3.60 - 3.71 
(m, 3H, sugar H), 3.40 - 3.57 (m, 5H, sugar-H, H-1’), 3.18 - 3.27 (m, 3H, sugar H, H-2’), 
1.99 - 1.86 (m, 2H, H-8’), 0.84 - 0.86 (m, 3H, H-9’); 13C NMR (CDCl3, 75 MHz): δ 
215.85, 174.07, 142.22, 126.47, 86.992, 79.52, 74.47, 73.99, 70.05, 69.31, 61.62, 56.10, 
54.17, 53.57, 28.56, 24.39, 23.48, 10.65; MS (ESI) calcd for C16H28N4O9S2 + H+: 












To a solution of compound 3.65 (10 mg, 20μmol) in mixed solvent of THF:MeOH: H2O   
(3:2:1) was added a 1M soln. of LiOH (1 mg, 24 μmol) followed by general 
saponification procedure (8.2.5) to obtain β-D-thiogalactopyranoside 3.70 as product (8 
mg, 16 %). Rf 0.2 (CH3CN/H2O 8:2);  
21
D + 4.3 (c 1.0, MeOH); 1H NMR (D2O, 300 
MHz): δ 8.08 (s, 1H, H-6’), 6.14 - 5.97 (1H, m, H-8’) 5.28 (d, J = 5.1Hz, 2H, H-9’9’) 
5.06 (d, J = 5.1Hz, 1H, H7’) 4.48 (d, J = 9.8Hz, 1H, H-1) 4.37 - 4.41(m, 1H, H-3’) 3.96 
(d, J = 3.4Hz, 1H, H-4) 3.74 - 3.61 (m, 2H,sugar H) 3.52 (t, J = 9.5Hz, 2H, H-1’) 3.31 - 
3.47 (m, 3H, sugar H) 3.12 - 3.20 (m, 2H, H-2’) 2.88 - 3.01 (m, 2H, H-4’); 13C NMR 
(CDCl3, 75 MHz): δ 215.86, 174.40, 143.17, 131.68, 125.91, 120.27, 86.99, 79.52, 74.46, 












To a solution of compound 3.66 (32 mg, 64 μmol) in mixed solvent of THF:MeOH:  H2O   
(3:2:1) was added a 1M soln of LiOH (3.2 mg, 77 μmol) followed by general 
saponification procedure (8.2.5) to obtain β-D-thiogalactopyranoside 3.71 (26 mg, 54 
μmol) as product. Rf 0.22 (CH3CN/H2O 8:2);  
21
D  - 4.04 (c 1.0, MeOH); 1H NMR (D2O, 
300 MHz): δ 8.03 (s, 1H, H-6’), 4.48 (d, J = 9.6Hz, 1H, H-1), 4.34 - 4.38 (m, 1H, H-7’), 
4.20 (dd, J = 4.7Hz, J = 8.3Hz, 1H, sugar-H), 3.95 (d, J = 3.0Hz, 1H, H-4), 3.60 - 3.74 
(m, 2H, sugar-H), 3.45 - 3.55 (m, 2H sugar-H), 3.35 (ddd, J = 4.5Hz, J = 10.5Hz, J = 
14.5Hz, 2H, H-1’), 3.13 (dd, J = 7.2Hz, J = 15.3Hz, 2H, H-2’), 2.96 (dd, J = 5.8Hz, J = 
9.9Hz, 2H, H-4’), 1.54 (d, J = 6.7Hz, 1H, H-8’,9’); 13C NMR (CDCl3, 75 MHz): δ 
215.89, 174.48, 142.53, 135.32, 128.30, 123.69, 87.09, 79.56, 74.52, 70.08, 69.33, 61.62, 
56.28, 54.87, 54.22, 28.97, 24.42, 22.58; MS (ESI) calcd for C16H28N4O9S2 + H+: 










To a solution of compound 3.67 (10 mg, 19 μmol) in mixed solvent of THF: MeOH: H2O 
(3:2:1) was added a 1M soln. of LiOH (1 mg, 22μmol) followed by general 
saponification procedure (8.2.5) to obtain β-D-thiogalactopyranoside 3.72 as product (9 
mg, 16 μmol); Rf 0.25 (CH3CN/H2O 8:2);  
21
D   + 4.6 (c 1.0, MeOH); 1H NMR (D2O, 
300 MHz): δ 7.99 (1H, s, H-6’), 4.89 - 4.85 (1H, m, H-7’), 4.39 (d, J = 9.6Hz, 1H, H-1), 
4.25 - 4.20 (1H, m, H-3’), 3.80 (d, J = 2.7Hz, 1H, H-4), 3.45 - 3.65 (3H, m, sugar-H), 
3.32 - 3.42 (2H, m, sugar-H), 3.2 - 3.3 (2H, m, H-1’), 2.95 - 3.1 (2H, m, H-2’), 2.7 - 2.9 
(2H, m, H-4’), 2.05 - 2.20 (2H, m, cyclopentyl-CH2), 1.80 - 1.95 (2H, m,cyclopentyl-
CH2), 1.54 - 1.63 (2H, m, cyclopentyl-CH2); 13C NMR (CDCl3, 75 MHz): δ 174.25, 
142.22, 124.91, 86.83, 79.56, 74.54, 70.14, 69.42, 63.99, 61.69, 56.205, 54.32, 33.36, 











To a solution of compound 3.68 (30 mg, 54 μmol) in mixed solvent of THF: MeOH :  
H2O (3:2:1) was added a 1M soln. of LiOH (2.7 mg, 64 μmol) followed by general 
saponification procedure (8.2.5) to obtain β-D-thiogalactopyranoside 3.73 as product (22 
mg, 41 μmol); Rf 0.3 (CH3CN/H2O 8:2);  
21
D + 6.28 (c 1.0, MeOH); 1H NMR (D2O, 300 
MHz): δ 7.90 (s, 1H, H-6’), 7.42 (d, J = 6.1Hz, 1H, HArom), 7.33 (d, J = 7.6Hz, 1H, 
HArom), 5.59 (s, 2H, H-7’), 4.47 (d, J = 9.6Hz, 1H, H-1), 4.17 (dd, J = 4.8Hz, J = 9.6Hz, 
2H, sugar-H), 3.97 (d, J = 2.8Hz, 1H, H-4), 3.62 - 3.74 (m, 2H, sugar-H), 3.45 - 3.57 (m, 
1H, sugar-H), 3.24 - 3.33 (m, 2H, H-1’), 3.04 (dd, J = 9.2Hz, J = 15.0Hz, 2H, H-2’), 2.84 
- 2.96 (m, 2H, H-4’); 13C NMR (CDCl3, 75 MHz): δ 176.30, 144.30, 135.64, 129.77, 
129.33, 128.58, 125.43, 97.09, 87.13, 79.58, 74.50, 70.12, 69.38, 61.67, 57.79, 54.49, 










Allyl magnesium bromide (125 mL of a 1 M soln in THF) was added to solution of α-
bromo-2,3,4,6-tetra-O-acetyl-β-D-galactopyranosyl(1→4)-2,3,6-tri-O-acetyl-β-D-
glucopyranoside (8.8 g, 12.6 mmol) in THF (15 ml) at -78oC. The mixture was warmed 
up to 23o C within 0.5 h after adding allyl magnesium bromide and then poured in to H2O 
(400 mL). Glacial acetic acid (40 mL) was added to dissolve the magnesium salts and the 
mixture was shaken with Et2O until two separate layers were observed. Then the aqueous 
layer was evaporated to dryness and the residue was stirred overnight with Ac2O (200 
mL), pyridine (200 mL) and catalytic amount of DMAP. After removal of the solvent , 
the remaining oil was diluted in EtOAc, washed with 1 M HCl soln, water, brine and 
dried over MgSO4, The concentrated crude product was purified by silica gel column 
chromatography (hexane:EtOAc 3:1) to afford the compound 3.77 (4.5 g, 6.8 mmol). Rf 
0.38 (DCM/MeOH 9.7:0.3);  
22
D  + 1 (c 1.0, CH2Cl2); 1H NMR (600 MHz, CDCl3) δ 
5.79 (td, J = 17.2, 6.7 Hz, 1H, H-2), 5.35 (d, J = 3.3Hz, 1H, H-4II), 5.17 (t, J = 9.3 Hz, 
1H, H-3II), 5.12 (t, J = 9.1 Hz, 1H, H-3I), 5.08 - 5.02 (m, 2H, H-3), 4.96 (dd, J = 10.4, 2.1 
Hz, 1H, H-2II), 4.83 (t, J = 9.6 Hz, 1H, H-2I ), 4.47 (dd, J  = 21.1, 9.9 Hz, 2H, H-1II, H-
6II), 4.14 - 4.04 (m, 4H, H-6II, H-6,6I, H-4I), 3.87 (t, J = 6.8 Hz, 2H, H-5I), 3.75 (t, J = 9.4 




2H. H-1), 2.16, 2.11, 2.07, 2.05, 2.04, 2.03, 1.97 (7S, 3H each,-C (O) CH3); 13C-NMR 
(150MHz) 
 170.33, 170.24, 170.07, 169.97, 169.87, 169.77, 132.83, 117.53, 100.97, 
76.78, 76.58, 76.36, 74.28, 71.84, 70.90, 70.52, 69.03, 66.53, 62.27, 60.72, 35.68, 29.63, 
20.80, 20.72, 20.60, 20.46; MS (ESI) calcd for C28H38O9 + [Na]+: 683.22, found 683.10. 
Compound 3.78 
     
To the solution of C-allyl lactose 3.77 (0.1 g 151 µMol) in 2 mL ACN:Water(1:1) was 
added NaIO4 4.2 eq (0.130 g, 605 µMol) and RuCl3 (catalytic) and stirred at RT for about 
1 hr. DCM was added and the reaction mixture was filtered, separated into two layers and 
the organic layer washed with NH4Cl, 1 N HCl and Brine solution. The organic layer was 
dried over MgSO4, evaporated and the crude product was purified by flash column 
chromatography using 1-5% MeOH in DCM to obtain compound 3.78 (51 mg, 75 µmol); 
Rf 0.2 (DCM/MeOH 9.7:0.3);  
25
D  + 18.99 (c 1.0, CH2Cl2); 1H-NMR (600 MHz) 
 5.35 
(d, J = 3.3Hz, 1H, H-4II), 5.19 (t, J = 9.2Hz, 1H, H-3II), 5.11 (dd, J = 8.0Hz, J = 10.2Hz, 
1H, H-3I), 4.95 (dd, J = 3.4Hz, J = 10.4Hz, 1H, H-2II), 4.85 (t, J = 9.6Hz, 1H, H-2I), 4.45 
(dd, J = 9.9Hz, J = 24.4Hz, 2H, H-1II, H-6 II), 4.15 - 4.05 (m, 3H, H-6 II, H-6,6 I), 3.92 - 
3.85 (m, 2H, H-1I,4I), 3.78 (t, J = 9.5Hz, 1H, H-5I), 3.63 (dd, J = 3.6Hz, J = 9.8Hz, 1H, 
H-5II), 2.53 - 2.46 (m, 2H, H-1), 2.16, 2.10, 2.07, 2.05, 2.04, 2.04, 1.97 (7S,3H each,-
C(O)CH3); 13C-NMR (151MHz) 




169.83, 169.06, 100.96, 76.69, 76.27, 73.92, 73.87, 71.66, 70.96, 70.66, 69.06, 66.60, 
62.09, 60.82, 36.75, 20.77, 20.76, 20.61, 20.60, 20.60, 20.48. HRMS (ESI) calcd for 
C28H38O9 + [Na]+ : 701.1905, found 701.1905. 
Compound 3.79 
 
To a solution of lactose acid 3.78 (0.338 g, 49 µMol), L-propargyl glycine methyl ester 
HCl (0.121 g, 74 mmol) and BOP reagent (0.330 g, 74 µMol) in Dry THF under nitrogen 
atmosphere was added DIPEA (0.303 mL, 1.7 mmol) drop wise and the reaction mixture 
left to stir overnight. The reaction mixture was concentrated and the residue dissolved in 
CH2Cl2 and washed with 1M KHSO4, NaHCO3 and brine solution. The organic layer was 
dried over MgSO4 and concentrated. The crude product was purified by column 
chromatography using 0.5-1% MeOH in DCM to obtain 3.79 (0.215 g, 107 µmol); Rf 
0.66 (DCM/MeOH 9.5:0.5);  
25
D  +17.532 (c 1.0, CH2Cl2); 1H-NMR (600 MHz) 
 6.89 
(d, J = 7.8Hz, 1H, NH), 5.35 (dd, J = 0.7Hz, J = 3.3Hz, 1H, H-4’’), 5.20 (t, J = 9.2Hz, 
1H, H-3’’), 5.11 (dd, J = 7.9Hz, J = 10.4Hz, 1H, H-3’), 4.96 (dd, J = 3.5Hz, J = 10.4Hz, 
1H, H-2’’), 4.85 (t, J = 9.7Hz, 1H, H-2’), 4.73 (dt, J = 9.5, 4.9 Hz, H-2) 4.56 (dd, J = 
1.8Hz, J = 12.1Hz,  1H, H-1’’), 4.49 (dd, J = 7.9Hz, J = 13.7Hz, 1H, H-6’’), 4.14 (dd, J = 
6.2Hz, J = 11.1Hz, 1H, H-6’’), 4.11 - 4.05 (m, 2H, H-6,6’), 4.14 (dd, J = 6.2Hz, J = 




1H, H-5’’), 2.82 - 2.74 (m, 2H, H-3), 2.49 (dd, J = 2.5Hz, J = 15.2Hz, 2H, H-1), 2.12 (t 
masked under singlet 1H, alkyne-H),  2.16, 2.13, 2.07, 2.05(6H), 2.04, 1.97(6S,3H each,-
C(O)CH3); 13C-NMR (150 MHz) 
 170.554, 170.413, 170.229, 170.093, 170.024, 
169.933, 169.711, 168.975, 168.811, 100.944, 78.587, 76.691, 75.974, 74.501, 73.803, 
71.407, 71.384, 70.915, 70.591, 69.026, 66.0520, 62.041, 60.728, 52.740, 50.634, 38.601, 
29.193, 22.196, 20.857, 20.754, 20.628, 20.582, 20.559, 20.448; HRMS (ESI)calcd for 
C34H45NO20 + [H] +: 788.2613 found: 788.2605. 
Compound 3.80 
 
a) To a solution of compound 3.79 (0.05 g, 63 μmol) in 2 mL THF:H2O (1:1), MeI (2eq) 
NaN3 (3 eq), CuSO4.5H2O (3 mg 20%) and sodium ascorbate (5 mg, 40%) were added 
and after 16 hrs of reaction time following the general procedure (7.2.1) described above, 
β-D-lactopyranoside 3.80 (27 mg, 24 µmol) was obtained. 
b) Methyl azide was distilled at 90oC while preparing it in another RBF (MeI (1 eq) + 
NaN3 (2eq) + DMF + Water (1:1)), then added to another RBF containing a solution of 
compound 3.79 (0.05 g, 63 μmol) in 2 mL THF:H2O (1:1), CuSO4.5H2O (3 mg 20%) and 
sodium ascorbate (5 mg, 40%) for 16h of reaction time following the general procedure 




Rf 0.25 (DCM:MeOH 9.7:0.3);  
25
D  + 9.44 (c 1.0, CH2Cl2); 1H-NMR (600 MHz) 
 1H-
NMR (600 MHz) 7.34 (s, 1H, H-4), 7.18 (d, J = 7.7Hz, 1H, NH), 5.28 (d, J = 3.4Hz, 1H, 
H-4II), 5.10 (t, J = 9.2Hz, 1H, H-3II), 5.05 (dd, J = 7.9Hz, J = 10.4Hz, 1H, H-3I), 4.90 
(dd, J = 3.5Hz, J = 10.4Hz, 1H, H-2II), 4.82 - 4.81 (m, 1H, H-2), 4.74 (t, J = 9.6Hz, 1H, 
H-2I), 4.50 (d, J = 11.8Hz, 1H, H-1II), 4.45 (d, J = 7.9Hz, 1H, H-6II), 4.08 (dd, J = 6.1Hz, 
J = 11.1Hz, 1H, H-6II), 4.03 - 4.00 (m, 2H, H-6I,6’), 4.01 (s, 1H, H-5), 3.82 (t, J = 6.8Hz, 
1H, H-1I), 3.78 (t, J = 9.7Hz, 1H, H-4I), 3.74 - 3.72 (m, 1H, H-5II), 3.66 (s, 1H, 
C(O)CH3), 3.60 (dd, J = 1.9Hz, J = 9.5Hz, 1H, H-5I), 3.2 - 3.16 (m, 2H, H-3), 2.37 - 
2.29 (m, 2H, H-1), 2.09, 2.03, 2.00,  1.99, 1.97, 1.96, 1.90 (7S,3H each,-C(O)CH3); 13C-
NMR (150MHz) 
 171.27, 170.415, 170.33, 170.16, 170.08, 169.88, 169.81, 169.01, 
142.90, 123.35, 100.91, 75.80, 74.28, 73.89, 71.36, 70.94, 70.56, 68.99, 66.55, 61.77, 
60.72, 53.71, 52.50, 51.65, 38.42, 36.58, 29.20, 27.52, 20.89, 20.78, 20.64, 20.61, 20.48. 
HRMS (ESI) calcd for C35H48N4O20 + [H] +: 845.2940 found: 845.2927. 
Compound 3.81 
 
A. To a solution of compound 3.79 (0.05 g, 63 μmol) in 2 mL THF:H2O (1:1), EtBr 




added and after 12h of reaction time at 40oC following the general procedure 
described above, β-D-lactopyranoside 3.81 (28 mg, 32 μmol ) was obtained. 
B. Ethyl azide was distilled at 90oC while preparing it in another RBF ( EtBr (1eq) + 
NaN3(2eq) + DMF + Water (1:1)) then added to another RBF containing the solution 
of compound 3.79 (0.05 g, 63 μmol) in 2 mL THF:H2O (1:1), CuSO4.5H2O (3 mg 
20%) and sodium ascorbate (5 mg, 40%) for 16 hrs of reaction time, following the 
general procedure (7.2.1) described above to obtain β-D-lactopyranoside 3.81 (35mg, 
40 μmol); Rf 0.28 (DCM/MeOH 9.7:0.3);  
25
D  + 3.61 (c 1.0, CH2Cl2); 1H-NMR 
(600 MHz) 
 7.39 (s, 1H, H-4), 7.24 (d, J = 7.4Hz, 1H, NH), 5.35 (d, J = 3.4Hz, 1H, 
H-4”), 5.17 (t, J = 9.2Hz, 1H, H-3”), 5.12 (dd, J = 8.0Hz, J = 10.3Hz, 1H, H-3’), 4.96 
(dd, J = 3.4Hz, J = 10.4Hz, 1H, H-2”), 4.90 - 4.89 (m, 1H, H-2), 4.81 (t, J = 9.6Hz, 
1H, H-2’), 4.58 (d, J = 12.1Hz, 1H, H-1”), 4.51 (d, J = 7.9Hz, 1H, H-6”), 4.38 (dd, J 
= 7.4Hz, J = 14.7Hz, 2H, H-5), 4.15 (dd, J = 6.1Hz, J = 11.1Hz, 1H, H-6”), 4.11 - 
4.06 (m, 2H, H-6’,6’), 3.88 (t, J = 6.8Hz, 1H, H-1’), 3.84 (t, J = 9.5Hz, 1H, H-4’), 
3.80 - 3.79 (m, 1H, H-5”), 3.72 (s, 3H, C(O)CH3) 3.67 (dd, J = 1.7Hz, J = 9.9Hz, 1H, 
H-5”), 3.35 - 3.19 (m, 2H, H-3), 2.47 - 2.34 (m, 2H, H-1), 2.16, 2.10, 2.07, 2.06, 2.04, 
2.02, 1.97 (7S,3H each,-C(O)CH3), 1.55 (t, 1H, J = 7.3Hz, H-6); 13C-NMR 
(150MHz) 
 171.24, 170.42, 170.32, 170.14, 170.07, 169.87, 169.79, 169.08, 169.01, 
142.83, 121.70, 100.96, 76.63, 75.85, 74.30, 73.96, 71.44, 71.00, 70.63, 69.06, 66.81, 
52.51, 51.87, 45.47, 38.47, 29.66, 27.53, 20.92, 20.80, 20.67, 20.62, 20.61, 20.49. 






To a solution of compound 3.79 (0.1 g, 126 μmol) in 2 mL THF:H2O (1:1), n-propyl 
azide (15 mg, 190 μmol) CuSO4.5H2O (6 mg 20%) and sodium ascorbate (10 mg, 40%) 
were added and after 16 hrs of reaction time following the general procedure (8.2.1) 
described above, β-D-lactopyranoside 3.82 (73 mg, 83 μmol) was obtained; Rf 0.25 
(DCM/MeOH 9.7:0.3);  
25
D  + 9.61 (c 1.0, CH2Cl2); 1H-NMR (600 MHz) 
 7.38 (s, 1H, 
H-4), 7.29 (d, J = 8.0Hz, 1H, NH), 5.34 (d, J = 3.4Hz, 1H,H-4”), 5.15 (t, J = 9.3Hz, 1H, 
H-3”), 5.10 (dd, J = 8.0Hz, J = 10.4Hz, 1H, H-3’), 4.94 (dd, J = 3.4Hz, J = 10.4Hz, 1H, 
H-2”), 4.87 (dd, J = 5.6Hz, J = 13.1 Hz, 1H, H-2), 4.80 (t, J = 9.7Hz, 1H, H-2’), 4.76 (dd, 
J = 6.7Hz, J = 13.4Hz, 1H, H-5), 4.56 (d, J = 11.1Hz, 1H, H-1”), 4.49 (d, J = 7.9Hz, 1H, 
H-6”), 4.13 (dd, J = 6.3Hz, J = 11.1 Hz, 1H, H-6”), 4.06 - 4.09 (m, 2H, H-6’,6’ ) 3.87 (t, 
J = 6.9 Hz, 1H, H-1’), 3.83 (t, J = 9.5 Hz, 1H, H-4’), 3.77 - 3.73 (m, 1H, H-5”), 3.69 (s, 
1H, C(O)CH3), 3.67 - 3.66 (m, 1H, H-5’), 3.24 (ddd, J = 5.4Hz, J = 15.0Hz, J = 19.6Hz, 
2H, H-3), 2.39 - 2.37 (m, 2H, H-1), 2.14, 2.09, 2.06, 2.04,  2.02, 2.01, 1.95 (7S,3H each,-
C(O)CH3), 1.55 (dd, J = 3.8Hz, J = 6.7Hz, 1H, H-6,7); 13C NMR (150 MHz, CDCl3) δ 
171.25, 170.33, 170.28, 170.11, 170.04, 169.84, 169.76, 169.05, 168.98, 142.54, 119.57, 




52.42, 51.71, 38.44, 29.63, 27.63, 22.93, 20.88, 20.76, 20.59, 20.46. HRMS (ESI) calcd 
for C37H52N4O20 + [H] +: 873.3253; found: 873.3246. 
Compound 3.83 
 
To a solution of compound 3.79 (0.1 g, 126 μmol) in 2 mL THF:H2O (1:1), n-propyl  
azide (15 mg, 190 μmol) CuSO4.5H2O (6 mg 20%) and sodium ascorbate (10 mg, 40%) 
were added and after 16 hrs of reaction time following the general procedure (7.2.1) 
described above, β-D-lactopyranoside 3.83 (70 mg, 80 μmol) was obtained;  Rf  0.3 
(DCM/MeOH 9.7:0.3);  
25
D  + 14.90 (c 1.0, CH2Cl2); 1H-NMR (600 MHz) 
 7.34 (s, 
1H, H-4’’), 7.23 (d, 1H, J = 8.0Hz, NH), 5.34 (d, 1H,  J = 3.3Hz, H-4’’), 5.16 (t, 1H, J = 
9.2Hz, H-3’’), 5.10 (dd, 1H, J = 8.1Hz, J = 10.3Hz, H-3’), 4.95 (dd, 1H, J = 3.4Hz, J = 
10.4Hz, H-2’’), 4.88 (dd, 1H, J = 5.6Hz, J = 12.8Hz, H-2), 4.80 (t, 1H, J = 9.6Hz, H-2’), 
4.56 (d, 1H, J = 12.0Hz, H-1’’), 4.50 (d, 1H, J = 7.9Hz, H-6’’), 4.27 (t, 2H, J = 7.0Hz, H-
6,6’), 4.13 (dd, 1H, J = 6.2Hz, J = 11.2Hz, H-6’’), 4.10 - 4.05 (m, 2H, H-5), 3.87 (t, 1H, J 
= 6.8Hz, H-1’), 3.83 (t, 1H, J = 9.5Hz, H-4’), 3.80 - 3.74 (m, 1H, H-5’), 3.70 (s, 3H, 
C(O)CH3), 3.67 (d, J = 6.2 Hz, H-5’’), 3.66-3.64 (m, 2H, H-3), 3.24 (ddd, 1H, J = 5.3Hz, 
J = 15.0Hz, J = 19.6Hz, H-1), 2.38, 2.14, 2.09, 2.06, 2.05, 2.02, 2.01 (7S,3H each,-




171.17, 170.39, 170.31, 170.13, 170.14, 170.06, 169.86, 169.79, 169.09, 169.00, 142.59, 
122.23, 100.93, 76.59, 75.82, 74.26, 73.94, 71.41, 70.97, 70.597, 69.02, 66.59, 61.80, 
60.74, 52.48, 51.68, 38.42, 27.47, 23.58, 20.89, 20.775, 20.64, 20.60, 20.47, 10.94; 
HRMS (ESI). calcd for C37H52N4O20 + [H] +: 873.3253 found: 873.3237. 
Compound 3.84 
 
To a solution of compound 3.79 (0.065 g, 82 μmol) in 2 mL THF:H2O (1:1), 2-
azidoethanol (10 mg, 123 μmol), CuSO4.5H2O (4 mg 20%) and sodium ascorbate (6 mg, 
40%) were added and after 16 hrs of reaction time following the general procedure 
(7.2.1) described above, β-D-lactopyranoside 3.84 (46 mg, 53 μmol) was obtained; Rf 
0.28 (DCM/MeOH 9.7:0.3);  
25
D  + 6.388 (c 1.0, CH2Cl2); 1H-NMR (600 MHz) 
 7.59 
(s, 1H, H-4), 7.31 (d, 1H, J = 6.3Hz, NH), 5.34 (d, 1H, J = 2.8Hz, H-4”), 5.16 (t, 1H, J = 
9.3Hz, H-3”), 5.09 (dd, 1H, J = 8.1Hz, J = 10.3Hz, H-2”), 4.96 (dd, 1H, J = 3.4Hz, J = 
10.4Hz, H-2”), 4.89 (dd, 1H, J = 5.5Hz, J = 13.0Hz, H-2), 4.78 (t, 1H, J = 9.6Hz, H-2’), 
4.54 (d, 1H, J = 12.1Hz, H-1”), 4.50 (d, 1H, J = 8.0Hz, H-6”), 4.48 - 4.41 (m, 2H, H-6), 
4.14 (dd, 1H, J = 6.1Hz, J = 11.1Hz, H-6”), 4.08 - 4.03 (m, 2H, H-6,6’), 4.00 (t, 2H, J = 
4.4Hz, H-5), 3.88 (t, 1H, J = 6.9Hz, H-1’), 3.81 (t, 1H, J = 9.5Hz, H-4’), 3.75 (s, 3H, 




2H, J = 4.4Hz, H-3), 2.37 - 2.36 (m, 2H, H-1), 2.15, 2.10, 2.07, 2.05, 2.02, 2.02, 1.96 
(7S,3H each,-C(O)CH3); 13C-NMR (151MHz) 
 171.12, 170.85, 170.35, 170.12, 170.03, 
169.90, 169.33, 169.24, 142.18, 124.12, 100.83, 76.47, 75.78, 74.29, 73.85, 71.36, 70.86, 
70.58, 69.09, 66.58, 61.84, 60.83, 60.73, 53.11, 52.64, 51.61, 38.37, 27.55, 20.93, 20.77, 




To a solution of compound 3.79 (0.1 g, 126 μmol) in 2 mL THF:H2O (1:1), benzyl azide 
(25 mg, 190 μmol) CuSO4.5H2O (6 mg, 20%) and sodium ascorbate (10 mg, 40%) were 
added and after 16 hrs of reaction time following the general procedure (7.2.1) described 
above, β-D-lactopyranoside 3.85 (81 mg, 88 μmol) was obtained; Rf 0.3 (DCM/MeOH 
9.7:0.3);  
22
D  + 8.26 (c 1.0, CH2Cl2); 1H-NMR (600 MHz) 
 7.43 - 7.35 (m, 3H, HArom), 
7.30 (s, 1H, H-4) 7.26 - 7.21 (m, 1H, HArom), 7.18 (d, 1H, J = 8.1Hz, NH), 5.48 (s, 1H, H-
5), 5.35 (d, 1H, J = 3.2Hz, H-4’’), 5.16 - 5.09 (m, 1H, H-3’’), 4.96 (dd, 1H, J = 3.5Hz, J 
= 10.4Hz, H-3’), 4.88 (td, 1H, J = 5.6Hz, J = 7.7Hz, H-2), 4.78 (t, 1H, J = 9.7Hz, H-2’), 
4.59 (dd, 1H, J = 1.4Hz, J = 12.1Hz, H-1’’), 4.49 (d, 1H, J = 8.0Hz, H-6’’), 4.14 (dd, 1H, 




= 3.9Hz, J = 12.3Hz, H-6’’), 3.88 (t, 1H, J = 6.9Hz, H-1’), 3.81 (t, 1H, J = 9.6Hz, H-4’), 
3.66 (s, 1H, C(O)CH3), 3.64 (dd, 1H, J = 4.9Hz, J = 8.0Hz, H-5’), 3.52 (ddd, 1H, J = 
1.9Hz, J = 3.6Hz, J = 10.1Hz, H-5’’), 3.23 (dq, 2H, J = 5.5Hz, J = 15.1Hz, H-3), 2.36 (m, 
2H, H-1), 2.16, 2.08, 2.07, 2.05, 2.04, 2.03,1.97 (7S,3H each,-C(O)CH3); 13C-NMR 
(150MHz) 
 171.111, 170.287, 170.214, 170.050, 169.959, 169.745, 169.703, 168.940, 
168.891, 134.520, 129.091, 128.996, 128.981, 128.778, 127.817, 121.900, 100.852, 
76.450, 75.687, 74.102, 73.757, 71.311, 70.834, 70.472, 68.885, 66.489, 61.548, 60.659, 
53.941, 52.319, 51.492, 38.349, 27.590, 20.791, 20.681, 20.547, 20.517, 20.494, 20.379; 
HRMS (ESI) calcd for C41H52N4O20 + [H] +: 921.3253, found: 921.3230. 
Compound 3.86 
 
To a solution of compound 3.79 (0.1 g, 126 μmol) in THF:H2O (1:1) 2 mL, cyclopentyl  
azide (21 mg, 190 μmol) CuSO4.5H2O (6 mg, 20%) and sodium ascorbate (10 mg, 40%) 
were added and after 16 hrs of reaction time following the general procedure (7.2.1) 
described above, β-D-lactopyranoside 3.86 (68 mg, 76 μmol) was obtained; Rf 0.25 
(DCM/MeOH 9.7:0.3);  
25
D  + 9.03 (c 1.0, CH2Cl2); 1H-NMR (600 MHz, CDCl3) 
 7.34 
(s, 1H, H-4), 7.24 (d, J = 8.0Hz, 1H, NH), 5.33 (d, J = 3.1Hz, 1H, H-4’’), 5.14 (t, J = 




10.4Hz, 1H, H-2’’), 4.85 (td, J = 7.4Hz, J = 10.0Hz, 2H, H-2, 5), 4.79 (t, J = 9.6Hz, 1H, 
H-2’), 4.55 (dd, J = 1.6Hz, J = 12.2Hz, 1H, H-1’’), 4.49 (d, J = 7.9Hz, 1H, H-6’’), 4.12 
(dd, J = 6.3Hz, J = 11.1Hz, 1H, H-6”), 4.06 (dd, J = 5.5Hz, J = 16.1Hz, 2H, H-6, 6’), 
3.86 (t, J = 6.9Hz, 1H, H-1’), 3.81 (t, J = 9.6Hz, 1H, H-4’), 3.76 - 3.72 (m, 1H, H-5’), 
3.68 (s, 3H, C(O)CH3), 3.64 (ddd, J = 1.8Hz, J = 3.9Hz, J = 10.0Hz, 1H, H-5”), 3.21 
(ddd, J = 5.5Hz, J = 15.1Hz, J = 19.7Hz, 2H, H-3), 2.40 - 2.33 (m, 2H, H-1), 2.23 - 2.20 
(m, 2H, cyclopentyl CH2) 2.13, 2.07, 2.04, 2.03, 2.01s, 2.00, 1.94 (7S, 3H each,-
C(O)CH3), 1.90 - 1.81 (m, 2H, cyclopentyl CH2), 1.78 - 1.72 (m, 2H, cyclopentyl CH2);  
13C-NMR (150MHz, CDCl3) 
 171.23, 170.30, 170.24, 170.07, 169.98, 169.79, 169.71, 
168.99, 168.94, 142.52, 120.53, 100.90, 76.55, 75.82, 74.26, 73.93, 71.43, 70.94, 70.57, 
69.00, 66.58, 61.80, 60.72, 53.36, 51.66, 38.43, 33.28, 33.23, 27.57, 23.92, 20.82, 20.72, 




To a solution of compound 3.80 (0.020 g, 23 μmol ) in 2 mL of dry methanol, 0.1 ml of 
NaOMe/MeOH solution (pH = 10) was added and stirred at RT for 4 hrs of reaction time 




lactopyranoside 3.87 (12 mg, 22 μmol); Rf  0.20 (CH2Cl2/MeOH 4:1);  
24
D  + 7.89 (c 1 
in MeOH); 1H NMR (600 MHz, D2O) δ 7.80 (s, 1H), 4.83 - 4.80 (m, 1H), 4.45 (d, J = 7.6 
Hz, 1H), 4.07 (s, 3H), 3.94 (d, J = 19.7 Hz, 2H), 3.86 - 3.78 (m, 2H), 3.76 (s, 3H), 3.71 
(d, J = 22.4 Hz, 2H), 3.68 - 3.58 (m, 4H), 3.54 (t, J = 8.8 Hz, 1H), 3.44 (s, 1H), 3.33 – 
3.15 (m, 3H), 2.78 (t, J = 12.6 Hz, 1H), 2.42 (dd, J = 14.7, 9.4 Hz, 1H); 13C NMR (150 
MHz, D2O) δ 173.99, 173.27, 143.21, 125.90, 103.37, 89.92, 88.83, 79.25, 76.54, 76.31, 
75.89, 73.34, 73.28, 72.01, 69.18, 61.69, 60.60, 53.66, 53.03, 38.89, 37.07, 27.49. HRMS 
(ESI) calcd for C20H34N4O14 + [H] +: 551.2201; found: 551.2197 
Compound 3.88 
 
To a solution of compound 3.82 (0.015 g, 17 μmol ) in 2 mL of dry methanol, 0.1 ml of 
NaOMe /MeOH solution (pH = 10) was added and stirred at RT for 4 hrs of reaction time 
following the general procedure (7.2.4) described above to obtain the deprotected β-D-C-
lactopyranoside 3.88 (9 mg, 16 μmol); Rf  0.18 (CH2Cl2/MeOH 4:1); 1H NMR (600 
MHz, D2O) δ 7.95 (s, 1H), 4.90 - 4.80 (m, 1H), 4.55 (dt, J = 19.7, 5.6 Hz, 1H), 4.47 - 
4.38 (m, 2H), 3.99 - 3.88 (m, 2H), 3.79 (s, 3H), 3.77 - 3.73 (m, 2H), 3.71 (dt, J = 15.0, 
7.2 Hz, 1H), 3.68 - 3.57 (m, 4H), 3.53 (dd, J = 9.7, 8.1 Hz, 1H), 3.46 - 3.27 (m, 4H), 3.11 




7.1 Hz, 1H), 1.53 (dd, J = 6.7, 1.4 Hz, 6H); 13C NMR (150 MHz, D2O) δ 173.47, 142.62, 
122.70, 103.51, 78.92, 78.82, 76.59, 76.36, 76.01, 73.31, 73.18, 71.61, 69.23, 61.70, 
60.76, 54.41, 53.67, 53.24, 38.68, 30.89, 27.60, 22.66; HRMS (ESI) calcd for 
C23H38N4O13+ [H] +: 579.2514, found: 579.2506. 
Compound 3.89 
 
To a solution of compound 3.83 (0.040 g, 45 μmol) in 2 mL of dry methanol, 0.2 ml of 
NaOMe/MeOH solution (pH = 10) was added and stirred at RT for 4 hrs of reaction time 
following the general procedure (7.2.4) described above to obtain the deprotected β-D-C-
lactopyranoside 3.89 (23 mg, 41 μmol); Rf  0.18 (CH2Cl2:MeOH 4:1);  
24
D  + 8.02 (c 1 
in MeOH); 1H NMR (600 MHz, D2O) δ 7.95 (s, 1H), 4.78 - 4.71 (m, 1H), 4.44 (d, J = 7.6 
Hz, 1H), 4.35 (t, J = 6.7 Hz, 2H), 3.92 (d, J = 2.8 Hz, 1H), 3.87 - 3.75 (m, 4H), 3.74 (s, 
3H), 3.72 (d, J = 8.8 Hz, 2H), 3.68 - 3.58 (m, 4H), 3.54 (dd, J = 17.6, 8.6 Hz, 1H), 3.44 
(d, J = 8.5 Hz, 1H), 3.33 – 3.15 (m, 3H), 2.85 - 2.62 (m, 1H), 2.50 - 2.33 (m, 1H), 1.93 - 
1.77 (m, 2H), 0.89 - 0.75 (m, 3H); 13C NMR (151 MHz, D2O) δ 173.78, 173.38, 143.27, 
124.88, 103.49, 78.87, 76.55, 76.33, 75.97, 73.29, 73.15, 71.58, 69.18, 61.66, 60.64, 
53.63, 53.20, 52.63, 38.68, 30.89, 27.49, 23.68, 10.68; HRMS (ESI) calcd for 






To a solution of compound 3.84 (0.043 g, 49 μmol ) in 2 mL of dry methanol, 0.2 ml of 
NaOMe/MeOH solution (pH = 10) was added and stirred at RT for 4 hrs of reaction time 
following the general procedure (7.2.4) described above to obtain the deprotected β-D-C-
lactopyranoside 3.90 (26 mg, 45 μmol); Rf  0.12 (CH2Cl2/MeOH 4:1);  
24
D  + 11 (c 1 in 
MeOH); 1H NMR (600 MHz, D2O) δ 7.87 (s, 1H), 4.81 (dd, J = 12.2, 6.0 Hz, 1H), 4.52 
(dd, J = 11.8, 6.8 Hz, 2H), 4.44 (d, J = 7.8 Hz, 1H), 3.97 (t, J = 5.1 Hz, 3H), 3.92 (d, J = 
3.3 Hz, 1H), 3.87 - 3.77 (m, 3H), 3.75 (s, 3H), 3.72 (tt, J = 12.8, 6.6 Hz, 2H), 3.62 (tdd, J 
= 15.8, 9.3, 3.5 Hz, 4H), 3.57 - 3.52 (m, 1H), 3.45 (dd, J = 4.6, 2.2 Hz, 1H), 3.33 - 3.19 
(m, 3H), 2.77 (tt, J = 16.4, 8.2 Hz, 1H), 2.42 (ddd, J = 22.9, 11.2, 6.6 Hz, 1H); 13C NMR 
(151 MHz, D2O) δ 173.34, 172.87, 142.70, 124.80, 102.95, 78.31, 78.32, 76.00, 75.79, 
75.43, 72.76, 72.61, 71.04, 68.65, 61.13, 60.19, 60.10, 53.14, 52.70, 52.54, 38.23, 38.14, 










To a solution of compound 3.85 (0.070 g, 76 μmol) in 2 mL of dry methanol, 0.2 ml of 
NaOMe/MeOH solution (pH = 10) was added and stirred at RT for 4 hrs of reaction time 
following the general procedure (8.2.4) described above to obtain the deprotected β-D-C-
lactopyranoside 3.91 (42 mg, 68 μmol); Rf  0.25 (CH2Cl2/MeOH 4:1);  
24
D  + 7.87 (c 1 
in MeOH); 1H NMR (600 MHz, D2O) δ 7.81 (s, 1H), 5.53 (s, 2H), 4.78 - 4.64 (m, 2H), 
4.41 (d, J = 7.7 Hz, 1H), 3.92 (d, J = 3.2 Hz, 1H), 3.77 (ddd, J = 15.7, 11.9, 6.3 Hz, 3H), 
3.72 – 3.68 (m, 3H), 3.67 (s, 3H), 3.66 – 3.61 (m, 2H), 3.54 (dddd, J = 19.1, 12.1, 9.3, 3.5 
Hz, 4H), 3.30 - 3.19 (m, 2H), 3.18 - 3.08 (m, 1H), 2.78 - 2.62 (m, 1H), 2.43 - 2.26 (m, 
1H); 13C NMR (150 MHz, D2O) δ 165.87, 165.42, 142.22, 135.85, 127.75, 121.98, 
121.59, 120.71, 117.04, 95.67, 71.01, 70.92, 68.65, 68.44, 68.15, 65.49, 65.36, 63.75, 
61.36, 53.84, 52.75, 46.59, 45.77, 45.21, 30.89, 23.04, 19.73; HRMS (ESI) calcd for 










To a solution of compound 3.86 (0.040 g, 44 μmol) in 2 mL of dry methanol, 0.2 ml of 
NaOMe/MeOH solution (pH = 10) was added and stirred at RT for 4 hrs of reaction time 
following the general procedure (8.2.4) described above to obtain the deprotected β-D-C-
lactopyranoside 3.92 (25 mg, 41 μmol); Rf  0.16 (CH2Cl2/MeOH 4:1);  
24
D  + 8.82 (c 1 
in MeOH); 1H NMR (600 MHz, D2O) δ 7.86 (s, 1H), 5.00 - 4.93 (m, 1H), 4.78 - 4.69 (m, 
1H), 4.44 (dd, J = 7.8, 1.0 Hz, 1H), 3.92 (t, J = 6.1 Hz, 1H), 3.86 - 3.75 (m, 4H), 3.74 (s, 
3H), 3.74 - 3.69 (m, 2H), 3.66 (dt, J = 6.6, 4.5 Hz, 2H), 3.64 - 3.58 (m, 2H), 3.54 (dd, J = 
17.4, 9.0 Hz, 2H), 3.46 - 3.38 (m, 1H), 3.31 - 3.14 (m, 4H), 2.83 - 2.70 (m, 1H), 2.43 (qd, 
J = 14.9, 9.3 Hz, 1H), 2.30 - 2.18 (m, 2H), 2.00 - 1.90 (m, 2H), 1.86 - 1.69 (m, 4H); 13C 
NMR (150 MHz, D2O) δ 174.26, 173.46, 143.19, 123.44, 103.49, 78.88, 76.57, 76.34, 
75.99, 73.37, 73.29, 73.17, 71.59, 69.20, 62.98, 61.67, 60.64, 53.65, 53.32, 53.16, 38.68, 










To a solution of compound 3.87 (10 mg, 1.8 μmol) in mixed solvent of THF:MeOH:H2O 
(3:2:1) was added LiOH.H2O 1M soln. (0.018mL, 1eq) and stirred for 2 hrs, according to 
general saponification procedure (8.2.5) to obtain 3.93 (9 mg, 95%); Rf  0.20 (ACN/ 
H2O 8:2);  
22
D  + 8.01 (c 1.0, H2O); 1H NMR (600 MHz, D2O) δ 7.83 (s, 1H), 4.43 (dd, 
J = 7.8, 3.6 Hz, 2H), 4.07 (d, J = 8.4 Hz, 3H), 3.92 (dd, J = 12.0, 5.4 Hz, 1H), 3.85 - 3.74 
(m, 3H), 3.74 – 3.68 (m, 3H), 3.63 (tdd, J = 12.3, 9.8, 5.6 Hz, 5H), 3.54 (dt, J = 13.7, 7.9 
Hz, 2H), 3.42 (t, J = 13.7 Hz, 1H), 3.35 - 3.28 (m, 1H), 3.27 - 3.17 (m, 2H), 2.76 (ddd, J 
= 32.3, 19.7, 12.3 Hz, 1H), 2.47 - 2.37 (m, 1H); 13C NMR (150 MHz, D2O) δ 103.51, 
90.11, 80.46, 78.86, 76.68, 76.39, 76.31, 75.99, 73.37, 73.18, 72.55, 71.61, 69.22, 61.70, 












To a solution of compound 3.88 (9 mg, 1.8 μmol) in mixed solvent of THF:MeOH:H2O   
(3:2:1) was added LiOH.H2O 1M soln. (0.018mL, 1eq) and stirred for 2 hrs, according to 
general saponification procedure (8.2.5) to obtain 3.94 (8mg, 90%); Rf  0.22 
(ACN/H2O 8:2); 1H NMR (600 MHz, D2O) δ 7.91 (s, 1H), 4.78 - 4.72 (m, 2H), 4.49 - 
4.42 (m, 1H), 3.95 (t, J = 10.4 Hz, 2H), 3.88 - 3.77 (m, 3H), 3.74 (ddd, J = 19.9, 11.9, 7.9 
Hz, 2H), 3.68 (dd, J = 10.3, 3.8 Hz, 2H), 3.64 - 3.59 (m, 3H), 3.59 - 3.52 (m, 1H), 3.50 - 
3.40 (m, 1H), 3.37 - 3.15 (m, 3H), 2.83 - 2.75 (m, 1H), 2.50 - 2.41 (m, 1H), 1.57 - 1.51 
(m, 6H); 13C NMR (150 MHz, D2O) δ 175.20, 173.66, 143.39, 122.92, 103.78, 78.91, 
76.59, 76.31, 76.07, 73.44, 73.38, 71.90, 69.34, 63.11, 61.81, 60.79, 57.94, 54.58, 53.26, 













To a solution of compound 3.89 (15 mg, 3.5 μmol) in mixed solvent of THF:MeOH:H2O 
(3:2:1) was added LiOH.H2O 1M soln. (0.025mL, 1eq) and stirred for 2 hrs, according to 
general saponification procedure (7.2.5) to obtain 3.95 (13 mg, 95%); Rf  0.22 (ACN 
/H2O 8:2);  
22
D  + 12.13 (c 1.0, H2O); 1H NMR (600 MHz, D2O) δ 7.86 (s, 1H), 4.74 
(ddd, J = 18.1, 8.0, 5.3 Hz, 1H), 4.46 – 4.42 (m, 1H), 4.35 (t, J = 6.8 Hz, 2H), 3.91 (d, J = 
3.3 Hz, 1H), 3.80 - 3.74 (m, 3H), 3.74 - 3.69 (m, 2H), 3.62 (dddd, J = 16.2, 13.1, 9.3, 3.6 
Hz, 2H), 3.57 - 3.50 (m, 3H), 3.46 - 3.38 (m, 1H), 3.37 - 3.14 (m, 3H), 2.81 - 2.70 (m, 
1H), 2.41 (dt, J = 15.2, 8.9 Hz, 1H), 1.92 - 1.80 (m, 2H), 0.87 - 0.79 (m, 3H); 13C NMR 
(150 MHz, D2O) δ 174.72, 173.81, 143.28, 125.02, 103.51, 78.90, 76.57, 76.35, 76.00, 
73.31, 73.18, 71.61, 69.22, 61.70, 60.64, 53.18, 52.76, 38.72, 27.54, 23.70, 23.69, 10.71; 











To a solution of compound 3.90 (15 mg, 3.5 μmol) in mixed solvent of THF:MeOH:H2O 
(3:2:1) was added LiOH.H2O 1M soln. (0.025 mL, 1eq) and stirred for 2 hrs, according to 
general saponification procedure (7.2.5) to obtain 3.96 (12 mg, 90%); Rf  0.19 
(ACN/H2O 8:2);  
22
D  + 16.12 (c 1.0, H2O); 1H NMR (600 MHz, D2O) δ 7.87 (s, 1H), 
4.76 - 4.66 (m, 1H), 4.54 - 4.49 (m, 2H), 4.44 (dd, J = 7.8, 2.5 Hz, 1H), 3.99 - 3.95 (m, 
2H), 3.92 (d, J = 3.4 Hz, 1H), 3.87 - 3.74 (m, 4H), 3.74 - 3.68 (m, 1H), 3.68 - 3.57 (m, 
4H), 3.57 - 3.51 (m, 1H), 3.47 - 3.41 (m, 1H), 3.35 - 3.16 (m, 3H), 2.77 (ddd, J = 14.9, 
7.9, 2.8 Hz, 1H), 2.42 (ddd, J = 14.6, 9.3, 5.2 Hz, 1H); 13C NMR (150 MHz, D2O) δ 
174.98, 173.76, 125.31, 103.51, 78.90, 76.58, 76.35, 75.99, 73.39, 73.33, 73.17, 71.61, 
69.22, 61.69, 60.76, 60.65, 53.45, 53.12, 38.74, 27.70; HRMS (ESI) calcd for 











To a solution of compound 3.91 (30 mg, 4.7 μmol) in mixed solvent of THF:MeOH:H2O 
(3:2:1) was added LiOH.H2O 1M soln. (0.047 mL, 1eq) and stirred for 2 hrs, according to 
general saponification procedure (7.2.5) to obtain 3.97 (26 mg, 90%); Rf  0.24 (ACN : 
H2O 8:2);  
22
D  + 8.22 (c 1.0, H2O); 1H NMR (600 MHz, D2O) δ 7.82 (s, 1H), 7.45 - 
7.34 (m, 3H), 7.32 - 7.19 (m, 2H), 5.53 (s, 2H), 4.75 - 4.68 (m, 1H), 4.42 - 4.36 (m, 1H), 
3.89 (t, J = 10.4 Hz, 1H), 3.81 – 3.73 (m, 2H), 3.73 – 3.66 (m, 2H), 3.66 – 3.57 (m, 3H), 
3.57 - 3.51 (m, 3H), 3.51 - 3.42 (m, 1H), 3.30 - 3.07 (m, 4H), 2.68 (dt, J = 6.1, 2.9 Hz, 
1H), 2.38 - 2.20 (m, 1H); 13C NMR (150 MHz, D2O) δ 166.96, 165.81, 136.05, 127.75, 
121.95, 121.58, 120.70, 117.12, 95.65, 70.97, 70.90, 68.66, 68.42, 68.14, 65.49, 65.36, 
63.76, 61.36, 53.84, 52.70, 46.60, 45.24, 23.03, 19.84; HRMS (ESI) calcd for 











To a solution of compound 3.92 (15 mg, 2.4 μmol) in mixed solvent of THF:MeOH: H2O 
(3:2:1) was added LiOH.H2O 1M soln. (0.024mL, 1eq) and stirred for 2 hrs, according to 
general saponification procedure (7.2.5) to obtain 3.98 (13 mg, 90%); Rf 0.20 
(ACN/H2O 8:2);  
22
D  + 10.35 (c 1.0, H2O); 1H NMR (600 MHz, D2O) δ 7.87 (dd, J = 
13.4, 5.9 Hz, 1H), 5.02 - 4.92 (m, 1H), 4.69 (dd, J = 17.7, 12.2 Hz, 1H), 4.43 (d, J = 7.8 
Hz, 1H), 3.92 (d, J = 3.3 Hz, 1H), 3.86 - 3.69 (m, 5H), 3.68 - 3.48 (m, 5H), 3.46 - 3.36 
(m, 1H), 3.36 - 3.23 (m, 2H), 3.21 - 3.10 (m, 1H), 2.75 (dd, J = 9.3, 2.3 Hz, 1H), 2.41 (dt, 
J = 15.0, 9.7 Hz, 1H), 2.29 - 2.16 (m, 2H), 2.00 - 1.89 (m, 2H), 1.80 (dd, J = 14.1, 8.1 Hz, 
2H), 1.75 (dd, J = 14.4, 7.1 Hz, 2H); 13C NMR (151 MHz, D2O) δ 172.62, 171.08, 
120.87, 100.88, 76.29, 76.11, 73.99, 73.74, 73.38, 70.70, 70.57, 69.00, 66.61, 60.43, 
59.08, 58.01, 50.84, 36.20, 36.11, 28.28, 25.19, 21.63; HRMS (ESI) calcd for 










To a solution of compound 3.79 (0.025 g, 31 μmol ) in 2 mL of dry methanol, 0.1 ml of 
NaOMe/MeOH solution (pH = 10) was added and stirred at RT for 4 hrs of reaction time 
according to general procedure (7.2.4) described above to obtain deprotected β-D-C-
lactopyranoside 3.99 (15 mg, 90%); Rf  0.22 (CH2Cl2/MeOH 4:1);  
24
D  + 6.54 (c 1 in 
MeOH); 1H NMR (600 MHz, D2O) δ 4.67 (td, J = 5.9, 2.7 Hz, 1H), 4.50 - 4.42 (m, 1H), 
3.93 (t, J = 4.0 Hz, 2H), 3.81 (d, J = 3.5 Hz, 1H), 3.79 (s, 3H), 3.78 - 3.75 (m, 2H), 3.75 - 
3.68 (m, 3H), 3.65 (dt, J = 19.3, 6.0 Hz, 3H), 3.58 - 3.49 (m, 2H), 3.33 (q, J = 9.2 Hz, 
1H), 2.90 - 2.72 (m, 3H), 2.55 - 2.41 (m, 2H); 13C NMR (150 MHz, D2O) δ 174.14, 
172.80, 103.31, 78.73, 76.54, 76.25, 75.97, 73.35, 73.20, 72.61, 71.24, 68.96, 61.70, 













To a solution of compound 3.99 (10 mg, 20 μmol) in mixed solvent of THF:MeOH:H2O 
(3:2:1) was added LiOH.H2O 1M soln. (0.02mL, 1eq) and stirred for 2 hrs, following the 
general saponification procedure (7.2.5) to obtain 3.100 (9 mg, 92%); Rf  0.19 (ACN 
/H2O 8:2);  
22
D  + 7.58 (c 1.0, H2O); 1H NMR (600 MHz, D2O) δ 4.58 (t, J = 5.8 Hz, 
1H), 4.47 (t, J = 7.2 Hz, 1H), 3.97 - 3.91 (m, 2H), 3.80 (ddd, J = 21.2, 11.8, 6.2 Hz, 3H), 
3.76 - 3.70 (m, 3H), 3.71 - 3.62 (m, 3H), 3.59 - 3.49 (m, 2H), 3.34 (dd, J = 17.3, 8.5 Hz, 
1H), 2.88 (dd, J = 20.2, 7.7 Hz, 1H), 2.81 - 2.76 (m, 2H), 2.52 (dd, J = 15.0, 9.3 Hz, 1H), 
2.45 (d, J = 1.6 Hz, 1H); 13C NMR (150 MHz, D2O) δ 103.51, 90.11, 80.46, 78.86, 
76.68, 76.39, 76.31, 75.99, 73.37, 73.18, 72.55, 71.61, 69.22, 61.70, 60.85, 52.55, 30.88, 













To a solution of α-bromo lactose 3.76 (2.2 g, 3.1 mmol) in 25 ml of acetone was added 
thiourea (0.359g, 4.7 mmol) and the reaction mixture refluxed overnight. The reaction 
mixture was concentrated to get the thiouronium salt. The thiouronium salt dissolved in 9 
ml of water and 12 ml of dichloromethane and 0.84 g 1.5 eq of K2S2O5 added then 
refluxed for 20 minutes. The reaction mixture was allowed to cool to room temperature. 
The organic and aq. layers were separated. The organic layer washed with satd. brine 
solution then dried over MgSO4 and concentrated to obtain 1.65 g of crude thiol 
galactose. The crude product was purified by flash column chromatography using 
dichloromethane alone to obtain 0.560 g of pure β-  lactose thiol 3.101 (60 %); Rf 0.25 
(EtOAc/Hexane 60:40);  
21
D  -10.5 (c 1.0, CH2Cl2); 1H-NMR (300 MHz), 5.34 (d, J = 
2.7Hz, 1H, H-4II), 5.18 (t, J = 9.2Hz, 1H, H-3II ), 5.10 (dd, J = 7.8Hz, J = 10.4Hz, 1H, H-
3I), 4.96 (d, J = 3.4Hz, 1H, H-2II), 4.86 (d, J = 9.5Hz, 1H, H-2I), 4.54 (d, J = 9.7Hz, 1H, 
H-1II), 4.44 - 4.40 (m, 1H, H-1I), 4.23 - 3.98 (m, 3H, H-6,6II, H-6I), 3.95 - 3.72 (m, 2H, 
H-6I, H-5I), 3.63 (ddd, J = 1.8Hz, J = 5.2Hz, J = 10.0Hz, 1H, H-5II), 2.25 (d, J = 9.7Hz, 
1H, SH), 2.15, 2.13, 2.07, 2.06, 2.04, 1.96 (7S,21H,-C(O)CH3); 13C-NMR (75MHz) 
 




73.824, 73.418, 70.925, 70.671, 69.009, 66.543, 62.168, 60.757, 20.830, 20.708, 20.591, 
20.568, 20.450; HRMS (ESI) calcd for C26H36O17S + [Na] +: 675.1571, found 675.1568. 
Compound 3.102 
 
To a solution of 6.15 (0.1 g, 153 μmol) and β-D-lactose thiol 3.101 (0.033 g, 153 μmol) 
in CH2Cl2 5mL was added 4 drops of TEA and stirred at RT overnight. The reaction 
mixture was concentrated on a rotovap and the crude purified by flash column 
chromatography using 1-2% MeOH in CH2Cl2 to obtain β-D-thiolactoyranoside 3.102 
(93 mg, 70%); Rf 0.4 (CH2Cl2/MeOH 9.7:0.3);  
21
D  -8.44 (c 1.0, CH2Cl2); 1H-NMR 
(600 MHz, CDCl3) 
 5.40 (d, J = 8.8Hz, 1H, NH), 5.34 (d, J = 3.3Hz, 1H, H-4II), 5.20 (t, 
J = 9.2Hz, 1H, H-3II), 5.09 (dd, J = 8.0Hz, J = 10.3Hz, 1H, H-3I), 4.96 (dd, J = 3.5Hz, J 
= 10.6Hz, 1H, H-2II), 4.92 (d, J = 9.9Hz, 1H, H-2I), 4.55 (dd, J = 6.4Hz, J = 11.0Hz, 1H, 
H-1II), 4.49 (d, J = 7.9Hz, 1H, H-1I), 4.32 (td, J = 5.0Hz, J = 9.7Hz, 1H, H-3), 4.12 - 4.04 
(m, 4H, H-6I,6I, 6II, 6II), 3.88 (t, J = 6.8Hz, 1H, H-4I), 3.80 (s, 3H, C(O)CH3), 3.77 (t, J = 
9.5Hz, 1H, H-5II), 3.46 - 3.33 (m, 2H, H-1), 3.44 (ddd, J = 5.1Hz, J = 11.4Hz, J = 
16.1Hz, 1H, H-2), 2.78 (ddq, J = 2.6Hz, J = 5.0Hz, J = 17.1Hz, 1H, H-4), 2.14, 2.13, 
2.05, 2.03, 2.03, 1.95 (6S,21H,-C(O)CH3); 13C-NMR (150MHz, CDCl3) 
 170.596, 




75.989, 73.423, 72.565, 70.850, 70.635, 69.791, 69.008, 66.540, 61.788, 60.729,54.941, 
54.258, 53.132, 24.117, 24.015, 20.786, 20.696, 20.628, 20.592, 20.576, 20.548, 20.444; 
HRMS (ESI) calcd for C34H47NO21S2 + [Na] +: 892.1980, found: 892.1960. 
Compound 3.103 
 
To a solution of compound 3.102 ( 0.065 g, 74 μmol) in 2 mL THF (dry),  methyl azide 
(7  mg, 112 μmol) CuI (1 mg 20%) and DIPEA (1 drop) were added and after 12 hrs of 
reaction time following the general procedure (8.2.3) described above, β-D-S 
lactopyranoside 3.103 (41 mg, 60%) was obatianed; Rf 0.26 (CH2Cl2/MeOH 9.7:0.3); 
 
24
D +1.16 (c 1.0, CH2Cl2); 1H-NMR (600 MHz, CDCl3) 
 7.47 (s, 1H, H-5), 5.92 (d, J 
= 8.5Hz, 1H, H-NH), 5.32 (d, J = 1.2Hz, 1H, H-4II), 5.18 (t, J = 9.2Hz, 1H, H-3II), 5.06 
(t, J = 9.1Hz, 1H, H-3I), 4.95 (dd, J = 2.9Hz, J = 10.4Hz, 1H, H-2II), 4.89 (t, J = 9.7Hz, 
1H, H-2I), 4.56 (d, J =10.1Hz, 1H, H-1II), 4.50 - 4.46 (m, 3H, H-1II, 3, 6II, 6), 4.10 - 4.02 
(m, 3H, H-6,6I, 6II), 4.06 (s, 3H, H-6), 3.88 (t, J = 6.6Hz, 1H, H-4I), 3.77 - 3.74 (m, 1H, 
H-5I), 3.74 (s, 3H, C(O)OCH3), 3.64 (dd, J = 5.7Hz, J = 7.6Hz, 1H, H-5II), 3.39 - 3.34 
(m, 2H, H-1), 3.31 - 3.25 (m, 2H, H-4), 2.98 - 2.95 (m, 2H, H-2), 2.12, 2.09, 2.03, 2.01, 
1.93 (5S, 21H, C(O)CH3);  13C-NMR (150MHz, CDCl3) 
 171.44, 170.53, 170.23, 




73.46, 70.85, 70.57, 69.83, 69.02, 66.56, 61.90, 60.69, 60.26, 55.17, 54.65, 52.88, 36.77, 
28.92, 24.23, 20.70, 20.65, 20.59, 20.52, 20.49, 20.38, 14.07; HRMS (ESI) calcd for 
C35H50N4O21S2 + [H] +: 927.2487; found: 927.2476. 
Compound 3.104 
 
To the solution of compound 3.102 ( 0.065 g, 74 μmol) in 2 mL THF (dry),  ethyl azide 
(8  mg, 112 μmol) CuI (1 mg 20%) and DIPEA (1 drop) were added and after 12 hrs of 
reaction time following the general procedure (8.2.3) described above, β-D-S 
lactopyranoside 3.104 (45 mg, 65%) was obtained; Rf 0.21 (CH2Cl2/MeOH 9.7:0.3); 
 
24
D + 0.74 (c 1.0, CH2Cl2); 1H-NMR (600 MHz, CDCl3) 
 7.52 (s, 1H, H-5), 5.93 (d, J 
= 8.5Hz, 1H, NH), 5.34 (d, J = 3.2Hz, 1H, H-4II), 5.20 (t, J = 9.2Hz, 1H, H-3II),  5.09 (dd, 
J = 7.9Hz, J = 10.3Hz, 1H, H-3I), 4.96 (dd, J = 3.5Hz, J = 10.4Hz, 1H, H-2II), 4.91 (t, J = 
9.7Hz, 1H, H-2’), 4.58 (d, J = 10.1Hz, 1H, H-1II), 4.52 - 4.46 (m, H-1I,H-6II, 3H, H-3), 
4.41 (q, J = 7.3Hz, 1H, H-6), 4.11 - 4.03 (m, 3H, H-6II, H-6I,6I), 3.89 (t, J = 6.9Hz, 1H, 
H-4’), 3.79 (d, J = 9.6Hz, 1H, H-5’ Partially masked under C(O)OCH3), 3.76 (s, 3H, 
C(O)OCH3 ), 3.66 (ddd, J = 1.7Hz, J = 5.7Hz, J = 9.9Hz, 1H, H-5II), 3.41 - 3.3.26 (m, 
4H, H-4, H-1), 3.00 – 2.98 (m, 1H, H-2), 2.14, 2.11, 2.05, 2.03, 2.03, 1.95 (6S, 21H, 





170.552, 170.248, 170.032, 169.943, 169.565, 169.536, 168.984, 141.792, 122.210, 
101.000, 83.768, 76.706, 76.051, 73.485, 70.869, 70.590, 69.857, 69.025, 66.561, 61.899, 
60.692, 55.231, 55.153,54.678, 52.916, 45.673, 28.831,  24.254, 20.729, 20.672, 20.605, 
20.541, 20.527, 20.509, 20.403, 15.217; HRMS (ESI) calcd for C36H52N4O21S2 + [H] +: 
941.2644, found: 941.2627. 
Compound 3.105 
 
To the solution of compound 3.102 (0.1 g, 114 μmol) in 2 mL THF (dry), isopropyl azide 
(14.6 mg, 172 μmol) CuI (1 mg 20%) and DIPEA (1 drop) were added and after 12 hrs of 
reaction time following the general procedure (8.2.3) described above, β-D-S 
lactopyranoside 3.105 (71 mg, 65%) was obtained; Rf  0.24 (CH2Cl2/MeOH 9.7:0.3); 
 
23
D   - 2.47 (c 1.0, CH2Cl2); 1H-NMR (600 MHz, CDCl3) 
 7.52 (s, 1H, H-5), 5.90 (d, J 
= 8.6Hz, 1H, NH), 5.35 (d, J = 2.8Hz, 1H, H-4II), 5.22 (t, J = 9.2Hz, 1H, H-3II), 5.10 (dd, 
J = 8.0Hz, J = 10.3Hz, 1H, H-3I), 4.97 (dd, J = 3.4Hz, J = 10.4Hz, 1H, H-2II), 4.93 (t, J = 
9.7Hz, 1H, H-2I), 4.86 - 4.79 (m, 1H, H-6), 4.59 (d, J = 10.1Hz, 1H, H-1II), 4.55 (d, J = 
12.0Hz, 1H, H-1I), 4.50 (dd, J = 9.9Hz, J = 16.0Hz, 2H, H-3, 6II), 4.13 - 4.05 (m, 3H, H-
6,6I, 6II), 3.90 (t, J = 6.8Hz, 1H, H-4I), 3.80 - 3.75 (m, 1H, H-5I part of the peak masked 




3.37 (dddd, J = 5.1Hz, J = 13.5Hz, J = 19.6Hz, J = 25.2Hz, 4H, H-1,4), 3.01 – 2.98 (m, 
2H, H-2), 2.15, 2.13, 2.06, 2.05, 2.04, 1.97 (7S,3H each,-C(O)CH3), 1.59 (d, J = 6.7Hz, 
1H, H-7,8); 13C-NMR (150MHz, CDCl3) 
 171.363, 170.637, 170.322, 170.110, 
170.025, 169.639, 169.600, 169.030, 141.491, 120.461,  101.113, 83.878, 76.143, 73.549, 
70.940, 70.671, 69.906, 69.071, 66.583, 61.906, 60.724, 55.160, 54.795, 53.662, 53.018, 
28.948, 24.332, 22.888, 22.845, 20.824, 20.757, 20.683, 20.629, 20.619, 20.594, 20.484. 
HRMS (ESI) calcd for C37H54N4O21S2 + [H] +: 955.2800, found: 955.2785. 
Compound 3.106 
 
To the solution of compound 3.102 (0.05 g, 57 μmol) in 2 mL THF (dry), n-propyl  azide 
(7 mg, 86 μmol), CuI (1 mg 20%) and DIPEA (1 drop) were added and after 12 hrs of 
reaction time following the general procedure described above (8.2.3), β-D-S 
lactopyranoside 3.106 (33 mg, 60%) was obtained; Rf 0.22 (CH2Cl2/MeOH 9.7:0.3); 
 
23
D  -0.528 (c 1.0, CH2Cl2); 1H-NMR (600 MHz, CDCl3) 
 7.39 (s, 1H, H-5 ), 5.76 (d, J 
= 8.7Hz, 1H, NH), 5.31 (d, J = 2.7Hz, 1H, H-4II), 5.18 (t, J = 9.2Hz, 1H, H-3II), 5.07 (dd, 
J = 7.9Hz, J = 10.4Hz, 1H, H-3I), 4.93 (dd, J = 3.5Hz, J = 10.4Hz, 1H, H-2II), 4.89 (t, J = 
9.7Hz, 1H, H-2 I), 4.55 (d, J = 10.1Hz, 1H, H-1II), 4.51 - 4.44 (m, 4H, H-1I, H-6II, H-3), 




5.8Hz, J = 12.2Hz, 1H, H-6II), 3.86 (t, J = 6.8Hz, 1H, H-4I), 3.75 (d, J = 9.6Hz, 1H, H-
5I), 3.72 (s, 3H, C(O)OCH3 ), 3.63 (ddd, J = 1.9Hz, J = 5.7Hz, J = 9.8Hz, 2H, H-5II), 
3.38 (ddd, J = 6.3Hz, J = 10.1Hz, J = 14.3Hz, 2H, H-1), 3.31 - 3.22 (m, 2H, H-4), 3.02 - 
2.94 (m, 2H, H-2), 2.11 2.09 2.02 2.01 2.00  1.89 (7S, 3H each, -C(O)CH3),  1.88 (q, J = 
7.3Hz, J = 14.5Hz, 1H, H-7), 0.91 (t, J = 7.4Hz, 3H, H-8); 13C-NMR (150 MHz, CDCl3) 

  171.501, 170.571, 170.271, 170.058, 169.976, 169.583, 169.552, 168.990, 142.013, 
122.110, 101.089, 83.875, 76.732, 76.149, 73.524, 70.905, 70.637, 69.886, 69.045, 
66.562, 61.919, 60.713, 55.263, 54.774, 52.882, 51.905, 29.626,  24.385, 23.590, 20.764, 
20.725, 20.652, 20.593, 20.557, 20.455, 10.967; HRMS (ESI) calcd for C37H54N4O21S2 + 
[H] +: 955.2800, found: 955.2785. 
Compound 3.107 
 
To the solution of compound 3.102 (0.065 g, 74 μmol) in 2 mL THF (dry), 2-azido 
ethanol (10  mg, 112 μmol), CuI (1 mg 20%) and DIPEA (1 drop) were added and after 
hrs of reaction time following the general procedure (8.2.3) described above, β-D-S 
lactopyranoside 3.107 (50 mg, 70%) was obtained; Rf 0.14 (CH2Cl2/MeOH 9.7:0.3); 
 
24
D -3.5 (c 1.0, CH2Cl2); 1H-NMR (600 MHz, CDCl3) 
 7.69 (s, 1H, H-5), 6.02 (d, J  = 




= 8.0Hz, J = 10.3Hz, 1H, H-3I), 4.98 (dd, J = 3.4Hz, J = 10.4Hz, 1H, H-2II), 4.92 (t, J = 
9.7Hz, 1H, H-2I), 4.60 (d, J = 10.1Hz, 1H, H-1II), 4.54 - 4.46 (m, 5H, H-1II, H-3, H-6II, 
H-6II), 4.14 - 4.05 (m, 3H, H-6,6I, 6II), 4.03 - 4.01 (m, 2H, H-7), 3.90 (t, J = 6.8Hz, 1H, 
H-5I Partially masked under C(O)OCH3), 3.79 (s, 3H, C(O)OCH3), 3.68 - 3.65 (m, 1H, 
H-5II), 3.40 - 3.27 (m, 4H, H-1,4), 3.05 - 2.93 (m, 2H, H-2 ), 2.15,  2.13, 2.06, 2.05, 2.04, 
1.97 (6S, 3H each and 1s 6H-C(O)CH3); 13C-NMR (150MHz, CDCl3) 
 171.466, 
170.783, 170.363, 170.104, 170.239, 169.726, 169.680, 169.131, 141.742, 124.258, 
101.062, 83.737, 76.076, 73.471, 70.907, 70.632, 69.877, 69.088, 66.588, 61.957, 60.942, 
60.720, 55.368, 54.727, 53.037, 52.980, 29.002, 24.164, 20.833, 20.757, 20.692, 20.623, 




To the solution of compound 3.102 ( 0.1 g, 114 μmol) in 2 mL THF (dry), benzyl  azide 
(22  mg, 172 μmol), CuI (1 mg 20%) and DIPEA (1 drop) were added and after 12 hrs of 
reaction time following the general procedure (8.2.3) described above, β-D-S 
lactopyranoside 3.108 (80mg, 70%) was obtained; Rf 0.2 (CH2Cl2/MeOH 9.7:0.3);  
24
D
+6.376 (c 1.0, CH2Cl2); 1H-NMR (600 MHz, CDCl3) 




7.24 - 7.23 (m, 2H, HArom) 5.87 (d, J = 8.7Hz, 1H, NH), 5.50 (s, 2H. H-6), 5.33 (d, J = 
3.1Hz, 1H, H-4II), 5.20 (t, J = 9.2Hz, 1H, H-3II), 5.09 (dd, J = 8.0Hz, J = 10.3Hz, 1H, H-
3I), 4.96 (dd, J = 3.4Hz, J = 10.4Hz, 1H, H-2II), 4.92 (t, J = 9.7Hz, 1H, H-2I), 4.58 (d, J = 
10.1Hz, 1H, H-1II), 4.52 - 4.44 (m, 3H, H-1I,3,6II), 4.11 - 4.03 (m, 3H, H-6II,6II,6’), 3.89 
(t, J = 6.8Hz, 1H, H-4I), 3.78 (t, J = 9.5Hz, 1H, H-5I), 3.69 (s, 3H, C(O)OCH3), 3.65 
(ddd, J = 1.8Hz, J = 5.7Hz, J = 9.8Hz, 1H, H-5II), 3.41 - 3.24 (m, 2H, H-2), 3.23 - 3.17 
(m, 2H, H-4), 2.98 - 2.89 (m, 2H, H-1), 2.13, 2.09, 2.04, 2.03, 2.02, 2.02, 1.95 (7S,3H 
each,-C(O)CH3); 13C-NMR (150MHz, CDCl3) 
 171.4, 170.5, 170.2, 170.0, 169.9, 
169.5, 169.5, 168.9, 142.4, 134.3, 129.0, 128.7, 127.9, 122.4, 101.0, 83.8, 76.6, 76.0, 
73.4, 70.8, 70.5, 69.8, 69.0, 66.5, 61.9, 60.6, 55.1, 54.6, 54.1, 52.824, 29.0, 24.3, 20.7, 
20.6, 20.6, 20.5, 20.5, 20.4; HRMS (ESI) calcd for C41H54N4O21S2 + [H] +: 1003.2800, 
found: 1003.2781.  
Compound 3.109 
 
To the solution of compound 3.102 (0.065 g, 74 μmol) in 2 mL THF (dry), cyclopentyl 
azide (12 mg, 112 μmol), CuI (1 mg 20%) and DIPEA (1 drop) were added and after 12 
hrs of reaction time following the general procedure (8.2.3) described above β-D-S 






D  -3.87 (c 1.0, CH2Cl2); 1H-NMR (600 MHz, CDCl3) 
 7.54 (s, 1H, H-5), 5.99 (d, J = 
8.6Hz, 1H,NH), 5.35 (d, J = 3.3Hz, 1H, H-4II), 5.21 (t, J = 9.2Hz, 1H, H-3II), 5.10 (dd, J 
= 7.9Hz, J = 10.3Hz, 1H, H-3I), 4.97 (dd, J = 3.5Hz, J = 10.4Hz, 1H, H-2II), 4.93 (t, J = 
9.6Hz, 1H, H-2I), 4.58 (d, J = 10.1Hz, 1H, H-1II, 4.55 - 4.47 (m, 3H, H-1I,H-6II,H-3), 
4.06 - 3.98 (m, 3H, H-6II, H-6I, H-6I), 3.90 (t, J = 6.9Hz, 1H, H-4I), 3.80 (d, J = 9.6Hz, 
1H, H-5I Partially masked under C(O)OCH3), 3.78 (s, 3H, C(O)OCH3), 3.61 - 3.58 (m, 
1H, H-5II), 3.39 - 3.22 (m, 4H, H-4, H-1), 2.99-2.92 (m, 2H, H-2), 2.22 - 2.17 (m, 2H, 
Cyclopentyl CH2), 2.10 - 2.04 (m, 2H, Cyclopentyl CH2), 2.15, 2.13, 2.06, 2.05, 2.04, 
1.96(6S, 21H, C(O)CH3), 1.93 - 1.86 (m, 2H, Cyclopentyl CH2), 1.80 - 1.74 (m, 2H, 
Cyclopentyl CH2); 13C-NMR (150MHz, CDCl3) 
 171.214, 170.619, 170.297, 170.077, 
169.992, 169.617, 169.575, 169.022, 141.256, 122.039, 101.048, 83.798, 32476.078, 
73.543, 70.920, 70.644, 69.908, 69.076, 66.591, 62.810, 61.904, 60.715, 55.076, 54.747, 
53.030, 33.257, 28.566, 24.234, 23.926, 20.789, 20.715, 20.641, 20.570, 20.439; HRMS 













To the solution of compound 3.102 (0.065 g, 74 μmol) in 2 mL THF (dry), 3-
azidopropionic acid (20  mg, 172 μmol), CuI (1 mg 20%) and DIPEA (1 drop) were 
added and after 12 hrs of reaction time following the general procedure (8.2.3) described 
above β-D-S lactopyranoside 3.110 (79 mg, 70%) was obtained; 1H-NMR (600 MHz, 
CDCl3) 7.65 (s, 1H, H-5), 6.00 (d, J = 8.8Hz, 1H, NH), 5.34 (d, J = 3.1Hz, 1H, H-4II), 
5.21 (t, J = 9.2Hz, 1H, H-3II), 5.08 (dd, J = 8.1Hz, J = 10.2Hz, 1H, H-3I), 4.98 (dd, J = 
3.4Hz, J = 10.4Hz, 1H, H-2II), 4.91 (t, J = 9.7Hz, 1H, H-2’), 4.64 (t, J = 5.9Hz, 2H, H-6), 
4.58 (d, J = 10.1Hz, 1H, H-1II), 4.54 - 4.49 (m, 1H, H-1I, H-6II), 4.49 - 4.40 (m, 1H, H-3), 
4.12 (dd, J = 6.3Hz, J=11.1Hz, 1H, H-6II), 4.07 (td, J = 7.0Hz, J = 12.2Hz, 2H, H-6I, 6I), 
3.90 (t, J = 6.8Hz, 1H, H-4I), 3.79 (t, J = 9.6Hz, 1H, H-5II), 3.76 (s, 1H, C(O)OCH3), 
3.67 (dt, J = 20.2, 10.0 Hz, 1H, H-5I), 3.38 - 3.30 (m, 1H, H-4), 3.29 - 3.20 (m, 3H, H-4, 
H-1), 3.00 (t, J = 5.8Hz, 1H, H-7), 2.93 (t, J = 8.1Hz, 1H, H-2), 2.14 2.11 2.05 2.04 2.03 
1.96 (5S, 3Heach, 1S, 6H, C(O)CH3); 13C-NMR (150MHz, CDCl3) 
 173.00, 171.696, 
170.86, 170.44, 170.12, 170.06, 169.81, 169.77, 169.22, 141.88, 123.89, 100.97, 83.70, 
76.68, 76.00, 73.50, 70.88, 70.56, 69.91, 69.11, 66.61, 62.02, 60.74, 55.42, 54.59, 52.94, 






To a solution of compound 3.103 (0.078 g, 84 μmol ) in 2 mL of dry methanol, 0.2 ml of 
NaOMe/MeOH solution (pH = 10) was added and stirred at RT for 4 hrs of reaction time 
following the general procedure (8.2.4) described above, to obtain the deprotected β-D-S-
lactopyranoside 3.111 (40 mg, 75%); Rf  0.1 (CH2Cl2/MeOH 5:1);  
23
D  - 10.14 (c 1 in 
MeOH); 1H NMR (600 MHz, D2O) δ 7.84 (s, 1H), 4.56 (t, J = 9.7 Hz, 1H), 4.44 (d, J = 
7.8 Hz, 2H), 4.08 (s, 3H), 3.99 - 3.92 (m, 1H), 3.91 (d, J = 3.0 Hz, 1H), 3.80 (s, 3H), 3.75 
(dd, J = 11.4, 7.7 Hz, 2H), 3.71 (dt, J = 13.6, 6.6 Hz, 2H), 3.68 - 3.62 (m, 2H), 3.56 - 3.50 
(m, 2H), 3.41 - 3.27 (m, 3H), 3.12 (dd, J = 14.9, 9.1 Hz, 2H), 3.02 (dt, J = 21.5, 11.1 Hz, 
1H), 2.98 – 2.86 (m, 1H), 2.86 - 2.76 (m, 1H); 13C NMR (150 MHz, D2O) δ 173.66, 
143.27, 126.27, 103.52, 86.28, 86.01, 79.34, 78.67, 76.36, 76.00, 73.17, 72.50, 71.59, 











To a solution of compound 3.104 (0.068 g, 63 μmol) in 2 mL of dry methanol, 0.2 ml of 
NaOMe/MeOH solution (pH = 10) was added and stirred at RT for 4 hrs of reaction time 
following the general procedure (8.2.4) described above, to obtain the deprotected β-D-S-
lactopyranoside 3.112 (30 mg, 72%); Rf  0.25 (CH2Cl2/MeOH 5:1);  
24
D  - 9.70 (c 1 in 
MeOH); 1H NMR (600 MHz, D2O) δ 7.90 (s, 1H), 4.56 (t, J = 9.6 Hz, 1H), 4.48 - 4.35 
(m, 4H), 4.00 - 3.93 (m, 1H), 3.91 (t, J = 7.6 Hz, 1H), 3.80 (s, 3H), 3.79 - 3.69 (m, 2H), 
3.68 - 3.57 (m, 2H), 3.54 (t, J = 8.8 Hz, 2H), 3.54 (t, J = 8.8 Hz, 2H), 3.34 (ddd, J = 19.8, 
16.1, 6.6 Hz, 5H), 3.12 (ddd, J = 14.9, 9.1, 2.1 Hz, 2H), 3.06 - 2.98 (m, 1H), 2.99 - 2.86 
(m, 1H), 2.84 - 2.74 (m, 1H), 1.49 (t, J = 7.4 Hz, 3H); 13C NMR (150 MHz, D2O) δ 
173.67, 143.24, 124.78, 103.52, 86.27, 79.35, 78.68, 76.36, 76.00, 73.17, 72.51, 71.59, 
69.20, 61.68, 60.78, 56.54, 54.28, 53.94, 46.35, 28.98, 28.96, 24.12, 15.37. HRMS (ESI) 










To a solution of compound 3.105 (0.057 g, 59 μmol) in 2 mL of dry methanol, 0.2 ml of 
NaOMe/MeOH solution (pH = 10) was added and stirred at RT for 4 hrs of reaction time 
following the general procedure (8.2.4) described above, to obtain the deprotected β-D-S-
lactopyranoside 3.113 (31 mg, 79%); Rf  0.17 (CH2Cl2/MeOH 4:1);  
23
D  - 10.84 (c 1 in 
MeOH); 1H NMR (600 MHz, D2O) δ 7.95 (d, J = 8.3 Hz, 1H), 4.87 - 4.80 (m, 1H), 4.55 
(dt, J = 19.7, 5.6 Hz, 1H), 4.47 - 4.37 (m, 2H), 3.95 (ddd, J = 13.8, 7.8, 5.6 Hz, 1H), 3.90 
(t, J = 8.9 Hz, 1H), 3.79 (s, 3H), 3.78 - 3.69 (m, 2H), 3.68 - 3.59 (m, 2H), 3.57 - 3.50 (m, 
2H), 3.44 - 3.27 (m, 5H), 3.11 (dd, J = 14.1, 10.0 Hz, 1H), 3.06 - 2.97 (m, 1H), 2.98 - 
2.87 (m, 1H), 2.79 (dt, J = 14.5, 7.1 Hz, 1H), 1.53 (dd, J = 6.7, 1.4 Hz, 6H); 13C NMR 
(150 MHz, D2O) δ 173.61, 143.00, 123.25, 103.51, 86.26, 79.35, 78.66, 76.36, 73.16, 
72.51, 71.58, 69.20, 61.67, 60.78, 56.54, 54.52, 54.16, 53.93, 28.98, 24.10, 23.90, 22.68. 










To a solution of compound 3.106 (0.068 g, 72 μmol) in 2 mL of dry methanol, 0.2 ml of 
NaOMe/MeOH solution (pH = 10) was added and stirred at RT for 4 hrs of reaction time 
following the general procedure (8.2.4) described above, to obtain the deprotected β-D-S-
lactopyranoside 3.114 (36 mg, 75%); Rf  0.17 (CH2Cl2/MeOH 4:1);   
24
D  - 13.15 (c 1 in 
MeOH); 1H NMR (600 MHz, D2O) δ 7.90 (s, 1H), 4.60 - 4.55 (m, 1H), 4.45 (dd, J = 7.7, 
6.5 Hz, 1H), 4.37 (q, J = 6.8 Hz, 2H), 4.03 - 3.94 (m, 1H), 3.92 (t, J = 8.4 Hz, 1H), 3.83 - 
3.80 (m, 1H), 3.78 (s, 3H), 3.69 - 3.62 (m, 4H), 3.60 - 3.50 (m, 2H), 3.48 - 3.28 (m, 5H), 
3.13 (ddd, J = 15.0, 9.3, 2.2 Hz, 1H), 3.09 - 3.01 (m, 1H), 3.00 - 2.91 (m, 1H), 2.84 (dt, J 
= 14.8, 7.6 Hz, 1H), 1.93 – 1.86 (m, 2H), 0.85 (dd, J = 7.9, 7.4 Hz, 3H); 13C NMR (150 
MHz, D2O) δ 173.65, 143.26, 126.27, 103.52, 86.27, 79.34, 78.67, 76.36, 76.00, 73.17, 
72.50, 71.59, 69.20, 61.67, 60.78, 56.47, 54.26, 53.94, 37.27, 28.93, 24.11, 23.89. HRMS 










To a solution of compound 3.107 (0.062 g, 64 μmol) in 2 mL of dry methanol, 0.2 ml of 
NaOMe/MeOH solution (pH = 10) was added and stirred at RT for 4 hrs of reaction time 
following the general procedure (8.2.4) described above, to obtain the deprotected β-D-S-
lactopyranoside 3.115 (30 mg, 70%); Rf  0.1 (CH2Cl2/MeOH 5:1);  
24
D  - 8.40 (c 1 in 
MeOH); 1H NMR (600 MHz, D2O) δ 7.95 (d, J = 11.9 Hz, 1H), 4.61 - 4.52 (m, 3H), 4.51 
- 4.41 (m, 3H), 4.04 - 3.93 (m, 4H), 3.91 (t, J = 7.1 Hz, 1H), 3.80 (s, 3H), 3.79 - 3.74 (m, 
2H), 3.71 (ddd, J = 11.5, 7.7, 3.1 Hz, 2H), 3.68 - 3.57 (m, 1H), 3.54 (t, J = 8.9 Hz, 1H), 
3.49 - 3.27 (m, 5H), 3.23 - 3.12 (m, 1H), 3.10 - 3.00 (m, 1H), 2.94 (ddd, J = 20.3, 11.7, 
5.9 Hz, 1H), 2.88 – 2.79 (m, 1H); 13C NMR (150 MHz, D2O) δ 173.67, 143.26, 126.27, 
103.51, 86.03, 79.33, 78.65, 76.36, 76.00, 73.16, 72.49, 72.45, 71.59, 69.20, 61.68, 60.76, 
56.44, 54.15, 53.95, 28.98, 24.12; HRMS (ESI) calcd for C22H38N4O15S2 +  [H] +: 










To a solution of compound 3.108 (0.050 g, 49 μmol) in 2 mL of dry methanol, 0.2 ml of 
NaOMe/MeOH solution (pH = 10) was added and stirred at RT for 4 hrs of reaction time 
following the general procedure (8.2.4) described above, to obtain the deprotected β-D-S-
lactopyranoside 3.116 (28 mg, 80%); Rf  0.3 (CH2Cl2/MeOH 5:1);  
23
D  - 9.28 (c 1 in 
MeOH); 1H NMR (600 MHz, D2O) δ 7.89 (s, 1H), 7.47 - 7.35 (m, 3H), 7.29 (d, J = 7.1 
Hz, 2H), 5.54 (s, 2H), 4.53 (dd, J = 9.9, 4.9 Hz, 1H), 4.43 (dd, J = 7.7, 3.1 Hz, 2H), 3.87 
(s, 3H), 3.83 - 3.74 (m, 2H), 3.73 (s, 4H), 3.72 - 3.68 (m, 2H), 3.68 - 3.60 (m, 2H), 3.56 
(dt, J = 17.7, 7.1 Hz, 4H), 3.41 - 3.20 (m, 6H), 3.06 (s, 1H), 3.01 - 2.94 (m, 1H), 2.88 (pd, 
J = 14.1, 5.7 Hz, 1H), 2.83 - 2.71 (m, 1H); 13C NMR (150 MHz, D2O) δ 173.57, 135.58, 
129.77, 129.41, 128.63, 103.55, 86.08, 79.34, 78.69, 76.39, 76.03, 73.20, 72.49, 71.61, 
69.22, 61.69, 60.81, 56.51, 54.55, 54.20, 53.90, 29.02, 24.11, 23.94. HRMS (ESI) calcd 










To a solution of compound 3.109 (0.050 g, 51 μmol) in 2 mL of dry methanol, 0.2 ml of 
NaOMe/MeOH solution (pH = 10) was added and stirred at RT for 4 hrs of reaction time 
following the general procedure (8.2.4) described above, to obtain the deprotected β-D-S-
lactopyranoside 3.117 (28 mg, 80%); Rf  0.34 (CH2Cl2/MeOH 5:1);  
23
D  - 7.39 (c 1 in 
MeOH); 1H NMR (600 MHz, D2O) δ 7.92 (s, 1H), 5.03 - 4.92 (m, 1H), 4.61 - 4.52 (m, 
1H), 4.49 - 4.38 (m, 2H), 3.95 (d, J = 10.5 Hz, 1H), 3.90 (t, J = 9.2 Hz, 1H), 3.81 (s, 3H), 
3.78 - 3.68 (m, 2H), 3.68 - 3.58 (m, 2H), 3.52 (dd, J = 23.0, 13.4 Hz, 2H), 3.41 - 3.26 (m, 
5H), 3.16 - 3.05 (m, 1H), 3.04 - 2.97 (m, 1H), 2.95 - 2.85 (m, 1H), 2.78 (dt, J = 14.8, 7.5 
Hz, 1H), 2.31 - 2.16 (m, 2H), 1.96 (dd, J = 12.3, 6.2 Hz, 2H), 1.81 (dd, J = 14.3, 7.7 Hz, 
2H), 1.77 - 1.70 (m, 2H); 13C NMR (150 MHz, D2O) δ 173.67, 143.24, 124.78, 103.52, 
86.27, 79.35, 78.68, 76.36, 73.17, 72.51, 71.59, 69.20, 61.68, 60.78, 56.54, 54.28, 53.94, 
46.35, 28.98, 24.12, 23.90, 15.37; HRMS (ESI) calcd for C25H42N4O14S2 + [H] +: 









To a solution of compound 3.110 (0.070 g, 71 μmol) in 2 mL of dry methanol, 0.2 ml of 
NaOMe/MeOH solution (pH = 10) was added and stirred at RT for 4 hrs of reaction time 
following the general procedure (8.2.4) described above, to obtain the deprotected β-D-S-
lactopyranoside 3.118 (36 mg, 74%); Rf  0.05 (CH2Cl2/MeOH 5:1);  
23
D  - 14.78 (c 1 in 
MeOH); 1H NMR (600 MHz, D2O) δ 7.92 (s, 1H, 1H), 5.30 - 5.16 (m, 1H), 5.00 - 4.86 
(m, 2H), 4.73 - 4.62 (m, 2H), 4.64 - 4.51 (m, 1H), 4.48 - 4.33 (m, 2H), 4.06 - 3.82 (m, 
3H), 3.83 - 3.74 (m, 3H), 3.72 (dt, J = 20.8, 8.8 Hz, 2H), 3.69 - 3.48 (m, 3H), 3.47 - 3.26 
(m, 5H), 3.12 (dd, J = 14.9, 9.1 Hz, 1H), 3.07 - 2.98 (m, 2H), 2.99 - 2.83 (m, 1H), 2.18 - 
2.04 (m, 2H); 13C NMR (150 MHz, D2O) δ 173.61, 143.07, 125.53, 103.74, 86.63, 83.27, 
79.69, 78.68, 75.53, 75.50, 72.97, 72.47, 71.43, 69.09, 62.07, 60.81, 56.88, 54.33, 46.28, 











To a solution of compound 3.111 (19 mg, 3 μmol) in mixed solvent of THF:MeOH:H2O 
(3:2:1) was added a 1M LiOH.H2O soln (0.03 mL, 1eq)  and stirred for 2 hrs, following 
the general saponification (8.2.5) procedure to obtain 3.119 (14 mg, 78%); Rf  0.18 
(ACN/H2O 8:2);  
21
D  - 4.9 (c 1.0, H2O); 1H NMR (600 MHz, D2O) δ 7.82 (s, 1H), 4.55 
(t, J = 9.7 Hz, 1H), 4.43 (d, J = 7.8 Hz, 2H), 4.09 (s, 3H), 3.97 - 3.91 (m, 1H), 3.90 (d, J 
= 3.0 Hz, 1H), 3.73 (dd, J = 11.4, 7.7 Hz, 2H), 3.70 (dt, J = 13.6, 6.6 Hz, 2H), 3.67 - 3.61 
(m, 2H), 3.55 - 3.49 (m, 2H), 3.37 - 3.24 (m, 3H), 3.09 (dd, J = 14.9, 9.1 Hz, 2H), 3.02 
(dt, J = 21.5, 11.1 Hz, 1H), 2.98 - 2.86 (m, 1H), 2.86 - 2.76 (m, 1H); 13C NMR (150 
MHz, D2O) δ 173.65, 143.28, 126.25, 103.55, 86.26, 86.03, 79.37, 78.65, 76.33, 75.98, 
73.15, 72.48, 71.54, 69.20, 61.68, 60.78, 56.50, 54.27, 54.14, 37.26, 28.9, 24.12, 23.89. 











To a solution of compound 3.112 (22 mg, 3 μmol) in mixed solvent of THF:MeOH:H2O 
(3:2:1) was added a 1M LiOH.H2O soln. (0.03mL, 1eq) and stirred for 2 hrs, following 
the general saponification procedure (8.2.5) to obtain 3.120 (16 mg, 75%); Rf  0.18 
(ACN/H2O 8:2);  
21
D  - 6.62 (c 1.0, H2O); 1H NMR (600 MHz, D2O) δ 7.89 (s, 1H), 4.55 
(t, J = 9.6 Hz, 1H), 4.46 - 4.33 (m, 4H), 4.00 - 3.94 (m, 1H), 3.89 (t, J = 7.6 Hz, 1H), 3.78 
- 3.68 (m, 2H), 3.68 - 3.57 (m, 2H), 3.54 (t, J = 8.8 Hz, 2H), 3.53 (t, J = 8.8 Hz, 2H), 3.31 
(ddd, J = 19.8, 16.1, 6.6 Hz, 5H), 3.11 (ddd, J = 14.9, 9.1, 2.1 Hz, 2H), 3.05 - 2.96 (m, 
1H), 2.97 - 2.85 (m, 1H), 2.84 - 2.74 (m, 1H), 1.49 (t, J = 7.4 Hz, 3H); 13C NMR (150 
MHz, D2O) δ 173.66, 143.14, 124.48, 103.51, 86.24, 79.25, 78.66, 76.35, 76.00, 73.15, 
72.49, 71.58, 69.19, 61.67, 60.75, 56.53, 54.27, 46.34, 28.97, 28.95, 24.11, 15.36. HRMS 











To a solution of compound 3.113 (22 mg, 3 μmol) in mixed solvent of THF:MeOH:H2O 
(3:2:1) was added a 1M LiOH.H2O soln. (0.03mL, 1eq) and stirred for 2 hrs, following 
the general saponification procedure (8.2.5) to obtain 3.121 (14 mg, 73%); Rf  0.19 
(ACN/H2O 8:2);  
21
D  - 8.23 (c 1.0, H2O); 1H NMR (600 MHz, D2O) δ 7.92 (s, 1H), 4.85 
- 4.78 (m, 1H), 4.54 (dt, J = 19.7, 5.6 Hz, 1H), 4.46 - 4.35 (m, 2H), 3.89 (ddd, J = 13.8, 
7.8, 5.6 Hz, 1H), 3.88 (t, J = 8.9 Hz, 1H), 3.76 - 3.67 (m, 2H), 3.65 - 3.59 (m, 2H), 3.56 - 
3.49 (m, 2H), 3.41 - 3.26 (m, 5H), 3.10 (dd, J = 14.1, 10.0 Hz, 1H), 3.05 - 2.96 (m, 1H), 
2.96 - 2.85 (m, 1H), 2.77 (dt, J = 14.5, 7.1 Hz, 1H), 1.52 (dd, J = 6.7, 1.4 Hz, 6H); 13C 
NMR (150 MHz, D2O) δ 173.60, 143.01, 123.24, 103.50, 86.27, 79.31, 78.61, 76.34, 
73.16, 72.52, 71.58, 69.19, 61.66, 60.75, 56.53, 54.51, 54.15, 28.96, 24.09, 23.89, 22.66. 











To a solution of compound 3.114 (16 mg, 2.4 μmol) in mixed solvent of 
THF:MeOH:H2O (3:2:1) was added a 1M LiOH.H2O soln. (0.03 mL, 1 eq) and stirred for 
2 hrs, following the general saponification procedure (8.2.5) to obtain 3.122 (13 mg, 
80%); Rf  0.19 (ACN/H2O 8:2);  
21
D  - 8.52 (c 1.0, H2O); 1H NMR (600 MHz, D2O) δ 
7.90 (s, 1H), 4.59 - 4.54 (m, 1H), 4.39 (dd, J = 7.7, 6.5 Hz, 1H), 4.35 (q, J = 6.8 Hz, 2H), 
3.99 - 3.95 (m, 1H), 3.89 (t, J = 8.4 Hz, 1H), 3.81 - 3.79 (m, 1H), 3.66 - 3.58 (m, 4H), 
3.59 - 3.50 (m, 2H), 3.47 - 3.26 (m, 5H), 3.10 (ddd, J = 15.0, 9.3, 2.2 Hz, 1H), 3.09 - 2.99 
(m, 1H), 2.98 - 2.89 (m, 1H), 2.84 (dt, J = 14.8, 7.6 Hz, 1H), 1.91 - 1.84 (m, 2H), 0.85 
(dd, J = 7.9, 7.4 Hz, 3H); 13C NMR (150 MHz, D2O) δ 173.64, 143.25, 126.24, 103.49, 
86.25, 79.33, 78.64, 76.35, 75.99, 73.16, 72.49, 71.57, 69.19, 61.66, 60.79, 56.44, 54.24, 











To a solution of compound 3.115 (28 mg, 4.2 μmol) in mixed solvent of 
THF:MeOH:H2O (3:2:1) was added a 1M LiOH.H2O soln. (0.05 mL, 1 eq) and stirred for 
2 hrs, following the general saponification procedure (8.2.5) to obtain 3.123 (19 mg, 
70%); Rf  0.15 (ACN/H2O 8:2);  
22
D  - 10.98 (c 1.0, H2O); 1H NMR (600 MHz, D2O) δ 
7.93 (d, J = 11.9 Hz, 1H), 4.59 - 4.49 (m, 3H), 4.47 - 4.37 (m, 3H), 4.06 - 3.89 (m, 4H), 
3.88 (t, J = 7.1 Hz, 1H), 3.77 - 3.72 (m, 2H), 3.70 (ddd, J = 11.5, 7.7, 3.1 Hz, 2H), 3.66 - 
3.56 (m, 1H), 3.53 (t, J = 8.9 Hz, 1H), 3.47 - 3.25 (m, 5H), 3.21 - 3.11 (m, 1H), 3.10 - 
3.00 (m, 1H), 2.92 (ddd, J = 20.3, 11.7, 5.9 Hz, 1H), 2.86 - 2.77 (m, 1H); 13C NMR (150 
MHz, D2O) δ 173.67, 143.22, 126.25, 103.50, 86.02, 79.31, 78.62, 76.34, 76.01, 73.15, 
72.46, 72.44, 71.55, 69.17, 61.65, 60.74, 56.44, 54.15, 28.98, 24.10. HRMS (ESI) calcd 











To a solution of compound 3.116 (16 mg, 2.4 μmol) in mixed solvent of 
THF:MeOH:H2O (3:2:1) was added a 1M LiOH.H2O soln. (0.03mL, 1 eq) and stirred for 
2 hrs, following the general saponification procedure (8.2.5) to obtain 3.124 (12 mg, 
77%); Rf  0.25 (ACN/H2O 8:2);  
22
D  - 2.79 (c 1.0, H2O); 1H NMR (600 MHz, D2O) δ 
7.75 (s, 1H), 7.47 - 7.35 (m, 3H), 7.29 (d, J = 7.1 Hz, 2H), 5.43 (s, 2H), 4.60 (dd, J = 9.9, 
4.9 Hz, 1H), 4.36 (dd, J = 7.7, 3.1 Hz, 2H), 3.40 - 3.49 (m, 2H), 3.73 (s, 4H), 3.70 - 3.66 
(m, 2H), 3.68 - 3.60 (m, 2H), 3.56 (dt, J = 17.7, 7.1 Hz, 4H), 3.35 - 3.20 (m, 6H), 3.06 (s, 
1H), 3.01 - 2.94 (m, 1H), 2.88 (pd, J = 14.1, 5.7 Hz, 1H), 2.83 - 2.71 (m, 1H); 13C NMR 
(150 MHz, D2O) δ 173.56, 135.54, 129.75, 129.43, 128.65, 103.51, 86.10, 79.24, 78.69, 
76.39, 76.03, 73.20, 72.50, 71.61, 69.22, 61.70, 60.88, 56.51, 54.55, 54.20, 29.02, 24.11, 











To a solution of compound 3.117 (16 mg, 2.4 μmol) in mixed solvent of 
THF:MeOH:H2O (3:2:1) was added a 1M LiOH.H2O soln. (0.03mL, 1eq) and stirred for 
2 hrs, following the general saponification procedure (8.2.5) to obtain 3.125 (11 mg, 
70%); Rf  0.22 (ACN/H2O 8:2);  
22
D  - 5.57 (c 1.0, H2O); 1H NMR (600 MHz, D2O) δ 
7.90 (s, 1H), 5.02 - 4.91 (m, 1H), 4.59 - 4.50 (m, 1H), 4.48 - 4.37 (m, 2H), 3.93 (d, J = 
10.5 Hz, 1H), 3.89 (t, J = 9.2 Hz, 1H), 3.77 - 3.68 (m, 2H), 3.66 - 3.57 (m, 2H), 3.50 (dd, 
J = 23.0, 13.4 Hz, 2H), 3.39 - 3.19 (m, 5H), 3.14 - 3.06 (m, 1H), 3.03 - 2.96 (m, 1H), 2.93 
- 2.86 (m, 1H), 2.68 (dt, J = 14.8, 7.5 Hz, 1H), 2.29 - 2.09 (m, 2H), 1.89 (dd, J = 12.3, 6.2 
Hz, 2H), 1.79 (dd, J = 14.3, 7.7 Hz, 2H), 1.75 - 1.69 (m, 2H); 13C NMR (150 MHz, D2O) 
δ 173.66, 143.19, 124.69, 103.49, 86.19, 79.33, 78.71, 76.35, 73.16, 72.52, 71.61, 69.21, 
61.68, 60.77, 56.54, 54.28, 46.35, 28.99, 24.12, 23.91, 15.37; HRMS (ESI) calcd for 










To a solution of compound 3.116 (16 mg, 2.4 μmol) in mixed solvent of 
THF:MeOH:H2O (3:2:1) was added a 1M LiOH.H2O soln. (0.03 mL, 1 eq) and stirred for 
2 hrs, following the general saponification procedure (8.2.5) to obtain 3.124 (12 mg, 
77%); Rf 0.25 (ACN/H2O 8:2);  
22
D  - 2.79 (c 1.0, H2O); 1H NMR (600 MHz, D2O) δ 
7.75 (s, 1H), 7.47 – 7.35 (m, 3H), 7.29 (d, J = 7.1 Hz, 2H), 5.43 (s, 2H), 4.60 (dd, J = 9.9, 
4.9 Hz, 1H), 4.36 (dd, J = 7.7, 3.1 Hz, 2H), 3.40 - 3.49 (m, 2H), 3.73 (s, 4H), 3.70 - 3.66 
(m, 2H), 3.68 - 3.60 (m, 2H), 3.56 (dt, J = 17.7, 7.1 Hz, 4H), 3.35 - 3.20 (m, 6H), 3.06 (s, 
1H), 3.01 - 2.94 (m, 1H), 2.88 (pd, J = 14.1, 5.7 Hz, 1H), 2.83 - 2.71 (m, 1H); 13C NMR 
(150 MHz, D2O) δ 173.56, 135.54, 129.75, 129.43, 128.65, 103.51, 86.10, 79.24, 78.69, 
76.39, 76.03, 73.20, 72.50, 71.61, 69.22, 61.70, 60.88, 56.51, 54.55, 54.20, 29.02, 24.11, 











To a solution of compound 3.118 (40 mg, 6 μmol) in mixed solvent of THF:MeOH:H2O 
(3:2:1) was added a 1M LiOH.H2O soln. (0.03 mL, 1 eq) and stirred for 2 hrs, following 
the general saponification procedure (8.2.5) to obtain 3.126 (28 mg, 72%); Rf  0.09 streak 
(ACN : H2O 8:2);   
22
D  - 7.36 (c 1.0, H2O); 1H NMR (600 MHz, D2O) δ 7.90 (s, 1H, 
1H), 5.29 - 5.15 (m, 1H), 5.01 - 4.84 (m, 2H), 4.74 - 4.59 (m, 2H), 4.66 - 4.49 (m, 1H), 
4.50 - 4.31 (m, 2H), 4.004 - 3.84 (m, 3H), 3.79 - 3.76 (m, 2H), 3.71 (dt, J = 20.8, 8.8 Hz, 
2H), 3.66 - 3.44 (m, 3H), 3.45 - 3.25 (m, 5H), 3.14 (dd, J = 14.9, 9.1 Hz, 1H), 3.07 - 2.98 
(m, 2H), 2.99 - 2.85 (m, 1H), 2.20 - 2.03 (m, 2H); 13C NMR (150 MHz, D2O) δ 173.41, 
142.86, 125.30, 103.64, 86.53, 83.16, 79.58, 78.48, 75.45, 75.33, 72.73, 72.26, 71.33, 
68.88, 61.91, 60.66, 56.77, 46.14, 35.07, 28.72, 24.17, 21.20; HRMS (ESI) calcd for 











To a solution of compound 3.102 (0.1 g, 127 μmol ) in 2 mL of dry methanol, 0.2 ml of 
NaOMe/MeOH solution (pH = 10) was added and stirred at RT for 4 hrs following the 
general procedure (8.2.4) described above, to obain the deprotected β-D-S-
lactopyranoside 3.127 (58 mg, 80%);  
24
D  - 9.54 (c 1 in MeOH); 1H NMR (600 MHz, 
D2O) δ 4.65 (t, J = 8.4 Hz, 1H), 4.49 - 4.39 (m, 2H), 3.98 (t, J = 13.5 Hz, 1H), 3.92 (d, J 
= 19.7 Hz, 1H), 3.83 (s, 3H), 3.79 (dt, J = 18.6, 4.9 Hz, 2H), 3.73 (dd, J = 11.6, 8.1 Hz, 
2H), 3.67 (dt, J = 10.4, 8.8 Hz, 4H), 3.65 - 3.58 (m, 4H), 3.58 - 3.50 (m, 1H), 3.42 (dd, J 
= 13.3, 5.2 Hz, 1H), 3.30 - 3.06 (m, 2H), 2.82 (d, J = 5.8 Hz, 1H); 13C NMR (150 MHz, 
D2O) δ 172.60, 102.95, 85.64, 78.82, 78.13, 75.79, 75.44, 72.60, 71.91, 71.02, 68.63, 
61.11, 60.23, 54.66, 53.89, 53.48, 23.66, 22.86; HRMS (ESI) calcd for C20H33NO14S2 + 












To a solution of compound 3.127 (40 mg, 69 μmol) in mixed solvent of THF:MeOH:H2O 
(3:2:1) was added a 1M LiOH.H2O soln. (0.06mL)  and stirred for 2 hrs, following the 
general saponification procedure (8.2.5) to obtain 3.128 (14 mg, 78%); Rf 0.20 
(ACN/H2O 8:2);  
22
D  - 4.76 (c 1.0, H2O); 1H NMR (600 MHz, D2O) δ 4.61 (d, J = 9.9 
Hz, 1H), 4.44 (dd, J = 7.8, 1.1 Hz, 2H), 4.26 (dt, J = 8.6, 4.3 Hz, 1H), 3.96 (dt, J = 17.3, 
8.7 Hz, 2H), 3.90 (dd, J = 14.1, 3.5 Hz, 2H), 3.82 - 3.73 (m, 4H), 3.73 - 3.68 (m, 3H), 
3.68 - 3.63 (m, 4H), 3.59 (ddd, J = 24.0, 15.9, 7.8 Hz, 5H), 3.53 (dd, J = 9.7, 8.0 Hz, 2H), 
3.38 (td, J = 9.9, 2.5 Hz, 1H), 3.16 (t, J = 7.9 Hz, 1H), 2.79 - 2.75 (m, 3H), 2.48 (q, J = 
2.5 Hz, 1H); 13C NMR (150 MHz, D2O) δ 174.96, 103.49, 86.35, 86.09, 80.27, 79.33, 
78.65, 76.33, 75.98, 73.15, 72.96, 72.47, 71.59, 69.19, 61.67, 60.78, 55.75, 54.26, 24.40, 
24.12, 23.76; HRMS (ESI) calcd for C19H31NO14S2 + [H] +: 584.1084, found: 584.1076. 
Compound 3.137 
 
To a solution of acceptor 3.136 (200 mg, 0.41 mmol) and 2,3,4,6-tetra-O-acetyl-α-D-




dichloromethane under nitrogen was added powdered molecular sieves (4 A, 0.5 g). The 
mixture was stirred for 2 h at room temperature, and then cooled to - 45oC. BF3.Et2O (50 
µL, 0.41mmol) was added drop wise. After 1 h the mixture was neutralized with 
triethylamine, diluted with dichloromethane (10 mL), filtered through celite, and washed 
with dichloromethane. The combined filtrate and washings were dried over MgSO4, 
filtered and concentrated. The syrupy residue was purified by silica gel chromatography 
to give 3.137 (272 mg, 82%); Rf =  0.31 (DCM : MeOH, 9.8 : 0.2, v/v); 1H NMR (600 
MHz, CDCl3): δ = 7.79 – 7.65  (m, 4H, Harom), 7.52 - 7.30 (m, 6H, Harom), 5.57 (d, 3JNH-
H2 = 8.0 Hz, 1H, AcNH), 5.37 (d, 3J3,4  = 3J4,5 = 3.4 Hz, 1H, H-4II), 5.20 (dd, 3J1,2  = 8.0 
Hz, 3J2,3 = 10.4 Hz, 1H, H-2II), 4.97 (dd, 3J3,4  = 3.4 et 3J2,3 = 10.4 Hz, 1H, H-3II), 4.87 (d, 
3J1,2  = 8.2 Hz, 1H, H-1I), 4.72 (d, 3J1,2  = 8.0 Hz, 1H, H-1II), 4.35 (dd, J = 59.0, 15.6 Hz, 
2H, H-6II), 4.15 (d, 4JH-H = 6.5 Hz, 2H, OCH2), 4.05 - 3.75 (m, 6H, H-3I, H-4I, H-5I, H-
5II, H-6I), 3.59 (dd, J = 17.5, 8.6 Hz, 1H, H-2I), 3.43 (d, 3J3,OH = 9.1 Hz, 1H, OH-3I), 2.44 
(t, 4JH,CH2 = 2.4 Hz, 1H, CCH), 2.16, 2.07, 2.04, 1.99 (4 x s, 9H, COCH3), 1.72 (s, 3H, 
NHCOCH3), 1.08 ppm (s, 9H, SiCMe3) ; 13C NMR (150 MHz, CDCl3): δ = 170.6, 
170.4, 170.1, 169.9, 169.1 (CO), 135.9, 135.5, 133.4, 132.5, 129.9, 129.9, 127.9, 127.7 
(Carom), 100.9 (C-1II), 97.6 (C-1I), 79.8 (CCH), 78.7 (CCH), 75.0 (C-4I), 74.6 (C-5I), 
71.6 (C-3I), 71.2 (C-5II), 70.8 (C-3II), 68.8 (C-2II), 66.9 (C-4II), 61.7 (C-6I), 61.2 (C-6II), 
56.5 (OCH2), 55.2 (C-2I), 26.8 (SiCMe3), 23.7 (NHCOCH3), 20.6, 20.6, 20.5, 20.3 
(COCH3), 19.3 ppm (SiCMe3). HRMS (ESI) calculated for C41H54NO15Si M + H+ : 






a)  To a solution of compound 3.137 (0.083 g, 100 μmol) in THF:H2O (1:1) 2 mL, MeI 
(2eq) NaN3 (3 eq), CuSO4.5 H2O (5 mg 20%) and sodium ascorbate (8 mg, 40%) were 
added and after 12h of reaction time at 40oC following the general procedure (7.2.1) 
described above, the LacNAc triazole derivative 3.138 (44 mg, 50 %) was obtained;  
b) Methyl azide was distilled at 90oC while preparing it in another RBF (MeI (1 eq) + 
NaN3 (2eq) + DMF + Water (1:1)) then added to a RBF containing the solution of 
compound 3.137 ( 0.083 g, 100 μmol) in THF:H2O (1:1) 2 mL, CuSO4.5H2O (5 mg 20%) 
and sodium ascorbate (8 mg, 40%). After 12 h of reaction time at 40oC following the 
general procedure (7.2.1) described above, the LacNAc triazole derivative  3.138 (79 mg, 
90 %) was obtained; Rf  =  0.23 (DCM/MeOH, 9.8:0.2, v/v);  
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D  - 2.23 (c 1.0, CHCl3); 
1H-NMR (600 MHz) δ = 7.73 (td, J = 5.6, 3.0 Hz, 4H, Harom), 7.49 (s, 1H, click-H), 7.47 
- 7.32 (m, 6H, Harom), 6.02 (d, 3JNH-H2 = 8.0 Hz, 1H, AcNH ), 5.36 (d, 3J3,4  = 3J4,5 = 3.4 
Hz, 1H, H-4II ), 5.19 (dd, 3J1,2  = 8.0 Hz, 3J2,3 = 10.4 Hz, 1H, H-2II), 4.97 (dd, 3J3,4  = 3.4 
and 3J2,3 = 10.4 Hz, 2H, H-3II, H-1I ), 4.73 (dd, J = 5.6Hz, J = 7.8Hz, 3H, H-6a6bII, H-1II), 
4.14 (d, 4JH-H = 6.5 Hz, 2H, OCH2), 4.05 (s, 3H, N-CH3), 3.88 (ddd, J = 14.6, 11.4, 4.7 
Hz, 4H, H-3I, H-4I, H-6a, 6bI), 3.71 (dd, J = 8.3Hz, J = 17.5Hz, 1H, H-2I), 3.43 (d, 3J3,OH 




NHCOCH3), 1.08 (s, 9H, SiCMe3); 13C NMR (150 MHz, CDCl3): δ = 170.8, 170.3, 
170.0, 169.8, 169.1 (CO), 144.87 (triazole-C) 135.8, 135.4, 133.4, 132.4, 129.9, 127.8, 
127.6 (Carom), 123.4 (triazole-C) 100.8 (C-1II), 99.6 (C-1I), 79.5 (C-4I), 74.6 (C-5I), 72.1 
(C-3I), 71.1 (C-5II), 70.7 (C-3II), 68.8 (C-2II), 66.8 (C-4II), 61.9 (C-6I), 61.8 (C-6II), 61.1 
(OCH2), 56.3 (C-2I), 36.6 (N-CH3), 26.8 (SiCMe3), 23.4 (NHCOCH3), 20.57, 20.53, 
20.48, 20.32 (COCH3), 19.32 ppm (SiCMe3). HRMS (ESI) calculated for C42H57N4O15Si 
M + H+ : 885.35842, found 885.35736. 
Compound 3.139 
 
a) To a solution of compound 3.137 (0.083 g, 100 μmol) in THF:H2O (1:1) 2 mL, EtBr 
(2eq) NaN3 (3 eq), CuSO4.5 H2O (5 mg 20%) and sodium ascorbate (8 mg, 40%) were 
added and after 12h of reaction time at 40oC following the general procedure (7.2.1) 
described above, the LacNAc triazole derivative 3.139 (50 mg, 55 %) was obtained. 
b) Ethyl azide was distilled at 90oC while preparing it in another RBF (EtBr (1eq) + 
NaN3 (2eq) + DMF + Water (1:1)) then added to a RBF containing the solution of 
compound 3.137 (0.083 g, 100 μmol) in THF: H2O (1:1) 2mL, CuSO4. 5H2O (5 mg 20%) 
and sodium  ascorbate (8 mg, 40%). After 12h of reaction time at 40oC following the 
general procedure ((7.2.1) described above the LacNAc triazole derivative  3.139 (82 mg, 
91 %) was obtained; Rf 0.27 (DCM/MeOH, 9.7 : 0.3, v/v) ;  
22




1H-NMR (600 MHz) δ = 7.72 (dd, J = 9.2, 4.1 Hz, 4H, Harom), 7.52 (s, 1H, click-H), 7.48 
- 7.30 (m, 4H, Harom), 6.15 (d, 3JNH-H2 = 7.8 Hz, 1H, AcNH), 5.36 (d, d, 1H, 3J3,4  = 3J4,5 = 
3.4 Hz, 1H, H-4II), 5.18 (dd, 3J1,2  = 8.1 Hz, 3J2,3 = 10.3 Hz, 1H, H-2II), 4.96 (dd, 3J3,4  = 
3.0 and 3J2,3 = 10.3 Hz, 2H, H-3II, H-1I), 4.72 (dd, J = 9.7Hz, J = 16.2Hz, 3H, H-6a6bII, 
H-1II), 4.36 (q, J=7.4Hz, 2H, N-CH2CH3), 4.14 (d, 4JH-H = 6.5 Hz, 2H, OCH2), 3.92 (ddd, 
J = 25.1, 19.5, 11.3 Hz, 4H, H-3I, H-4I, H-6a,6bI), 3.72 (dd, J = 8.1Hz, J = 14.8Hz, 1H, 
H-2I), 3.42 (d, 3J3,OH = 8.4 Hz, 1H, OH-3I ), 2.14, 2.05, 1.98, 1.97 (4 x s, 9H, COCH3),   
1.72, (s, 3H, NHCOCH3), 1.52 (t, J = 7.4Hz, 3H, N-CH2CH3) 1.07 (s, 9H, SiCMe3); 13C 
NMR (150 MHz, CDCl3): δ = 170.8, 170.3, 170.0, 169.8, 169.1 (CO), 144.87 (triazole-
C) 135.8, 135.4, 133.4, 132.4, 129.9, 127.8, 127.6 (Carom), 121.8 (triazole-C) 100.7 (C-
1II), 99.6 (C-1I), 79.5 (C-4I), 74.6 (C-5I), 72.1 (C-3I), 71.1 (C-5II), 70.7 (C-3II), 68.7 (C-
2II), 66.8 (C-4II), 61.9 (C-6I), 61.7 (C-6II), 61.1 (OCH2), 56.3 (C-2I), 45.23 (N-CH2CH3), 
26.7 (SiCMe3), 23.4 (NHCOCH3), 20.53, 20.49, 20.45, 20.28 (COCH3), 19.28 (SiCMe3), 
15.38 ppm (N-CH2CH3). HRMS (ESI) calculated for C43H59N4O15Si M + H+ : 
899.37407, found 899.37341. 
Compound 3.140 
 
To a solution of compound 3.137 (0.083 g, 100 μmol) in THF:H2O (1:1) 2 mL, isopropyl  
azide (13 mg, 150 μmol) CuSO4.5H2O (5 mg 20%) and sodium ascorbate (8 mg, 40%) 




described above, the LacNAc triazole derivative 3.140 (87 mg, 95 %) was obtained; Rf 
0.23 (DCM:MeOH, 9.5:0.5, v/v); ;  
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D - 20.6 (c 1.0, CHCl3); 1H NMR (600 MHz, 
CDCl3) δ 7.88 - 7.65 (m, 4H, Harom), 7.49 (s, 1H, click-H), 7.46 - 7.29 (m, 6H, Harom), 
6.10 (d, 3JNH-H2 = 7.7 Hz, 1H, AcNH), 5.36 (d, 3J3,4 = 3J4,5 = 3.4 Hz, 1H, H-4II ), 5.19 (dd, 
3J1,2  = 8.1 Hz, 3J2,3 = 10.4 Hz, 1H, H-2II), 4.97 (dd, 3J3,4  = 3.0 and 3J2,3 = 10.3 Hz, 2H, H-
3II, H-1I), 4.77 (qd, J = 6.6Hz, J = 14.9Hz, 4H, H-6a6bII, H-1II, N-CH(CH3)2), 4.13 (d, 
4JH-H = 6.7 Hz, 2H, OCH2), 4.09 - 3.79 (m, 6H, H-3I, H-4I, H-6a, 6bI, H-5I, H-5II), 3.70 (d, 
J = 9.5 Hz, 1H, H-2I), 3.44 (d, 3J3,OH = 8.4 Hz, 1H, OH-3I), 2.16, 2.06, 1.99, 1.98, (4 x s, 
9H, COCH3),  1.73 (s, 3H, NHCOCH3) 1.56 (dd, J = 6.7, 1.4 Hz, 2H, N-CH(CH3)2), 1.08 
(s, 9H, SiCMe3); 13C NMR (150 MHz, CDCl3) δ 170.80, 170.34, 170.06, 169.84, 169.09 
(CO), 144.29 (triazole-C), 135.85, 135.43, 133.44, 132.44, 129.84, 127.82, 127.63 
(Carom), 119.92 (triazole-C), 100.79 (C-1II), 99.59 (C-1I), 79.59 (C-4I), 74.66(C-5I), 72.17 
(C-3I), 71.14(C-5II), 70.76(C-3II),  68.79 (C-2II), 66.83 (C-4II), 62.06 (C-6I), 61.78 (C-6II), 
61.11 (OCH2), 56.44 (C-2I), 52.96 (N-CH(CH3)2), 26.78 (SiCMe3), 23.46 (NHCOCH3), 
22.95, 22.92 (N-CH(CH3)2), 20.56, 20.52, 20.47, 20.29 (COCH3), 19.30 (SiCMe3); 











To a solution of compound  3.137 (0.083 g, 100 μmol) in THF:H2O (1:1)  2 mL, n-propyl  
azide (13 mg, 150 μmol) CuSO4.5H2O (5 mg 20%) and sodium ascorbate (8 mg, 40%) 
were added and after 12h of reaction time following the general procedure ((7.2.1) 
described above, the LacNAc triazole derivative 3.141 (86 mg, 94%) was obtained; Rf 
0.22 (DCM/MeOH, 9.8 : 0.3, v/v);  
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D  - 7.23 (c 1.0, CHCl3); 1H-NMR (600 MHz) δ = 
7.79 - 7.69  (m, 4H, Harom), 7.50 (s, 1H, click-H), 7.48 - 7.32 (m, 6H, Harom), 6.06 (d, 
3JNH-H2 = 7.7 Hz, 1H, AcNH), 5.37 (d, d, 1H, 3J3,4  = 3J4,5 = 3.4 Hz, 1H, H-4II), 5.20 (dd, 
3J1,2  = 8.1 Hz, 3J2,3 = 10.4 Hz, 1H, H-2II), 4.97 (dd, 3J3,4  = 3.0 and 3J2,3 = 10.3 Hz, 2H, H-
3II, H-1I), 4.75 (dd, J = 6.6Hz, J = 14.9Hz, 3H, H-6a6bII, H-1II), 4.29 (t, J = 7.2Hz, 1H, N-
CH2CH2CH3), 4.15 (d, 4JH-H = 6.7 Hz, 2H, OCH2), 3.90 (ddd, J = 15.6, 13.5, 9.0 Hz, 6H, 
H-3I, H-4I, H-6a,6bI, H-5I, H-5II), 3.75 - 3.73 (m, 1H, H-2I), 3.45 (d, 3J3,OH = 8.4 Hz, 1H, 
OH-3I), 2.16, 2.06, 1.99, 1.98, (4 x s, 9H, COCH3), 1.92 - 1.89 (m, 2H, N-CH2CH2CH3), 
1.73 (s, 3H, NHCOCH3), 1.08 (s, 9H, SiCMe3), 0.96 (t, J = 7.4Hz, 3H, N-CH2CH2CH3 ); 
13C NMR (150 MHz, CDCl3): δ=170.8, 170.4, 170.1, 169.9, 169.1 (CO), 144.87 
(triazole-C) 135.9, 135.4, 133.5, 132.5, 129.9, 127.8, 127.6 (Carom), 122.39 (triazole-C) 
100.8 (C-1II), 99.7 (C-1I), 79.7 (C-4I), 74.7 (C-5I), 72.2 (C-3I), 71.2 (C-5II), 70.8 (C-3II), 




CH2-CH2-CH3), 26.8 (SiCMe3), 23.4 (NHCOCH3), 23.51 (N-CH2-CH2-CH3), 20.60, 
20.55, 20.51, 20.33 (COCH3), 19.35 (SiCMe3), 11.02 ppm (N-CH2CH3). HRMS (ESI) 
calculated for C44H61N4O15Si M + H+ : 913.38972, found 913.38885. 
Compound 3.142 
 
To a solution of compound 3.137 (0.083 g, 100 μmol) in THF:H2O (1:1)  2 mL, 2-azido 
ethanol (13 mg, 150 μmol) CuSO4.5H2O (5 mg 20%) and sodium ascorbate (8 mg, 40%) 
were added and after 12h of reaction time following the general procedure ((7.2.1) 
described above, the LacNAc triazole derivative 3.142 (83 mg, 91%) was obtained; Rf 
0.20 (DCM/MeOH, 9.5:0.5, v/v);  
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D - 24.10 (c 1.0, CHCl3); 1H-NMR (600 MHz) δ = 
7.75 (ddd, J = 7.6, 6.2, 2.1 Hz, 4H, Harom), 7.60 (s, 1H, click-H), 7.51 - 7.33 (m, 6H, 
Harom), 6.32 (d, 3JNH-H2 = 7.2 Hz, 1H, AcNH), 5.36 (d, 3J3,4  = 3J4,5 = 3.2 Hz, 1H, H-4II), 
5.18 (dd, 3J1,2  = 8.0 Hz, 3J2,3 = 10.4 Hz, 1H, H-2II), 5.03 - 4.93 (m, 3H, H-3II, H-6a,6bII), 
4.78 - 4.65 (m, 2H, N-CH2-CH2-OH), 4.58 - 4.33 (m, 2H, N-CH2-CH2-OH), 4.13 (d, 4JH-
H = 6.6 Hz, 2H, OCH2), 3.83 - 3.71  (m, 6H, H-3I, H-4I, H-6a,6bI, H-5I, H-5II), 3.44 (d, 
3J3,OH = 7.9 Hz, 1H, OH-3I), 3.13 (dd, J = 17.4, 8.1 Hz, 1H, H-2I), 2.15, 2.04, 1.98, 1.85 
(4 x s, 9H, COCH3), 1.73(s, 3H, NHCOCH3), 1.08(s, 9H, SiCMe3) 13C NMR (150 MHz, 
CDCl3): δ = 171.4, 170.2, 170.1, 169.9, 169.06 (CO), 143.24 (triazole-C) 135.9, 135.4, 




80.18 (C-4I), 74.5 (C-5I), 71.1 (C-3I), 70.68 (C-5II), 70.3 (C-3II), 68.7 (C-2II), 66.8 (C-4II), 
66.7 (C-6I), 61.7 (C-6II), 61.1 (N-CH2CH2-OH) 60.72 (OCH2),  58.0 (OCH2), 56.4 (C-2I), 
53.40 (N-CH2-CH2-OH), 26.6 (SiCMe3), 23.4 (NHCOCH3), 23.28 (N-CH2-CH2-CH3), 
20.56, 20.51, 20.48, 20.3 (COCH3), 19.31 (SiCMe3). HRMS (ESI) calcd for 
C43H59N4O16Si M + H+ : 915.36898, found 915.36782. 
Compound 3.143 
 
To a solution of compound 3.137 (0.083 g, 100 μmol) in THF:H2O (1:1)  2 mL, benzyl 
azide (20 mg, 150 μmol) CuSO4.5 H2O (5 mg 20%) and sodium ascorbate (8 mg, 40%) 
were added and after 12h of reaction time following the general procedure ((7.2.1) 
described above, the LacNAc triazole derivative 3.143 (91 mg, 95 %) was obtained; Rf 
0.35 (DCM/MeOH, 9.8:0.2, v/v);  
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D  - 2.30 (c 1.0, CHCl3);  1H-NMR (600 MHz, 
CDCl3) δ 7.82 - 7.62 (m, 4H ), 7.47 - 7.31 (m, 10H), 7.29 - 7.21 (m, 2H), 6.07 (d, J = 7.8 
Hz, 1H), 5.48 (s, 2H), 5.36 (d, J = 3.3 Hz, 1H), 5.19 (dd, J = 10.4, 8.0 Hz, 1H), 5.05 - 
4.87 (m, 2H), 4.72 (dd, J = 13.7, 5.9 Hz, 3H), 4.14 (d, J = 6.5 Hz, 2H), 4.01 - 3.77 (m, 
6H), 3.70 (d, J = 8.0 Hz, 1H), 3.41 (s, 1H), 2.15, 2.04, 1.98, 1.85 (4 x s, 9H, COCH3), 
1.73(s, 3H, NHCOCH3); 13C NMR (150 MHz, CDCl3): δ=170.7, 170.3, 170.0, 169.8, 
169.0 (CO), 144.87 (triazole-C) 135.8, 135.4, 134.4, 133.4, 132.4, 129.8, 129.0, 128.7, 




74.5 (C-5I), 72.1 (C-3I), 71.1 (C-5II), 70.7 (C-3II), 68.7 (C-2II), 66.8 (C-4II), 61.8 (C-6I), 
61.7 (C-6II), 61.0 (OCH2), 56.2 (C-2I), 54.07 (N-CH2-Ph), 26.7 (SiCMe3), 23.3 
(NHCOCH3), 20.5, 20.48, 20.43, 20.26 (COCH3), 19.25 (SiCMe3) ppm. HRMS (ESI) 
calculated for C48H61N4O15Si M + H+ : 961.38972, found 961.38948. 
Compound 3.144 
 
To a solution of compound 3.137 (0.083 g, 100 μmol) in THF:H2O (1:1) 2 mL, 
cyclopentyl  azide (17 mg, 150 μmol) CuSO4.5H2O (5 mg 20%) and sodium ascorbate (8 
mg, 40%) were added and after 12h of reaction time following the general procedure 
((7.2.1) described above, the LacNAc triazole derivative 3.144 (87 mg, 93 %) was 
obtained; Rf  0.3 (DCM/MeOH, 9.8:0.2, v/v) ;  
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D - 15.17 (c 1.0, CHCl3); 1H-NMR 
(600 MHz) δ = 7.73 (dd, J = 9.5, 4.1 Hz, 4H, Harom) 7.50 (s, 1H,click-H) 7.48 - 7.29 (m, 
6H, Harom), 6.24 (d, 3JNH-H2 = 11.6 Hz, 1H, AcNH) 5.35 (d, d, 1H, 3J3,4  = 3J4,5 = 3.2 Hz, 
1H, H-4II ) 5.18 (dd, 3J1,2  = 8.0 Hz, 3J2,3 = 10.4 Hz, 1H, H-2II ) 5.03 - 4.92 (m, 3H, H-3II, 
H-6a,6bII ) 4.81 - 4.69 (m, 3H, H-1I, H-6a,6bII) 4.39 (ddd, J = 2.8Hz, J = 7.2Hz, J = 
11.8Hz, 1H, N-CH cyclopentyl) 4.13 (d, 4JH-H = 6.6 Hz, 2H, OCH2) 3.92 (ddd, J = 25.1, 21.3, 
11.3 Hz, 6H, H-3I, H-4I, H-6a,6bI, H-5I, H-5II ), 3.70 (d, J = 9.2 Hz, 1H, H-2I) 3.42 (d, 
3J3,OH = 7.9 Hz, 1H, OH-3I ), 2.40 – 2.19 (m, 2H, CH2cyclopentyl), 2.14, 2.04, 1.97, 1.95 (4 x 




CH2cyclopentyl), 1.71 (s, 3H, NHCOCH3), 1.07 (s, 9H, SiCMe3) 1.01 - 0.78 (m, 2H, 
CH2cyclopentyl); 13C NMR (150 MHz, CDCl3): δ = 170.8, 170.3, 170.0, 169.8, 169.0 (CO), 
143.99 (triazole-C) 135.8, 135.3, 133.3, 132.4, 129.8, 127.7, 127.5 (Carom), 120.3 
(triazole-C) 100.7 (C-1II), 99.6 (C-1I), 79.5 (C-4I), 74.6 (C-5I), 72.2 (C-3I), 71.0 (C-5II), 
70.7 (C-3II), 68.7 (C-2II), 66.8 (C-4II), 62.0 (C-6I), 61.7 (C-6II), 61.0 (OCH2), 60.03 (N-
Ccyclopentyl) 56.4 (C-2I), 33.4, 33.3 (N-Ccyclopentyl) 26.7 (SiCMe3), 25.0, 24.9 (N-Ccyclopentyl) 
23.3 (NHCOCH3), 20.5 (N-Ccyclopentyl), 20.60, 20.55, 20.51, 20.33 (COCH3), 19.35 




To a solution of compound  3.137 (0.083 g, 100 μmol) in THF:H2O (1:1) 2 mL, 
cyclohexyl  azide (13 mg, 150 μmol) CuSO4.5H2O (5 mg 20%) and sodium ascorbate (8 
mg, 40%) were added and after 12h of reaction time following the general procedure 
((7.2.1) described above, the LacNAc triazole derivative  3.145 (90 mg, 94 %) was 
obtained; Rf 0.15 (DCM/MeOH, 9.8:0.2, v/v)  ;  
21
D  - 8.23 (c 1.0, CHCl3); 1H-NMR 
(600 MHz) δ = 7.75 - 7.71 (m, 4H, Harom), 7.50 (s, 1H,click-H), 7.47 - 7.23 (m, 6H, 
Harom), 6.24 (,3JNH-H2 = 11.6 Hz, 1H,AcNH), 5.35 (d, d, 1H, 3J3,4  = 3J4,5 = 3.2 Hz, 1H, H-




4.81 – 4.69 (m, 3H, H-1I, H-6a,6bII), 4.39 (ddd, J = 2.8Hz, J = 7.2Hz, J = 11.8Hz, 1H, N-
CH cyclohexyl), 4.13 (d, 4JH-H = 6.6 Hz, 2H, OCH2), 4.04 - 3.83 (m, 6H, H-3I, H-4I, H-
6a,6bI, H-5I, H-5II),  3.71 - 3.69 (m, 1H, H-2I), 3.42 (d, 3J3,OH = 7.9 Hz, 1H,OH-3I), 2.29 - 
2.20 (m, 2H, CH2 cyclohexyl), 2.15, 2.05, 1.98, 1.97 (4 x s, 9H, COCH3), 1.71 (s, 3H, 
NHCOCH3), 1.88 - 1.85 (m, 2H, CH2cyclohexyl), 1.07 (s, 9H, SiCMe3), 1.0 - 0.95 (m, 2H, 
CH2 cyclohexyl), some multiplets belonging to CH2 cyclohexyl  masked under singlets at 2.4-1.5 
ppm. 13C NMR (150 MHz, CDCl3): δ = 170.8, 170.3, 170.0, 169.8, 169.0 (CO), 143.99 
(triazole-C) 135.8, 135.3, 133.3, 132.4, 129.8, 127.7, 127.5 (Carom), 120.3 (triazole-C) 
100.7 (C-1II), 99.6 (C-1I), 79.5 (C-4I), 74.6 (C-5I), 72.2 (C-3I), 71.0 (C-5II), 70.7 (C-3II), 
68.7 (C-2II), 66.8 (C-4II), 62.0 (C-6I), 61.7 (C-6II), 61.0 (OCH2), 60.03 (N-Ccyclohexyl) 56.4 
(C-2I), 33.4, 33.3 (N-Ccyclohexyl) 26.7 (SiCMe3), 25.0, 24.9 (N-Ccyclohexyl) 23.3 
(NHCOCH3), 20.5 (N-Ccyclohexyl), 20.60, 20.55, 20.51, 20.33 (COCH3), 19.35 (SiCMe3); 
HRMS (ESI) calculated for C47H65N4O15Si M + H+ : 953.42157, found : 953.42160. 
Compound 3.146 
 
To a solution of compound 3.138 (0.025 g, 28 μmol) in 1.5 mL THF (Dry) was added a 
1M TBAF/THF soln (0.056 ml, 2eq) and the reaction mixture stirred overnight under 
nitrogen atmosphere, then the reaction mixture was evaporated under reduced pressure. 
Dry methanol 2 mL and 1 ml of NaOMe/MeOH (pH 10) were added then stirred for 4 




reaction mixture was washed with acid base mix resin in water to remove the traces of 
TBAF, and lyophilized to obtain white foam like compound 3.146 (13 mg, 95%); Rf  0.11 
(ACN/H2O 5.8:1.5, v/v);  
24
D  + 8.6 (c 1.0, H2O); 1H NMR (600 MHz, D2O) δ 7.87 (d, J 
= 96.5 Hz, 1H), 4.91 (d, J = 12.9 Hz, 1H), 4.80 (d, J = 8.5 Hz, 1H), 4.60 (d, J = 8.1 Hz, 
1H), 4.46 (d, J = 7.8 Hz, 1H), 4.11 (d, J = 5.0 Hz, 3H), 4.01 - 3.97 (m, 1H), 3.92 (t, J = 
3.5 Hz, 1H), 3.84 (dd, J = 12.3, 5.2 Hz, 1H), 3.80 - 3.62 (m, 8H), 3.59 (ddd, J = 9.3, 5.2, 
2.2 Hz, 1H), 3.57 - 3.50 (m, 1H), 1.91 (s, 3H); 13C NMR (150 MHz, D2O) δ 175.03, 
144.12, 126.75, 103.53, 100.64, 79.01, 76.00, 75.49, 73.16, 72.89, 72.71, 71.62, 69.20, 
63.13, 62.57, 61.67, 60.70, 55.67, 37.19, 22.66; HRMS (ESI) m/z calculated for  
C18H30N4O11 [M+H]+ 479.1989; found 479.1984. 
Compound 3.147 
 
To a solution of compound 3.139 (0.038 g, 42 μmol) in 1.5 mL THF (Dry) was added a 1 
M TBAF/THF soln. (0.084 ml 2eq) and the reaction mixture stirred overnight under 
nitrogen atmosphere, Then the reaction mixture was evaporated under reduced pressure. 
Then dry methanol 2 mL and 1 ml of NaOMe/MeOH (pH 10) were added, then stirred 
for 4 hrs. Acid resin was then added to neutralize the reaction mixture and evaporated.  
The reaction mixture was washed with acid base mix resin in water to remove the traces 




0.15 (ACN/H2O, 5.8:1.5, v/v);  
24
D  - 22.30 (c 1.0, H2O); 1H NMR (600 MHz, D2O) δ 
8.01 (s, 1H), 4.91(d, J = 12.9 Hz, 1H), 4.83 (d, J = 8.5 Hz, 1H), 4.60 (d, J = 7.8 Hz, 1H), 
4.49 - 4.42 (m, 3H), 3.98 (dd, J = 12.2, 2.0 Hz, 1H), 3.94 - 3.90 (m, 2H), 3.83 (dt, J = 
13.8, 7.0 Hz, 1H), 3.79 - 3.64 (m, 8H), 3.59 (dd, J = 12.4, 10.3 Hz, 1H), 3.53 (dd, J = 
10.0, 7.8 Hz, 1H), 1.90 (s, 3H), 1.51 (t, J = 7.4 Hz, 3H); 13C NMR (150 MHz, D2O) δ 
175.00, 144.07, 125.29, 103.53, 100.71, 79.01, 76.00, 75.47, 73.17, 72.87, 71.62, 69.20, 
62.62, 61.67, 60.70, 55.68, 46.34, 22.68, 15.28; HRMS (ESI) calculated for  
C19H32N4O11 [M+H]+ 493.2146, found 493.2146. 
Compound 3.148 
 
To a solution of compound 3.140 (0.067 g, 73 μmol) in 1.5 mL THF (Dry) was added 1 
M TBAF/THF soln (0.146 ml, 2eq) and the reaction mixture stirred overnight under 
nitrogen atmosphere. Then, the reaction mixture was evaporated under reduced pressure 
and dry methanol 2 mL and 1 ml of NaOMe/MeOH (pH 10) were added, then stirred for 
4 hrs. Acid resin was then added to neutralize the reaction mixture and evaporated. The 
reaction mixture was washed with acid base mix resin in water to remove the traces of 
TBAF, and lyophilized to obtain white foam like compound 3.148 (35 mg, 92%); Rf  0.15 
(ACN/H2O, 5.8:1.5, v/v);   
24
D  - 10.74 (c 1.0, H2O); 1H NMR (600 MHz, D2O) δ 8.08 




1H), 4.49 (d, J = 7.8 Hz, 1H), 4.00 (d, J = 10.8 Hz, 1H), 3.96 - 3.91 (m, 1H), 3.86 (dd, J 
= 12.2, 5.1 Hz, 1H), 3.81 - 3.66 (m, 8H), 3.65 - 3.59 (m, 1H), 3.57 (dd, J = 17.6, 9.5 Hz, 
1H), 1.93 (s, 3H), 1.58 (d, J = 6.8 Hz, 6H); 13C NMR (150 MHz, D2O) δ 174.95, 123.65, 
103.47, 100.70, 78.96, 75.94, 75.39, 73.11, 72.79, 71.57, 69.15, 62.63, 61.61, 60.65, 
55.65, 54.43, 31.04, 22.66, 22.60; HRMS (ESI) calculated for  C20H34N4O11 [M + H]+ 
507.2302, found 507.2295. 
Compound 3.149 
 
To a solution of compound 3.141 (0.080 g, 87 μmol) in 1.5 mL THF (Dry) was added 1 
M TBAF/THF soln (0.174 ml, 2eq) and the reaction mixture stirred overnight under 
nitrogen atmosphere. Then, the reaction mixture was evaporated under reduced pressure 
and dry methanol 2 mL and 1 ml of NaOMe/MeOH (pH 10) were added, then stirred for 
4 hrs. Acid resin was then added to neutralize the reaction mixture and evaporated. The 
reaction mixture was washed with acid base mix resin in water to remove the traces of 
TBAF, and lyophilized to obtain white foam like compound 3.149 (40 mg, 92%); Rf 0.15 
(ACN/H2O, 5.8:1.5, v/v);  
24
D  - 16.92 (c 1.0, H2O); 1H NMR (600 MHz, D2O) δ 8.03 
(d, J = 5.1 Hz, 1H), 4.93 (d, J = 12.9 Hz, 1H), 4.83 (d, J = 12.4 Hz, 1H), 4.66 - 4.60 (m, 
1H), 4.49 (d, J = 7.8 Hz, 1H), 4.41 (t, J = 6.9 Hz, 3H), 4.03 - 3.98 (m, 1H), 3.94 (t, J = 




3.56 (dd, J = 9.9, 7.9 Hz, 1H), 1.96 - 1.89 (m, 5H), 0.88 (t, J = 7.4 Hz, 4H); 13C NMR 
(150 MHz, D2O) δ 174.95, 144.04, 125.77, 103.47, 100.72, 78.96, 75.94, 75.40, 73.11, 
72.80, 71.56, 69.15, 62.57, 61.61, 60.65, 55.64, 52.65, 23.65, 22.63, 10.71; HRMS (ESI) 
calculated for  C20H34N4O11 [M + H] + 507.2302, found 507.2294. 
Compound 3.150 
 
To a solution of compound 3.142 (0.022 g, 24 μmol) in 1.5 mL THF (Dry) was added 1 
M TBAF/THF soln (0.047 ml, 2eq) and the reaction mixture stirred overnight under 
nitrogen atmosphere. Then, the reaction mixture was evaporated under reduced pressure 
and dry methanol 2 mL and 1 ml of NaOMe/MeOH (pH 10) were added, then stirred for 
4 hrs. Acid resin was then added to neutralize the reaction mixture and evaporated. The 
reaction mixture was washed with acid base mix resin in water to remove the traces of 
TBAF, and lyophilized to obtain white foam like compound 3.150 (11 mg, 90%); Rf  0.10 
(ACN/H2O, 5.8:1.5, v/v);  
24
D  - 5.48 (c 1.0, H2O); 1H NMR (600 MHz, D2O) δ 8.05 (d, 
J = 23.8 Hz, 1H), 4.95 (d, J = 13.0 Hz, 1H), 4.87 (d, J = 8.5 Hz, 1H), 4.64 (t, J = 8.9 Hz, 
2H), 4.61 - 4.57 (m, 1H), 4.49 (d, J = 7.8 Hz, 1H), 4.05 - 4.00 (m, 3H), 3.95 (t, J = 3.4 
Hz, 1H), 3.90 - 3.83 (m, 1H), 3.80 - 3.67 (m, 8H), 3.63 (dd, J = 7.3, 5.3 Hz, 1H), 3.56 
(dd, J = 9.8, 8.0 Hz, 1H), 1.93 (s, 3H); 13C NMR (150MHz, D2O) δ 174.94, 144.08, 




60.67, 55.60, 53.11, 22.63; HRMS (ESI) calculated for  C19H32N4O12 [M + H]+ 
509.2095, found 509.2088. 
Compound 3.151 
 
To a solution of compound 3.143 (0.050 g, 52 μmol) in 1.5 mL THF (Dry) was added 1 
M TBAF/THF soln (0.103 ml, 2eq) and the reaction mixture stirred overnight under 
nitrogen atmosphere. Then, the reaction mixture was evaporated under reduced pressure 
and dry methanol 2 mL and 1 ml of NaOMe/MeOH (pH 10) were added, then stirred for 
4 hrs. Acid resin was then added to neutralize the reaction mixture and evaporated. The 
reaction mixture was washed with acid base mix resin in water to remove the traces of 
TBAF, and lyophilized to obtain white foam like compound 3.151 (27 mg, 94%); Rf 0.19 
(DCM/ MeOH 8:2);  
24
D  - 19.35 (c 1.0, H2O); 1H NMR (600 MHz, D2O) δ 8.01 (s, 1H), 
7.50 – 7.41 (m, 3H), 7.38 (d, J = 6.7 Hz, 2H), 5.65 - 5.57 (s, 2H), 4.88 (t, J = 13.0 Hz, 
1H), 4.80 - 4.75 (m, 1H), 4.63 - 4.53 (m, 1H), 4.49 (dd, J = 16.0, 6.0 Hz, 1H), 3.97 - 3.90 
(m, 2H), 3.87 - 3.63 (m, 8H), 3.60 - 3.52 (m, 2H), 1.81 (s,3H); 13C NMR (150 MHz, 
D2O) δ 174.96, 144.53, 135.35, 129.82, 129.49, 128.82, 125.79, 103.49, 100.82, 78.92, 
75.97, 75.39, 73.14, 72.81, 71.59, 69.17, 62.63, 61.64, 60.63, 55.61, 54.56, 22.58; 






To a solution of compound 3.144 (0.061 g, 64 μmol) in 1.5 mL THF (Dry) was added 1 
M TBAF/THF soln (0.12 ml, 2eq) and the reaction mixture stirred overnight under 
nitrogen atmosphere. Then, the reaction mixture was evaporated under reduced pressure 
and dry methanol 2 mL and 1 ml of NaOMe/MeOH (pH 10) were added, then stirred for 
4 hrs. Acid resin was then added to neutralize the reaction mixture and evaporated. The 
reaction mixture was washed with acid base mix resin in water to remove the traces of 
TBAF, and lyophilized to obtain white foam like compound 3.152 (49 mg, 88%) Rf 0.1 
(DCM/ MeOH 8:2).  
24
D  - 8.74 (c 1.0, H2O); 1H NMR (600 MHz, D2O) δ 8.06 (d, J = 
5.1 Hz, 1H), 5.08 - 5.00 (m, 1H), 4.92 (d, J = 13.0 Hz, 1H), 4.82 (d, J = 9.4 Hz, 1H), 4.65 
- 4.59 (m, 1H), 4.49 (d, J = 7.8 Hz, 1H), 4.00 (dd, J = 12.2, 1.8 Hz, 1H), 3.96 - 3.92 (m, 
1H), 3.86 (dt, J = 11.9, 6.0 Hz, 1H), 3.82 - 3.66 (m, 9H), 3.62 (dd, J = 7.2, 4.6 Hz, 1H), 
3.56 (dd, J = 9.8, 8.0 Hz, 1H), 2.30 (td, J = 13.4, 7.4 Hz, 2H), 2.30 (td, J = 13.4, 7.4 Hz, 
2H), 2.00 (td, J = 13.4, 6.4 Hz, 2H), 1.92 (s, 3H), 1.91 - 1.83 (m, 2H), 1.83 - 1.73 (m, 
2H); 13C NMR (150 MHz, D2O) δ 124.37, 103.51, 100.75, 79.04, 75.96, 75.42, 73.15, 
72.82, 71.58, 69.16, 62.97, 62.65, 61.61, 60.69, 55.66, 33.46, 24.19, 22.67; HRMS (ESI) 







To a solution of compound 3.145 (0.068 g, 71 μmol) in 1.5 mL THF (Dry) was added 1 
M TBAF/THF soln (0.146 ml, 2eq) and the reaction mixture stirred overnight under 
nitrogen atmosphere. Then, the reaction mixture was evaporated under reduced pressure 
and dry methanol 2 mL and 1 ml of NaOMe/MeOH (pH 10) were added, then stirred for 
4 hrs. Acid resin was then added to neutralize the reaction mixture and evaporated. The 
reaction mixture was washed with acid base mix resin in water to remove the traces of 
TBAF, and lyophilized to obtain white foam like compound 3.153 (36mg, 93%); Rf 0.1 
(DCM/MeOH 8:2);  
24
D  - 9.68 (c 1.0, H2O); 1H NMR (600 MHz, D2O) δ 8.07 (s, 1H), 
4.93 (d, J = 13.0 Hz, 1H), 4.83 (d, J = 11.9 Hz, 1H), 4.67 - 4.60 (m, 1H), 4.55 (tt, J = 
11.8, 3.7 Hz, 1H), 4.50 (d, J = 7.8 Hz, 1H), 4.01 (d, J = 10.7 Hz, 1H), 3.95 (t, J = 5.2 Hz, 
1H), 3.87 (dd, J = 12.3, 5.1 Hz,1H), 3.83 - 3.66 (m, 9H), 3.62 (m, 1H), 3.59 - 3.54 (m, 
1H), 2.18 (d, J = 11.0 Hz, 2H), 1.93 (s, 3H), 1.79 (ddd, J = 35.7, 17.9, 8.4 Hz, 2H), 1.50 
(q, J = 12.9 Hz, 2H), 1.38 – 1.27 (m, 2H); 13C NMR (150 MHz, D2O) δ 174.89, 143.73, 
123.85, 103.56, 100.81, 79.09, 76.01, 75.95, 75.46, 75.40, 73.19, 72.86, 71.63, 69.21, 
62.70, 61.66, 61.27, 60.73, 55.70, 33.57, 25.25, 22.73; HRMS (ESI) calculated for  





Camptothecin Azide (4.3) 
 
To a solution of camptothecin in dry DCM 5ml, was added 6-azidohexanoic acid (4.2), 
Sc(OTf)3 and DMAP. This was stirred at RT for 30 min, then diisopropylcabodiimide 
(DIPC) was added and stirred at reflux for about 16 hrs, then the reaction mixture was 
concentrated and purified by flash column chromatography with just dichloromethane to 
flush the urea byproduct of DIPC. Once all the urea was eluted, the solvent was changed 
to 20-30% ethyl acetate in hexane to elute the product 4.3 (0.056 g, 85%). Rf 0.33 
(EtOAc:Hexane 8.5:1.5) 1H NMR (CDCl3, 300 MHz): δ 8.42 (s, 1H, H-16), 8.23 (d, J = 
8.6Hz, 1H, H-18), 7.97 (d, J = 8.4Hz, 1H, H-21), 7.86 (t, J = 7.0Hz, 1H, H-19), 7.69 (t, J 
= 7.5Hz, 1H, H-20), 7.22 (s, 1H, H-25), 5.64 (d, J = 17.2 Hz, 1H, H-11), 5.37 (d, J = 17.2 
Hz, 1H, H-11), 5.31 (s, 2H, H-14), 3.24 (t, J = 6.8Hz, 2H, H-5), 2.53 (dt, J = 4.6Hz, J = 
7.3Hz, 2H, H-1), 2.29 - 2.08 (m, 2H, H-8), 1.68 - 1.52 (m, 4H, H-2,H-3), 1.47 (dd, J = 
6.0Hz, J = 9.2Hz, 2H, H-4), 0.99 (t, J = 7.5Hz, 3H, H-9); 13C NMR (CDCl3, 75 MHz): δ 
172.41, 167.54, 157.35, 152.36, 148.86, 146.22, 145.87, 131.26, 130.72, 129.54, 128.46, 
128.23, 128.18, 128.06, 120.31, 118.43, 95.90, 75.78, 67.11, 51.12, 49.90, 33.56, 31.84, 








To a solution of compound 4.3 (0.02 g, 40 μmol) in THF:H2O (3:1)  2 mL, camptothecin   
azide 4. 3 (0.020 g, 41 μmol), CuSO4.5H2O (2 mg 20%) and sodium ascorbate (3 mg, 
40%) were added. After 12h of reaction time following the general procedure (8.2.1) 
described above, the β-D-galactopyranoside conjugate 4.4 (0.030g, 78%) was obtained. 
Rf 0.30 (EtOAc:Hexane 8.5:1.5);  
22
D  + 5.43 (c 1.0, CH2Cl2); 1H NMR (CDCl3, 300 
MHz): δ 8.41 (s, 1H, H-24), 8.19 (d, J = 8.4Hz, 1H, H-26), 7.95 (d, J = 7.8Hz, 1H, H-29) 
7.83 (t, J = 7.3Hz, 1H, H-27), 7.67 (t, J = 7.1Hz, 1H, H-28), 7.32 (s, 1H, H-8), 7.22 (d, J 
= 8.0Hz, 1H, NH), 7.19 (s, 1H, H-33),  5.68 (d, J = 17.3 Hz, 1H, H-19), 5.40 (d, J = 14.0 
Hz, 1H, H-19), 5.43 (s, 1H), 5.29 (d, J=0.8Hz, 1H, H-4sugar), 5.14 - 5.01 (m, 2H, H-2, 
H-3sugar), 4.88 (dd, J = 4.7Hz, J = 12.3Hz, 1H, H-3), 4.36-4.21 (m, 1H, H-6), 4.10-4.04 
(m, 3H, H-5, 6, 6’ sugar), 3.96 - 3.88 (m, 1H, H-1 sugar), 3.69 (s, 1H, H-5), 3.30 - 3.13 
(m, 2H, H-9), 2.54 - 2.45 (m, 1H, H-13), 2.27 (dd, J = 7.5Hz, J = 14.0Hz, 1H, H-10), 
2.13, 2.03, 1.97, 1.97 (4S,3H each,-C(O)CH3),  1.93 - 1.83 (m, 2H, H-12), 1.73 - 1.64 (m, 
2H, H-11), 1.45-1.35 (m, H-16), 0.97 (t, J = 7.4Hz, 1H, H-17); 13C NMR (CDCl3, 75 
MHz): δ 172.31, 171.22, 170.32, 170.24, 170.07, 169.86, 169.23, 167.58, 157.34, 148.80, 




118.47, 95.91, 75.85, 75.03, 74.10, 71.89, 68.57, 67.54, 67.10, 61.18, 52.47, 51.78, 49.95, 
38.68, 33.36, 31.81, 30.65, 29.78, 29.34, 27.61, 25.64, 23.90, 20.73, 20.63, 20.57, 7.54. 
HRMS (ESI) calcd for C48H54N6O17 + [H]+ : 987.3624, found 987.3608. 
Compound 4.5 
 
To a solution of 4.4 in 2 ml of dry methanol was added 2 ml of NaOMe/MeOH (pH = 8 - 
9) and stirred at RT overnight. The reaction mixture was concentrated under vacuum to 
obtain the crude product, which was purified by flash column chromatography using 5-
10% water in ACN to get final product 4.5 (19 mg, 84%) Rf 0.28 (H2O/ACN 1:9); 1H 
NMR (300 MHz, CD3OD) δ 8.64 (s, 1H), 8.22 - 8.12 (m, 1H), 8.07 (d, J = 7.8 Hz, 1H), 
7.96 - 7.80 (m, 1H), 7.77 - 7.64 (m, 1H), 7.36 (s, 1H), 5.68 - 5.57 (m, 1H), 5.67 - 5.39 (m, 
1H), 4.79 - 4.55 (m, 2H), 4.34 (dd, J = 11.2, 9.4, 4.7 Hz, 2H), 3.86 (d, J = 6.8 Hz, 3H), 
3.70 (dd, J = 8.2, 4.3 Hz, 2H), 3.67 - 3.58 (m, 4H), 3.51 - 3.37 (m, 3H), 3.35 - 3.33 (m, 
2H), 3.13 (ddd, J = 15.4, 11.3, 6.4 Hz, 2H), 2.72 (dd, J = 10.4, 4.9 Hz, 2H), 2.58 (t, J = 
7.1 Hz, 2H), 2.48 - 2.29 (m, 2H), 2.28 - 2.07 (m, 2H), 1.90 (dt, J = 7.3, 6.3 Hz, 2H), 1.79 
- 1.64 (m, 2H), 1.02 (t, J = 7.4 Hz, 3H); 13C NMR (75 MHz, CDCl3) δ 173.84, 172.75, 
149.72, 148.09, 133.10, 131.46, 129.76, 129.20, 124.17, 97.83, 80.35, 78.46, 77.31, 




32.11, 30.93, 30.76, 30.70, 28.47, 26.88, 26.85, 25.30, 25.12, 7.98; HRMS (ESI) calcd 
for C40H46N6O13 + [H]+ : 819.31956, found 819.31778.  
Compound 5.8 
 
To a solution of 3-(tetra-O-benzyl--D-galactopyranosyl)1-propene 5.6 (100 mg, 177 
µmol) and N-acryloyl-(S)-4-benzyl-2-oxazolidinone 5.15 (196 mg, 531 µmol) in 5 mL 
dry dichloromethane was added Grubbs 2nd generation catalyst (15 mg, 0.1%). The 
reaction was refluxed under nitrogen environment for 12 hrs. The reaction mixture was 
concentrated on rotovap and the crude product was purified by flash column 
chromatography to obtain 5.8 (80 mg, 60%) using 10% ethyl acetate in hexane; Rf 0.38 
(EtOAc/Hexane 4:6);  
22
D  + 37.06 (c 1.0, CH2Cl2); 1H NMR (300 MHz, CDCl3) δ 7.45 
- 7.24 (m, 25H), 7.19 (d, J = 6.9 Hz, 1H), 5.07 - 4.90 (m, 2H), 4.83 - 4.57 (m, 5H), 4.55 - 
4.38 (m, 2H), 4.11 (d, J = 5.4 Hz, 2H), 4.03 (d, J = 2.4 Hz, 1H), 3.77 (t, J = 9.2 Hz, 1H), 
3.67-3.56 (m, 4H), 3.52 - 3.38 (m, 1H), 3.27 (dd, J = 13.4, 3.0 Hz, 1H), 2.91 - 2.64 (m, 
2H), 2.64 - 2.46 (m, 1H); 13C NMR (75 MHz, CDCl3) δ 164.60, 153.08, 147.78, 138.58, 
138.14, 138.09, 137.88, 135.28, 129.26, 128.74, 128.27, 128.23, 128.21, 128.06, 127.89, 




76.93, 75.06, 74.34, 73.53, 73.36, 71.99, 68.65, 65.84, 55.03, 37.66, 35.12; HRMS (ESI) 
calculated for C48H49NO8 H+: 768.3536, found 768.3537. 
Compound 5.9 
 
To a solution of 3-(tetra-O-benzyl--D-galactopyranosyl)-1-propene 5.6 (200 mg, 354 
µmol) and N-acryloyl-(S)-4-isopropyl-2-oxazolidinone 5.12 (196 mg, 0.1 mmol) in 5 mL 
dry dichloromethane was added Grubbs 2nd generation catalyst (30 mg, 0.1%). The 
reaction was refluxed under nitrogen environment for 12 hrs. The reaction mixture was 
concentrated on rotovap and the crude product purified by flash column chromatography 
using 10% EtOAc in hexane to obtain pure 5.9 (161 mg, 62%); Rf 0.15 
(EtOAc:Hexane 3:7);  
22
D  + 3.64 (c 1.0, CH2Cl2); 1H NMR (300 MHz, CDCl3) δ 7.41 - 
7.21 (m, 25H), 7.16 (dd, J = 15.5, 6.7 Hz, 1H), 4.93 (dd, J = 11.3, 8.7 Hz, 2H), 4.65 (ddd, 
J = 17.3, 11.7, 7.6 Hz, 4H), 4.51 - 4.32 (m, 3H), 4.23 - 4.09 (m, 3H), 3.98 (d, J = 2.6 Hz, 
2H), 3.70 (t, J = 9.2 Hz, 1H), 3.63 - 3.48 (m, 1H), 3.38 (td, J = 8.7, 3.6 Hz, 4H), 2.81-
2.71 (m, 1H), 2.56 - 2.40 (m, 1H), 2.39-2.26 (m, 1H), 0.87 (d, J = 7.0 Hz, 3H), 0.80 (d, J 
= 6.9 Hz, 3H); 13C NMR (75 MHz, CDCl3) δ 180.37, 164.67, 153.78, 147.57, 138.61, 
138.14, 138.12, 137.88, 128.31, 128.27, 128.25, 128.09, 127.95, 127.84, 127.81, 127.59, 




72.02, 68.62, 63.08, 58.32, 35.21, 28.28, 17.89, 14.53; HRMS (ESI) calculated for 
C44H50NO8 M + H+: 720.35364, found 720.35359. 
Compound 5.16 
 
To a solution of 5.9 (20 mg, 27 µmol) in dichloromethane (5 mL) was added thioacetic 
acid (2 mg, 26 µmol) and one drop of triethylamine. The reaction mixture was stirred at 
room temperature for 12 hrs, then concentrated to obtain 1,4-addition product 5.16 (16 
mg, 77%) with a ds ratio of 60:40 based on the 1H NMR quantification of the thioacetate 
singlet proton. The diastereomers were inseparable by flash chromatography for NMR 
characterization. Rf 0.32 (EtOAc:Hexane 3:7). 
Compound 5.17 
 
To a solution of 5.8 (20 mg, 26 µmol) in dichloromethane (5 mL) was added thioacetic 
acid (2 mg, 26 µmol) and one drop of triethylamine. Then reaction mixture was stirred at 




mg, 85%) with a ds ratio of 60:40 based on the 1H NMR quantification of the thioacetate 
singlet proton. The diastereomers were inseparable by flash chromatography for NMR 
characterization. Rf 0.32 (EtOAc:Hexane 3:7). 
Compound 5.18 
 
CuBr.DMS (26 mg, 126 µmol) and a stir bar were added to oven dried 5 mL RBF, which 
was then sealed with rubber septum and purged with nitrogen. Dry THF (1 mL) was 
added via a syrange in to the flask under nitrogen atmosphere. The solution was cooled to 
-78oC and EtMgBr (1M solution in diethyl ether) was added drop wise while controlling 
the temperature at -78oC. The reaction mixture was allowed to stir at -78oC for 30 
minutes. Solution of 5.9 (20 mg, 26 µmol) in dry THF (0.5 mL) was prepared under 
nitrogen atmosphere and added drop wise to the round bottom flask containing EtMgBr  
while maintaining the temperature at -78oC. After 30 minutes of reaction time the mixture 
was quenched using saturated NH4Cl and concentrated. The crude was taken up with 
dichloromethane, washed with brine solution and dried over MgSO4 and concentrated to 
get crude 1, 4 - addition product 5.18 with a ratio of ds 60:40 (18 mg, 87%). 
Diastereoselectivity was quantified unambiguously using HPLC. The diastereomers were 
inseparable via flash column for NMR characterization. Rf 0.44 (EtOAc : Hexane 3 : 7); 






CuBr.DMS (26 mg, 126 µmol) and a stir bar were added to oven dried 5 mL RBF, which 
was then sealed with rubber septum and purged with nitrogen. Dry THF (1 mL) was 
added via a syrange in to the flask under nitrogen atmosphere. The solution was cooled to 
-78oC and EtMgBr (1M solution in diethyl ether) was added drop wise while controlling 
the temperature at -78oC. The reaction mixture was allowed to stir at -78oC for 30 
minutes. Solution of 5.9 (20 mg, 26 µmol) in dry THF (0.5 mL) was prepared under 
nitrogen atmosphere and added drop wise to the round bottom flask containing EtMgBr  
while maintaining the temperature at -78oC. After 30 minutes of reaction time the mixture 
was quenched using saturated NH4Cl and concentrated. The crude was taken up with 
dichloromethane, washed with brine solution and dried over MgSO4 and concentrated to 
get crude 1, 4 - addition product 5.19 with a ratio of ds 97:3 (18 mg, 87%). 
Diastereoselectivity was quantified unambiguously using HPLC. The crude product was 
used to quantify the diasreoselectivity to avoid any kind of separation of diastereomers by 
flash column chromatography, although this was was more challenging compared to 
previous procedures; Rf 0.22 (EtOAc : Hexane 2 : 8);  
22
D  + 29.75 (c 1.0, CH2Cl2); 1H 




4.60 (m, 4H), 4.60 - 4.52 (m, 1H), 4.45 (q, J = 11.7 Hz, 2H), 4.14 - 3.96 (m, 3H), 3.72 - 
3.47 (m, 5H), 3.40 - 3.22 (m, 2H), 3.05 (dd, J = 5.9, 5.9 Hz, 1H), 2.85 (dd, J = 7.5, 7.4 
Hz, 1H), 2.69 (dd, J = 13.2, 9.8 Hz, 1H), 2.23 (m, 1H), 1.92 - 1.75 (m, 1H), 1.69 - 1.54 
(m, 3H), 1.44 (dd, J = 11.2, 7.3 Hz, 2H), 1.26 (s, 1H), 0.89 (t, J = 7.4 Hz, 3H); 13C NMR 
(75 MHz, CDCl3) δ 172.94, 153.31, 138.82, 138.48, 138.39, 138.12, 135.47, 129.40, 
128.87, 128.37, 128.34, 128.29, 128.19, 128.16, 128.03, 127.84, 127.62, 127.55, 127.54, 
127.49, 127.22, 85.00, 79.06, 77.67, 76.85, 75.34, 74.49, 73.79, 73.42, 72.23, 68.91, 
65.90, 55.26, 38.74, 37.87, 34.84, 32.65, 27.05, 11.09; HRMS (ESI) calculated for 
C50H56NO8 +  H+ : 798.40059, found 798.3988. 
Compound 6.15 
 
To a suspension of L-propargylglycine methyl ester HCl 6.7 (0.672 g, 4.1 mmol) in 
dichloromethane (26 mL) was added DIPEA (0.16 mL) and allowed to stir in order to 
dissolve 6.7 completely. The reaction mixture was cooled to 0oC. 2-
bromoethanesulfonylchloride (1.02 g, 4.9 mmol) was dissolved in DCM (52 mL) and 
added drop wise to the reaction mixture keeping the temperature at 0oC. The reaction 
mixture was allowed warm up to RT and stirred overnight. Then the reaction mixture was 
diluted with DCM, washed with 5% citric acid, 5% NaHCO3 and brine then dried over 
MgSO4 and rotovapped to obtain crude product. The product was purified by flash 




6.15 (500 mg, 56%); Rf  0.11 (CH2Cl2:MeOH 9.7:0.3); 1H NMR (300 MHz, CDCl3) δ 
6.57 (ddd, J = 16.5, 9.8, 0.6 Hz, 1H), 6.27 (d, J = 16.5 Hz, 1H), 5.94 (d, J = 9.8 Hz, 1H), 
5.29 (d, J = 8.9 Hz, 1H), 4.17 (dt, J = 9.4, 4.8 Hz, 1H), 3.81 (s, 3H), 2.90 - 2.65 (m, 2H), 
2.10 (dd, J = 2.9, 2.4 Hz, 1H); 13C NMR (75 MHz, CDCl3) δ 170.33, 136.25, 126.73, 
72.48, 53.99, 53.07, 24.10; MS (ESI) calcd for C8H11NO4S + H+: 218.04; found: 218.1. 
Compound 6.17 
 
To a suspension of L-propargylglycine methyl ester HCl 6.7 (0.140 g, 0.85 mmol) in dry 
THF (18 mL) was added maleic anhydride (83 mg, 0.85 mmol) and DIPEA (0.45 mL, 
0.25 mmol). The reaction mixture was stirred overnight then N-OH succinamide (98 mg, 
0.85 mmol) and DCC (206 mg, 0.11 mmol) were added and stirring continued another 12 
hrs. The reaction was concentrated and crude dissolved in DCM and purified by gravity 
silica gel chromatography using DCM as eluent. The product elutes with dicyclohexyl 
urea (DCU) side product which is separated by dissolving the evaporated fractions 
containing the product in EtOAc and leaving them in the freezer at -20oC overnight. The 
DCU precipitates and can be filtered to obtain 6.17 (106 mg, 60%) as product; Rf  0.88 
(CH2Cl2:MeOH 9.5:0.5); 1H NMR (300 MHz, CDCl3) δ 6.78 (s, 2H), 4.89 (dd, J = 11.0, 




MHz, CDCl3) δ 169.53, 168.06, 134.23, 78.83, 70.87, 53.02, 50.45, 19.39; MS (ESI) 
calcd for C10H9NO4 + H+: 208.0, found 208.2. 
Compound 6.18 
 
To a solution of L-propargyl maleimide 6.17 (5 mg, 2µmol) in 2 ml phosphate buffer (pH 
7.4) was added cysteine (excess) and allowed to stirr at room temperature. The reaction 
was monitored by TLC and was observed to be completed in 10 min.  
Compound 6.19 
 
To a solution of vinyl sulfonamide 6.15 (5 mg, 2µmol) in 2 ml phosphate buffer (pH 7.4) 
was added cysteine (excess) and allowed to stirr at room temperature. The reaction was 






To a solution of compound 6.17 (0.120 g, 5 μmol) in toluene (5 mL) was added n-propyl 
azide (0.059 g, 5.8 μmol) CuI (5 mg, 2%) and DIPEA (0.08 mL, 2%). After 12 hrs of 
reaction time following the general procedure described above (8.2.3), maleimido triazole 
6.21 (101 mg, 60 %) was obtained; Rf 0.44 (CH2Cl2 : MeOH 9.5 : 0.5); 1H NMR (300 
MHz, CDCl3) δ 7.33 (s, 1H), 6.68 (s, 2H), 5.11 - 4.90 (m, 1H), 4.25 (t, J = 7.0 Hz, 2H), 
3.77 (s, 3H), 3.59 (d, J = 7.8 Hz, 10.2 Hz, 2H), 1.88 (dd, J = 14.3, 7.1 Hz, 2H), 0.90 (t, J 
= 7.4 Hz, 3H); 13C NMR (75 MHz, CDCl3) δ 169.61, 168.86, 142.95, 134.14, 122.16, 




To a solution of compound 6.17 ( 0.100 g, 4.8 μmol) in toluene (5 mL) was added allyl 
azide (0.060 g, 5.8 μmol) CuI (5 mg, 2%) and DIPEA (0.08 mL, 2%). After 12 hrs of 
reaction time following the general procedure described above (8.2.3), maleimide triazole 
6.22 (80 mg, 57%) was obtained; Rf 0.46 (CH2Cl2 : MeOH 9.5 : 0.5); 1H NMR (300 
MHz, CDCl3) δ 7.35 (s, 1H), 6.66 (s, 2H), 6.01-5.85 (m, 1H), 5.37 - 5.22 (m, 1H), 5.16 
(d, J = 17.5 Hz, 1H), 4.95 (dt, J = 14.5, 7.2 Hz, 1H), 4.87 (d, J = 5.9 Hz, 2H), 3.72 (s, 




131.21, 121.75, 119.67, 52.84, 52.41, 51.53, 29.57, 25.13; MS (ESI)calcd for 
C13H14N4O4 + H+: 291.10, found 291.1. 
Compound 6.23 
 
To a solution of compound 6.17 (0.100 g, 4.8 μmol) in toluene (5 mL) was added 
isopropyl azide (0.049 g, 5 μmol) CuI (5 mg, 2%) and DIPEA (0.08 mL, 2%). After 12 
hrs of reaction time following the general procedure described above (8.2.3), maleimide 
triazole 6.23 (84 mg, 60 %) was obtained; Rf 0.43 (CH2Cl2 : MeOH 9.5 : 0.5); 1H NMR 
(300 MHz, CDCl3) δ 7.34 (s, 1H), 6.67 (s, 1H), 4.98 (dd, J = 9.4, 5.9 Hz, 1H), 4.72 (dd, J 
= 13.3, 6.7 Hz, 1H), 3.76 (s, 3H), 3.55 – 3.41 (m, 2H), 1.51 (d, J = 6.5 Hz, 6H); 13C 
NMR (75MHz, CDCl3) δ 169.56, 168.82, 142.46, 134.09, 119.34, 52.75, 52.69, 51.45, 
25.06, 22.76; MS (ESI) calcd for C13H14N4O4 + H+: 293.12, found 293.1. 
Compound 6.24 
 
To a solution of compound 6.17 ( 0.90 g, 4.3 μmol) in toluene (5 mL) was added 




12 hrs of reaction time following the general procedure described above (8.2.3) 
maleimide triazole 6.24 (85 mg, 75%) was obtained; Rf 0.41 (CH2Cl2 : MeOH 9.5 : 0.5); 
1H NMR (300 MHz, CDCl3) δ 7.33 (s, 1H), 6.68 (s, 2H), 4.98 (dd, J = 9.7, 5.7 Hz, 1H), 
4.93 – 4.70 (m, 1H), 3.76 (s, 3H), 3.70 - 3.40 (m, 3H), 2.30 - 2.08 (m, 2H), 2.04 - 1.89 
(m, 2H), 1.89 - 1.78 (m, 2H), 1.73 (d, J = 7.2 Hz, 2H); 13C NMR (75 MHz, CDCl3) δ 
169.67, 168.95, 142.68, 134.17, 120.27, 76.58, 61.62, 52.86, 51.61, 33.25, 29.62, 25.19, 
23.93; MS (ESI) calcd for C15H18N4O4 + H+: 318.13, found 318.1. 
Compound 6.25 
 
To a solution of compound 6.17 (0.100 g, 5 μmol) in toluene (5 mL) was added benzyl 
azide (0.059 g, 2.8 μmol) CuI (5 mg, 2%) and DIPEA (0.08 mL, 2%). After 12 hrs of 
reaction time following the general procedure described above (8.2.3) maleimide triazole 
6.25 (123 mg, 75%) was obtained; Rf 0.48 (CH2Cl2 : MeOH 9.5 : 0.5); 1H NMR (300 
MHz, CDCl3) δ 7.43 - 7.30 (m, 3H), 7.27 (s, 1H), 7.18 (dd, J = 6.5, 3.0 Hz, 2H), 6.64 (s, 
2H), 5.60 - 5.38 (m, 2H), 5.30 (s, 2H), 5.10 - 4.84 (m, 1H), 3.75 (s, 3H), 3.51 (d, J = 11.4 
Hz, 2H); 13C NMR (75 MHz, CDCl3) δ 169.61, 168.86, 142.95, 134.14, 129.17, 128.90, 








To a solution of L-propargyl glycine methyl ester HCl (0.67 g, 4.1mmol) and DIPEA 
(1.59 g, 12.3 mmol) in dry CH2Cl2, cooled to 0oC in an ice bath was added 2-bromo 
ethane sulfonyl chloride drop wise (1.02g, 4.9 mmol). The reaction mixture was allowed 
to come up to RT and stirred overnight. The reaction mixture was washed with 5% citric 
acid, 5% NaHCO3 solution, and brine, then dried over MgSO4. The crude compound 
purified by flash column chromatography using CH2Cl2 alone to obtain compound 6.15 
(0.499 g, 2.3 mmol); Rf 0.75 (CH2Cl2 : MeOH 9.7 : 0.3); 1H NMR (CDCl3, 300 MHz): δ 
6.57 (ddd, J = 16.5, 9.8, 0.6 Hz, 1H, H-7), 6.27 (d, J = 16.5 Hz, 1H, H-8a), 5.94 (d, J = 
9.8 Hz, 1H, H-8b), 5.29 (d, J = 8.9 Hz, 1H, NH), 4.16 (dt, J = 9.4, 4.8 Hz, 1H, H-4), 3.81 
(s, 3H, H-6), 2.88 - 2.69 (m, 2H, H-3), 2.09 (dd, J = 2.9, 2.4 Hz, 1H, H-1); 13C NMR 
(CDCl3, 75 MHz): δ170.56 (C-5), 136.48 (C-7), 126.96 (C-8), 72.71(C-2), 54.21 (C-1), 






To a solution of compound 6.15 (0.080 g, 368 μmol) in THF:H2O (3:1.5) 2.5 mL was 
added, n-propyl azide (0.062 g, 736 μmol) CuSO4.5H2O (14 mg, 20%) and sodium 
ascorbate (30 mg, 40%). After 12 hrs of reaction time following the general procedure 
described above (8.2.1), vinyl sulfonamide 6.26 (102 mg, 339 μmol) was obtained; Rf 
0.22 (CH2Cl2:MeOH 9.5:0.5); 1H NMR (CDCl3, 300 MHz): δ 7.47 (s, 1H, H-4), 6. 39 
(6.45 (ddd, J = 16.5, 9.8, 1.9 Hz, 1H, H-10), 6.15 (dd, J = 16.6, 2.4 Hz, 1H, H-11a), 5.85 
(d, 1H, J = 8.79 Hz, NH), 5.78 (dd, 1H, J = 9.8, 2.22 Hz, H-11b), 4.24 (dd, J = 9.9, 4.3 
Hz,2H, H-3), 4.18 - 4.09 (m, 1H, H-7), 3.65 (s, 3H, H-9), 3.22 (d, J = 5.5 Hz, 2H, H-6), 
2.04 - 1.73 (m, 2H, H-2), 0.89 (dt, J = 7.4, 1.9 Hz, 3H, H-1); 13C NMR (CDCl3, 75 
MHz): δ171.28 ( C-8 ),141.80 ( C-5), 136.05 (C-4), 126.31 (C-10), 122.45 (C-11), 55.09 
(C-7), 52.66 (C-9), 52.73 (C-3), 29.17 (C-6), 23.48 (C-2), 10.82 (C-1); MS (ESI) calcd 
for C11H18N4O4S + H+: 303.10, found: 303.20. 
Compound 6.27 
 
To a solution of compound 6.15 (0.080 g, 368 μmol) in THF:H2O (3:1.5) 2.5 mL was 
added, allyl   azide (0.061 g, 737 μmol) CuSO4.5H2O (14 mg, 20%) and sodium 
ascorbate (30 mg, 40%). After 12h of reaction time following the general procedure 
described above (8.2.1), vinyl sulfonamide 6.27 (94 mg, 313 μmol) was obtained; Rf 0.22 




J = 9.88Hz, H-10), 6.13 (d, 1H, J = 14 Hz,  H-11a), 5.98 (dddd, J = 15.3, 10.3, 6.9, 5.3 
Hz, 1H, H-2), 5.81 (d, 1H, J = 7.69 Hz, H-11b), 5.74 (d, 1H, J = 7.69 Hz, NH), 5.25 (2d, 
2H, J = 10.16, 17.03 Hz, H-1a,b), 4.87 (d, 2H, J = 4.94 Hz, H-3), 4.35 - 4.21 (m, 1H, H-
7), 3.67 (s, 3H, H-9), 3.20 (d, 2H, J = 5.49 Hz, H-6); 13C NMR (CDCl3, 75 MHz): δ 
171.53 (C-8), 142.378 ( C-5), 136.33 (C-4), 131.40 (C-10), 126.75 (C-11), 122.072( C-2), 
120.25(C-1), 55.33 (C-3), 53.05 (C-7) 52.82 (C-9) 29.58 (C-6); MS (ESI) calcd for 
C11H16N4O4S + H+: 301.08, found 301.2. 
Compound 6.28 
 
To a solution of compound 6.15 (0.030 g, 138 μmol) in THF:H2O (3:1.5) 1.5 mL, was 
added isopropyl azide (0.0235 g, 276 μmol) CuSO4.5H2O (5 mg, 20%) and sodium 
ascorbate (11 mg, 40%). After 12h of reaction time following the general procedure 
described above (8.2.1), vinyl sulfonamide 6.28 (31 mg, 103 μmol) was obtained; Rf 0.21 
(CH2Cl2:MeOH 9.5:0.5); 1H NMR (CDCl3, 300 MHz): δ 7.43 (s, 1H, H-4), 6. 43 (dd, 
1H, J = 9.88, 9.61 Hz, H-10), 6.14 (d, 1H, J = 16.48 Hz,  H-11a), 5.81 (d, 1H, J = 9.88 
Hz, H-11b), 5.68 (d, 1H, J = 8.24 Hz, NH), 4.77 (hept, J = 6.7 Hz, 1H, H-3), 4.28-4.18 
(m, 1H, H-7), 3.69 (s, 3H, H-9), 3.20 (d, 2H, J = 5.49 Hz, H-6), 1.50 (d, 6H, J = 6.59Hz, 




126.45 (C-10), 120.01 (C-11), 55.09 (C-7), 52.93 (C-9), 52.78 (C-2), 29.40 (C-6), 22.89, 
22.87(2C, C-1,2); MS (ESI) calcd for C11H18N4O4S + H+: 303.10, found 303.2. 
Compound 6.29 
 
To a solution of compound 6.15 (0.080 g, 368 μmol) in THF:H2O (3:1.5) 2.5 mL, was 
added cyclopentyl azide (0.081 g, 736 μmol) CuSO4.5H2O (14 mg, 20%) and sodium 
ascorbate (30 mg, 40%). After 12h of reaction time following the general procedure 
described above (8.2.1), vinyl sulfonamide 6.29 (112 mg, 342 μmol) was obtained; Rf 
0.24 (CH2Cl2 : MeOH 9.5 : 0.5); 1H NMR (CDCl3, 300 MHz): δ 7.43 (s, 1H, H-6), 6. 41 
(dd, 1H, J = 9.61, 9.88 Hz, H-12), 6.12 (d, 1H, J = 16.48 Hz,  H-13a), 5.79 (d, 1H, J = 
9.88 Hz, H-13b), 4.94 – 4.78 (m, 1H, H-5), 4.22 – 4.20 (m, 1H, H-9), 3.67 (s, 3H, H-11), 
3.18 (d, 2H, J = 5.27 Hz, H-8), 2.34 - 2.12 (m, 2H, CH2Cyclopentyl), 2.11 - 1.90 (m, 2H, 
CH2Cyclopentyl), 1.89 - 1.79 (m, 2H, CH2Cyclopentyl), 1.79 - 1.65 (m, 2H, CH2Cyclopentyl); 13C 
NMR (CDCl3, 75 MHz): δ171.61 (C-10), 136.40 (C-6), 126.57 (C-12), 62.04 (C-5), 
55.37 (C-9), 53.00 (C-11), 33.50 (2c, C-1 and 4)) 29.55 (C-8), 24.19 (2C, C-2 and 3); MS 









To a solution of compound 6.15 (0.080 g, 368 μmol) in THF : H2O (3:1.5) 2.5 mL, was 
added benzyl azide (0.098 g, 737 μmol) CuSO4.5H2O (14 mg, 20%) and sodium 
ascorbate (30 mg, 40%). After 12h of reaction time following the general procedure 
described above (8.2.1), vinyl sulfonamide 6.30 (103 mg, 294 μmol) was obtained; Rf  
0.31 (CH2Cl2:MeOH 9.5:0.5); 1H NMR (CDCl3, 300 MHz): δ7.37 (s, 1H, H-8), 7.36 – 
7.25 (m, 3H, HAromatic), 7.20 (td, J = 6.3, 1.3 Hz, 2H, HAromatic),  6. 36 (dd, 1H, J = 9.88, 
9.89 Hz, H-14), 6.10 (d, 1H, J = 16.75 Hz,  H-15a), 5.74 (d, 1H, J = 9.88 Hz, H-15b), 
5.428 (d, J = 2.9 Hz, 2H, H-7), 4.30 – 4.15 (m, 1H, H-11), 3.64 (s, 3H, H-13), 3.17 (d, 
2H, J = 5.49 Hz, H-10); 13C NMR (CDCl3, 75 MHz): δ δ171.57 (C-12), 141.84 (C-9), 
136.32 (C-8), 134.92 (C-6), 129.28-128.18(5C, C1-5), 126.70 (C-15) 122.86 (C-14), 
55.40 (C-7), 54.26 (C-11), 53.00 (C-13), 29.56 (C-10); MS (ESI) calcd for C15H18N4O4S 
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